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ABSTRACT
In 1990 a team of scientist at Johns Hopkins proposed that human colon cancer is caused by a
succession of defined genetic alterations including mutation of the Adenomatous Polyposis Coli
(APC) tumor suppressor gene, reduced DNA methylation, mutation of the N- or Ki-ras proto-
oncogene, inactivation of the Deleted in Colorectal Cancer (DCC) gene, and mutation of the p53
tumor suppressor gene. To test the veracity of this genetic model of colon cancer, the technique of
gene targeting was used to create genetic alterations in mice that are similar to those observed in
human colonic tumors and their effects on the biology of normal and neoplastic intestine was
examined.
In the first part of this study, mice were created that are constitutionally heterozygous for a
mutation of the mouse homologue of the APC gene and were found to be predisposed to intestinal
adenomas. In the second part, these mice were used to ask whether DNA hypomethylation plays
an early and causative role in the formation of intestinal tumors. These findings indicate that,
contrary to the prediction of the Hopkins model, reducing DNA methylation in cells of intestine
suppresses the formation of adenomas. In the third part, the effect of inactivation of the Deleted in
Colorectal Cancer (DCC) gene on formation and progression of intestinal adenomas was tested.
The findings failed to provide support for a tumor suppressor function for Dcc, but showed that
Dcc-deficient mice did have defects in the formation of commissures in the spinal cord and the
brain that were strikingly similar to those observed in mice deficient in netrin-1, an axonal
chemoattractant. In the last part, the effects of inactivation of the p53 tumor suppressor gene on
the incidence of apoptotic cell death was examined. The findings suggest that wild type p53 retards
the progression of benign colonic adenoma to malignant carcinomas by mechanism(s) other than
the promotion of apoptosis.
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NOMENCLATURE
In referring to genes and proteins, I have used the nomenclature that is widely used by those in the
field. However, the system of nomenclature described below was used when possible.
The name of species are italicized (e.g. Caenorhabditis elegans and Drosophila melanogaster ).
The abbreviation for the human gene is capitalized for all letters but only the first letter of the
abbreviation for the mouse gene is capitalized but all the subsequent letters are lower case (e.g.
human APC gene versus mouse Apc gene). Whereas genes are italicized, the same abbreviation
referring to the protein product of the gene is not and is used for both species (e.g. APC protein for
both human and mouse). For a targeted mutation of a gene in mouse that is shown to be a loss-of-
function mutation (or a null mutation) the (-) symbol in superscript is used to refer to the null allele
(e.g. Apc-, p53- or Dcc-). One exception to this rule is the netrin-1 mutation which is a leaky or
hypomorphic mutation and yet is called netrin-l-. In some instances, the name used by the creators
of the allele are used (e.g. ApcMin , Apc8 or DnmtS).
In C. elegans, all letters in the abbreviation for the protein are capitalized while the gene is not but
is italicized (e.g. UNC-40 protein encoded by the unc-40 gene).
CHAPTER 1
Genetic Model Of Human Colon Cancer
In 1990, a team of scientist at Johns Hopkins University proposed a genetic model for colon
cancer (Fearon and Vogelstein, 1990) that was largely based on the data regarding the
chromosomal sites of and the frequency of loss of heterozygosity in colorectal tumors .Loss of
heterozygosity (LOH) represents a process often used by developing tumor cell clones to eliminate
both copies of a tumor suppressor gene(Cavenee et al., 1983). Initially, one gene copy is
inactivated by mutation; thereafter the second, still intact gene copy is discarded, frequently
accompanied by duplication of the chromosomal arm carrying the mutant allele.
According to this genetic model, human colon cancer is caused by a succession of defined
genetic alterations and these alterations include inactivation of the Adenomatous Polyposis Coli
(APC) tumor suppressor gene on chromosome 5q, reduced DNA methylation, mutation of the N-
or Ki-ras proto-oncogene, inactivation of the Deleted in Colorectal Cancer (DCC) gene on 18q, and
loss of the p53 tumor suppressor gene on 17p (Figure 1). More recent findings have suggested that
mutations of components of the DNA mismatch repair system may help increase the rate of
progression leading to colonic tumors by increasing the rate of mutations of APC, DCC and p53
(for a review see Kinzler and Vogelstein, 1996).
Figure 1
Fearon and Vogelstein's genetic model for formation of colon cancer. Human colon cancer is
proposed to develop by a succession of defined genetic alterations: inactivation of the
Adenomatous Polyposis Coli (APC) tumor suppressor gene on chromosome 5q, reduced DNA
methylation, mutation of the N- or Ki-ras proto-oncogene, inactivation of the Deleted in Colorectal
Cancer (DCC) gene on 18q, and loss of the p53 tumor suppressor gene on 17p.
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Mutations of APC are important for the formation of most colon carcinomas, in that mutant
alleles of this gene, created by somatic mutations, are found in 90% of the non-familial or sporadic
cases of this disease (Adams et al., 1993; Alvarez et al., 1988). Mutations of APC are found in the
same frequency in early-stage adenomas and in advanced adenocarcinomas, indicating that the loss
of APC function plays an important role in an early step in colon cancer progression (Adams et al.,
1993). Inheritance of a mutant allele of the APC gene located on chromosome 5q21-22 causes the
familial adenomatous polyposis (FAP) disease, a dominantly inherited form of intestinal cancer that
is characterized by the formation of hundreds to thousands of benign polyps in the colon and
rectum by the third or fourth decade of life (1, 2).
Reductions in the global level of DNA methylation are also proposed to be an early step in
the formation of colonic tumors because both early adenomas and advanced carcinomas show a
similar decrease in the global level of DNA methylation compared to cells of normal colon
(Feinberg et al., 1988; Gama-Sosa et al., 1983). To the extent that these changes in DNA
methylation are thought to contribute to the oncogenic process, it has been proposed that their
effects are mediated through changes in the expression levels of proto-oncogenes and tumor-
suppressor genes. One model proposes that the commonly observed global DNA hypomethylation
in human tumors is of selective advantage to the tumor cell through facilitated proto-oncogene
expression (Feinberg and Vogelstein, 1983) (Hanada et al., 1993; Rao et al., 1989; Vorce and
Goodman, 1991). In the alternative model, high expression of the DNA methyltransferase is
thought to drive hypermethylation of specific loci such as tumor-suppressor genes or genes
specific to differentiated cell types (Baylin et al., 1991; El-Deiry et al., 1991; Greger et al., 1989;
Issa et al., 1994; Issa et al., 1993; Kautiainen and Jones, 1986; Ohtani-Fujita et al., 1993;
Silverman et al., 1989). There is, however, no direct evidence that either mechanism is operative in
colon carcinogenesis.
The K-ras proto-oncogene is also mutated in 50% of intermediate adenomas (Bos et al.,
1987; Vogelstein et al., 1988) . LOH of 18q appears to play a part in a relatively early step during
the development of about 30% of colorectal tumors when small adenomas (polyps) progress to
more dysplastic, larger, intermediate adenomas (Barlow, 1993). In the advanced adenomas - the
immediate precursors of carcinomas - the incidence of 18q LOH approaches 65% (Alhonen et al.,
1987; Allen et al., 1988; Barlow, 1993). Consistent with the possibility that 18q carries a colonic
tumor suppressor gene are chromosome transfer experiments demonstrating that one normal copy
of chromosome 18 is sufficient to suppress the tumorigenicity of human colon carcinoma cell lines
(Bartolucci et al., 1989; Barton et al., 1991). The DCC gene has been identified as the target of
LOH on chromosome 18q. However, experiments to date have failed to provide conclusive proof
that DCC is a tumor suppressor gene. For instance, in one study, analysis of the DCC alleles
retained in 60 human colonic tumors affected by 18q LOH led to the discovery of mutant alleles in
only 2 tumors (Cho et al., 1994). Thus, the DCC gene represents an anomaly to the common
observation that both alleles of tumor suppresor genes are inactivated during tumor pathogenesis.
LOH of the p53 gene in human colonic adenomas coincides with the appearance of highly
dysplastic cells within less dysplastic, intermediate grade adenomas (Boehm and Drahovsky,
1983). Such highly dysplastic adenomatous cells are presumably the immediate precursors of
colon carcinomas. At this transition point, one allele of the p53 gene acquires a point mutation that
converts it to a dominant-negative allele of p53 (Hollstein et al., 1991; Nigro et al., 1989).
Subsequently, the second allele of p53 gene is deleted just before the adenoma is transformed into
a carcinoma (Ohue et al., 1994).
The present study was designed to examine the role of three proposed colonic tumor
suppressor genes APC, DCC and p53 in the initiation and progression of colonic adenomas by
mutating their counterparts in mice. In addition, in order to assess the role of DNA
hypomethylation in colon cancer, the effect of reduced DNA methylation on the formation of
intestinal adenomas was examined in mice through partial inactivation of their DNA
methylatransferase, the enzyme that is responsible for the bulk of the methylation of the cytosine
residue in CpG dinucleotides.
Techniques of gene targeting (Capecchi, 1989) were used to generate mice that are
constitutionally heterozygous for a targeted mutation in genes implicated in APC and DCC. Mice
carrying germ-line mutations in the DNA methyltransferase gene and the p53 gene had been created
prior to this study (Jacks et al., 1994; Li et al., 1993; Li et al., 1992) using the same techniques.
Briefly, embryonic stem (ES) cells are transfected with a fragment of DNA that is homologous to
the gene of interest. A mutation that would disrupt the function of the endogenous gene is
introduced into the gene by homologous recombination. ES cells heterozygous for the targeted
allele are then used to generate chimeric mice. If heterozygous cells contribute the germ cells, the
chimeric mice generate progeny that are constitutionally heterozygote.
Figure 2
Targeted mutagenesis in mice. Embryonic stem (ES) cells are transfected with a fragment of DNA
that is homologous to the gene of interest. A mutation that would disrupt the function of the
endogenous gene is introduced into the gene by homologous recombination. ES cells heterozygous
for the targeted allele are then used to generate chimeric mice. If heterozygous cells contribute the
germ cells, the chimeric mice generate progeny that are constitutionally heterozygote.
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Figure 3
Construction of a mouse model for colon cancer. In this study, techniques of gene targeting are
used to generate mice that are constitutionally heterozygous for a targeted mutation in genes
implicated in APC and DCC. Mice carrying germ-line mutations in the DNA methyltransferase
gene and the p53 gene had been created prior to this study. The effects on intestinal adenoma
formation and progression of inactivating the Apc, Dcc, DNA methyltransferase gene, and p53
genes are examined in this study.
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CHAPTER 2
Attenuated Adenomatous Polyposis And Facial Osteomas
in a Mouse with a Hypomorphic Allele of Apc
Introduction
Familial adenomatous polyposis (FAP) is a dominantly inherited form of intestinal neoplasia that is
caused by the inheritance of a mutant allele of the human Adenomatous Polyposis Coli (APC) gene
(Bodmer et al., 1987; Groden et al., 1991; Kinzler et al., 1991; Nishisho et al., 1991). The FAP
disease is characterized by the development of large numbers of adenomatous polyps (adenomas or
polyps) in the intestine by 20-30 years of age; most of these polyps are found in the colon (Bulow,
1990). Gardner's syndrome (GS) and Turcot's syndrome (TS) are two variant forms of the FAP
disease that are distinguished by the additional presence of extracolonic tumors (Hamilton et al.,
1995; Nishisho et al., 1991). The GS patients frequently develop facial osteomas, fibromas of
various tissues, epidermoid cysts in skin and desmoid tumors (Bulow, 1990; Gregory and Ho,
1992; Gurbuz et al., 1994; Leppard and Bussey, 1975; Leppard, 1974) while the TS patients are
often afflicted by medulloblastomas (Hamilton et al., 1995; Mori et al., 1994). No correlation
exists between specific mutant alleles of APC and the extracolonic manifestations of the FAP
disease listed above, suggesting the existence of other genetic elements that influence the formation
of these non-colonic tumors (Hamilton et al., 1995; Nishisho et al., 1991).
Mutations of APC are also important for the formation of sporadic colon carcinomas, in
that mutant alleles of this gene, created by somatic mutations, are found in 90% of the non-familial
cases of this disease (Miyoshi et al., 1992; Powell et al., 1992). Mutations of APC are found in the
same frequency in early-stage adenomas and advanced adenocarcinomas, indicating that the loss of
APC function plays an important role in an early step in colon cancer progression (Powell et al.,
1992).
The APC protein encodes a 312 kilodalton (Kd) cytoplasmic protein which has a series of
heptad repeats in its N-terminal 900 amino acids, seven armadillo repeats between amino acids 453
and 766, several beta-catenin binding sites in its middle third, and microtubule binding sites in its
C-terminus (Polakis, 1995). The N-terminal 171 amino acids of APC are sufficient for homo-
oligomerization of this protein in vitro although the minimal oligomerization domain of APC may
be smaller (Joslyn et al., 1993; Su et al., 1993). The large majority of APC mutations (>95%) are
chain-terminating mutations that result in the deletion of the C-terminal domains of the encoded
protein (Miyoshi et al., 1992).
Genetic studies have revealed a correlation between the site of mutation in the APC gene
and the severity of polyposis. One class of mutations are chain-terminating mutations in the third
and the fourth exons of APC, and affect the first 156 codons of the APC reading frame (Spirio et
al., 1993; Su et al., 1993). These mutations cause attenuated polyposis (AAPC) (Spirio et al.,
1993). In families carrying these alleles, some carriers develop no polyps even by the age of 40
while others may display as many as one hundred polyps (Spirio et al., 1993). The majority of
APC mutations belong to a second class that cause classical polyposis characterized by the
formation of hundreds to thousands of adenomas (Nagase et al., 1992). The boundary between
these two classes of mutations is very small: there are only ten codons that separate the most
downstream AAPC mutation from the most 5' mutation in a classical FAP family (Fodde et al.,
1992; Spirio et al., 1993; Spirio et al., 1992).
Two mechanistic models have been proposed to account for the difference in the severity of
the alleles that cause the attenuated and the classical polyposis (Spirio et al., 1993). One model
states that the AAPC alleles are true nulls and that the classical polyposis alleles, in contrast,
function in a dominant-negative fashion (Bourne, 1991; Spirio et al., 1993; Su et al., 1993). Thus,
the truncated APC proteins of classical polyposis patients may form a complex with and
compromise the functioning of co-expressed wild-type APC protein, resulting in a phenotypic
effect even in heterozygous colonic epithelial cells.
Studies to date have provided conflicting evidence on the mechanism of action of such
truncated gene products. For example, truncated APC proteins like the protein encoded by the
ApcMin allele caused by chain termination at codon 850 in the mouse Apc gene that in
heterozygous configuration (ApcMin/+) predisposes mice to multiple intestinal adenomas have
been shown to override a GO/G1 block imposed by wild type APC and cause the entry of cultured
NIH 3T3 cells into the S phase of the cell cycle (Baeg et al., 1995). Other evidence in favor of the
dominant-interfering hypothesis comes from recent experiments showing that the ApcMin allele,
co-expressed with wild-type allele in heterozygous intestinal cells, cooperates with the activated v-
Ha-ras gene to promote tumorigenesis in nude mice (D'Abaco et al., 1996).
Yet other observations argue against a dominant-negative mode of action of C-terminally
truncated APC proteins. Prominent among these observations is the report of three patients who
carried deletions of chromosome 5q21 encompassing the entire APC gene and developed classic
familial polyposis (Herrera et al., 1986; Joslyn et al., 1991; Lindgren et al., 1992). Another
observation that would seem to militate against the dominant-negative mode of action comes from
studies of mice, which have shown that the wild type allele of Apc gene is lost in nearly 100% of
the intestinal adenomas in the Min mice and other mice that carry C-terminal truncations of Apc
(Fodde et al., 1994; Laird et al., 1995; Levy et al., 1994; Luongo et al., 1994; Oshima et al.,
1995). This outcome can be interpreted in several ways. For example, the Apc Min allele may in
heterozygous configuration reduce but not eliminate the wild type function; the residual wild type
function may then be lost through deletion of the wild type allele, conferring even growth
advantage on intestinal epithelial cells. Finally, ectopic expression of truncated APC in the mouse
intestine failed to result in any pathology (Oshima et al., 1995). This result is also subject to
several interpretations. For instance, the introduced mutant Apc allele may not have been expressed
in the proper cells and in proper amounts to trigger polyp formation.
Another explanation for the low number of polyps in attenuated polyposis families was
proposed by Varesco et al., who observed that mutation of an intronic splice donor site results in
the skipping of exon 9, reduced levels of APC transcript, and a late onset polyposis in an FAP
family (Varesco et al., 1994). Although the effect of this and other AAPC mutations on the
expression of APC protein is not known, these investigators have proposed that inefficient splicing
could delay the onset of of polyposis (Varesco et al., 1994). Here we describe a germline mutation
in the mouse homologue of the APC gene (Apc) that drastically reduces but does not completely
eliminate the expression of APC protein. This mutation causes attenuated polyposis and supports
the model of Varesco et al. that the expression of small amounts of APC protein reduces the
severity of polyposis and a delay in the onset of disease. Moreover, the phenotype of the embryos
homozygous for this mutation connects the role of APC in differentiation with its role in
tumoriogenesis.
Materials and methods
8 del 8Construction of Apcand Apc- -- Tarreting Vectors
The Apc8 targeting vector was constructed by inserting fragments of murine Apc gene extending
from intron 7 to intron 8 (isolated from a 129Sv mouse genomic DNA library) into the plasmid
pPNT (Tybulewicz et al., 1991). The regions of homology consist of a 9.5 Kb and a 3.4 Kb
fragments. The pgk-neo -polA expression cassette was inserted at the Pml-I site in the eighth exon
of Apc leading to the generation of a new Eco RV restriction site within the eighth exon of a
targeted gene. The HSV-tk cassette (also under the control of the pgk promoter) was inserted
adjacent to the sequences from the eighth Apc intron. The HSV-tk and pgk-neo -polA cassettes are
transcribed in the same transcriptional orientation as the Apc gene. Southern analysis on Eco-RV-
digested DNA from Apc8/  mice using a probe from intron 8 displays an Apc8-specific 5.0 Kb
restriction fragment in addition to the 6.2 Kb fragment corresponding to the wild-type allele.
del 8The Apc targeting vector was constructed by introducing a termination codon at the
second codon of exon 8 by oligonucleotide insertional mutagenesis. The remaining sequences of
the eighth exon and a 0.9 Kb portion of intron 8 were deleted and replaced by the pgk-neo -polA
expression cassette. The neo and the HSV-tk cassettes were inserted in the same orientation as the
del 8Apc. The presence of the targeted Apc allele in the genomic DNA was detected by Southern
analysis on Hind ifI-digested genomic DNA using a probe from intron 7. This probe detected a 4.2
Kb band in the heterozygous cells in addition to the wild-type 7.0 Kb fragment.
Generation of Heterozygous Mice
Electroporation of Apc 8 and Apcdel 8 KO vectors into 129Sv D3 and J1 ES cells respectively,
subsequent drug selection (180 micrograms of G418 per ml of medium) and Southern blottings
were done using standard procedures. Chimeric mice were generated using techniques described in
Teratocarcinomas and Embryonic Stem Cells (Robertson, 1987). Chimeric animals were crossed
with 129Sv inbred mice and the progeny were progenies were screened for the Apc mutation. The
heterozygous progeny of this cross were inbred 129Sv.
Tumor Analysis
After euthanization, the entire gastrointestinal tract of a mouse was removed, dissected along the
cephalo-caudal axis, and washed in phosphate buffer saline. Adenomas were at least twice as wide
as a villus and at most 5-6 millimeters in diameter and were readily visible in the intestines upon
inspection under a dissecting microscope. Adenomas were removed surgically, fixed in Bouin's
fixative, dehydrated in graded solutions of alcohol, embedded in paraffin, sectioned at 6 gLm, and
stained with hematoxylin and eosin (H&E).
For LOH analysis, adenomas were removed surgically and DNA was prepared from them
using standard methods. The facial osteomas were freed from the normal surrounding tissue under
a dissecting microscope and DNA was prepared from the tumor. Southern blot analysis for the p53
locus was performed as previously described (Jacks et al., 1994).
All mice in this study were maintained in the facilities of the Whitehead Institute for
Biomedical Research and were fed ad libitum. Their diet consisted of Agway Prolab Rat, Mouse
and Hamster 3000 chow, which has a crude protein content of at least 22%, a crude fat content of
at least 5% and a crude fiber content of at most 5%.
Mouse Genotyping
Apc8 mice were genotyped by PCR using the primers (Apc Code:
5'AGCTTCAGAGTGGCCTA3', Apc Rev: 5'ACCTTTGTCCCCAGATG3' and Neo 18.5:
5'TCCTCGTGCTTTACGGTATC3'; one cycle of 1 minute (min) 95"C; followed by 30 cycles of
1 min 950C, 1 min 500C, 2 min 72"C; followed by one cycle of 5 min 72"C).
C57BL/B6 ApcMin + mice were purchased from the Jackson laboratory (Bar Harbor,
Maine) and crossed to 129 sv mice. 129 sv/B6 Min pups were genotyped by PCR (one cycle of 2
min 94"C; followed by 35 cycles of 1 min 94"C, 2 min 55 0C, 3 min 72"C; followed by one cycle
of 5 min 72"C) using oligos specific for the ApcM in
(5'2532TGAGAAAGACAGAAGTTA 25493') and the wild type allele
(5224 1GCCATCCCTTCACGTTAG 22583') and a universal downstream primer
(5'28 59TTCCACTTTGGCATAAGGC 284 13') (Luongo et al., 1994).
P53 mice were generated in the laboratory of R.A.W. (Jacks et al., 1994). Mice were
genotyped for the p53 locus using p53X6S (5'TTATGAGCCACCCGAGGT3'), p53X7AS
(5'TATACTCAGAGCCGGCCT3') and Neo 18.5 primers using the conditions used for the Apc 8
PCR.
ENU Mutagenesis
ENU was injected intraperitoneally and according to the protocol of Moser et al. (Moser et al.,
1993).
Generation of Homozygous Mutant and Control Embryonic Fibroblasts
Heterozygous inbred 129Sv Apc8/ + mice were intercrossed and embryos were extracted at E 11.5.
Cells were extracted from the embryos using the techniques in Teratocarcinomas and Embryonic
Stem Cells (Robertson, 1987) and genotyped for Apc 8 by PCR.
Generation of Homozygous Mutant Embryonic Stem Cells
Homozygous Apc8/ 8 ES cells were generated from 129Sv Apc8/ + ES cells using the techniques of
Mortensen et al.(Mortensen et al., 1992). 104or 105 heterozygous cells were plated on gelatinized
10-cm dishes and 24 hours later medium containing 400 to 600 micrograms of G418 per ml of
medium was added to the cells. In each dish, on average ten colonies survived two weeks of
culturing in medium containing G418. These colonies were picked, passaged and genotyped. Ten
percent of the picked colonies had lost the wild type allele of Apc and showed only the mutant
DNA fragment upon Southern analysis (data not shown). We assumed that these colonies had lost
the wild type Apc and duplicated the Apc8 allele and its pgk-neo-polA cassette and thus became
resistant to high concentrations of G418 by virtue of having two copies of the neo. The colonies
that survived high G418 but remained heterozygous served as the control for the homozygous
mutant cells. The homozygous mutant or the control heterozygous ES cells were injected into
C57BL/6 blastocysts to generate chimeric mice.
C57BL/6 ApcMin/ M in ES cells were generated using the protocols in Teratocarcinomas
and Embryonic Stem Cells (Robertson, 1987).
Protein Analysis
Western blottings were performed using the FE9 anti-N-terminal APC monoclonal antibody
(Oncogene Science) and using 3% low melting agarose gels according to the protocol of Smith et
al. (Smith et al., 1993). Total cellular protein was extracted from cells using two buffers: a
denaturing buffer (125 millimolar (mM) Tris-HC1 PH 6.8, 20% V/V Glycerol, 2% W/V SDS, 2%
V/V betamercaptoethanol, 0.001% W/V bromophenol Blue) or a non-denaturing buffer (50 mM
Tris-HC1 PH 7.5; 100 mM NaCl, 1% NP40, 1 mM PMSF, 1 microgram/ml Aprotinin and
Leupeptin each). APC protein was readily detectable in the agarose westerns performed on the
denatured extracts but the existence of SDS in the buffer was incompatible with the standard
protein assays used to quantify the concentration of protein. On the other hand, the use of the non-
denaturing buffer allowed us to measure the concentration of protein in the extracts but prevented
the detection of APC protein using the FE9 antibody. Thus for each western blot, the experiment
was done in two parts. The cells in each preparation were counted and protein was extracted from
one half using the non-denaturing buffer and from the second half using an equal volume of
denaturing buffer. The protein concentration was measured in the non-denaturing preparation and
the volume of the extract that contained 5 milligrams of total protein was determined. Then, an
equal fraction of the denatured preparation was western blotted. This method of quantitation was
relatively accurate because equal fractions of the two preparations contained equal amounts of the
retinoblastoma protein used as internal standard (data not shown). The ratio of the amount of APC
protein in the lanes corresponding to wild-type and the Apc8/ 8 mutant cells was determined using a
Computing Densitometer (Model 300A, Molecular Dynamics).
RNA Analysis
Reverse transcription (RT) using random hexamer oligos and PCR were performed using standard
protocols. Primers used in the RTPCR analyses on the total cellular RNA in the sense orientation
were Apc exon 1 (5 67 CTTCGACAAGAGCTAGAAG 853'), Apc exon 3
(5'27 9 CTACGGAAGTCGGGAAGG 29 63'), Apc exon 6
(5' 644GAATAGCCAGGATCCAGC 66 13'), Apc exon 7
(5'727TCATCTCAGAGCAGGCAT7443'), Apc exon 9
(5' 023CTGTATATCCATGCGGCAG 10413') and Apc exon 9a
(5' 249ACCTGTTGGGAGTGGCAG 2673'). The primers in the antisense orientation were Apc
exon 5 (5'548 GTCATGTCTGTCTGTAAGG 5 30 3'), Apc exon 9
(5' CTGCCGCATGGATATACAG 102 3')' Apc exon 10
(5' 1328ATGCTCAACAGGAGCTGG310 3') and Apc exon 14
(5' 1756CGCTITTGAGGGTTGATTC 17 383'). Sequencing of the PCR reaction products was
performed according to the protocol of Sarkar et al. (Sarkar et al., 1993).
Results
Construction of Apc8 + mice
To create a mutation altering the murine homologue of the APC gene (Apc), we constructed
a vector that targets the eighth exon of this gene which spans codons 278-311 (Fig. lA). This
targeted mutation was designed to recapitulate a mutation in the eighth exon that was found in a
Gardner's syndrome family (Nishisho et al., 1991).
The Apc8 targeting vector (Fig. lA) was introduced into 129/Sv D3 embryonic stem (ES)
cells (Gossler et al., 1986; Mansour et al., 1988; Robertson, 1987). The resulting ES cell colonies
were screened for those in which alteration of an Apc gene had occurred through homologous
recombination with this vector. Of two hundred G418- and gancyclovir-resistant ES cell clones
screened, three had targeted a copy of the neomycin transferase (neo) gene into the Apc locus by
homologous recombination (data not shown). Mouse chimeras generated by two of the
heterozygous ES cell clones transmitted the mutant Apc through their germline (Fig. IB). Breeding
of resulting heterozygous Apc mice resulted in no viable homozygous offspring, indicating that
the functioning of the Apc gene is essential for normal development. As described below,
homozygous mutant embryos die between days 9.5 and 12.5 of development.
Figure 1
(A) The Apc 8 targeting vector was constructed using fragments of murine Apc gene extending
from intron 7 to intron 8. The regions of homology consist of a 9.5 Kb and a 3.4 Kb fragments.
The pgk-neo -polA expression cassette was inserted at the Pml-I site in the eighth exon of Apc
leading to the generation of a new Eco RV restriction site within the eighth exon of a targeted gene.
The HSV-tk cassette (also under the control of the pgk promoter) was inserted adjacent to the
sequences from the eighth Apc intron. The HSV-tk and pgk-neo -polA cassettes are transcribed in
the same transcriptional orientation as the Apc gene (shown with an arrow). X (Xba I), H (Hind
III), RV (Eco RV), P (Pml I) and K (Kpn I) are restriction endonuclease sites. (B) Germ-line
transmission of Apc 8 . Southern analysis on Eco-RV-digested DNA from Apc8/ + mice using a
probe from intron 8 displayed an Apc8-specific 5.0 Kb restriction fragment in addition to the 6.2
Kb fragment corresponding to the wild-type allele. Lanes 2, 5, 6, 7, and 9 correspond to
heterozygote mice. Lane 10 is DNA size marker.
A
Wild Type Allele
X H
II
P
RV X X
Exon 8
HH H RV X
PI I I I
PROBE = 0.6 Kb
jI 6-6 .2 Kb -
Apc8 Knock-out Vector
RV
X X H H RV X 1 I  X
Exon 8
Exon 8
Apc 8 Allele
XH
I I
I I
RV
I
RV
X o X X
xon 8
K RV
HH IRV RV
TK
HH H RV
PROBE = 0.6 Kb
5.0 Kb
B
Mut
12345678910
X H
I I
I
'' ''
Expression of Targeted Apc8-Allele
The APC protein is expressed ubiquitously in most if not all human cell types (Groden et
al., 1991; Kinzler et al., 1991). To examine the effect of the targeted mutation on Apc expression,
we examined the expression of the mouse APC protein in homozygous Apc8 embryonic
fibroblasts (EF) using a monoclonal antibody that recognizes the N-terminus of human APC
(Smith et al., 1993). The Apc 8/ 8 fibroblasts were prepared from embryos at day 11.5 of gestation.
Embryo fibroblasts were used in this experiment because cultures of Apc8/ 8 intestinal epithelial
cells were difficult to establish.
While protein species corresponding to the full-length 300 kd APC protein were present in
the immunoprecipitates derived from both wild-type and heterozygous cells, neither a truncated nor
a full-length APCprotein was detectable in the lanes corresponding to theApc8/8 embryo
fibroblasts upon initial western immunoblot analysis (Fig. 2A). However, upon extended exposure
of lanes containing several-fold more protein from Apc 8/ 8 cells, an apparently full-length APC
protein was detectable. Densitometric analysis of three independently prepared homozygous mutant
and control cell lysates showed expression of an apparently full-length APC protein in
homozygous mutant Apc8/ 8 cells at significantly reduced levels compared to those seen in wild-
type cells (Fig. 2A).We estimated from densitometric analysis of these gels that intensity of the
APC protein band from the homozygous mutant cells were at most one percent of that seen in the
wild-type cells.
Figure 2
Comparison of the effects of Apc8 and Apc in mutations on Apc expression. (A) The APC
protein was western blotted using an anti-N-terminal antibody (Smith et al., 1993) .Lanes 1 and 2
are control wild-type 129 embryonic fibroblasts and lanes 3 and 4 correspond to fibroblasts from
homozygous mutant Apc8/ 8 littermates. The location of electrophoretic migration of wild-type
APC (300 Kd) and the truncated Min (100 Kd) protein are indicated by arrows. Lanes 5 and 6
Min/+ Min/Min
correspond to C57BL/6 Apc and Apc embryonic stem cells. (B) Products of PCR
reactions on reverse-transcribed RNA from 129Sv Apc +/ + control and 129Sv Apc8/ 8 embryonic
fibroblasts are shown in Lanes 1 and 2, respectively. The wild type and the mutant cells each
express two mRNA species. In each lane, the larger species correspond to the mRNA molecules
containing exon 9a and the smaller species correspond to the mRNA molecules without exon 9a.
Both species in Apc81 cells also lack the 99 nucleotides corresponding to exon 8 into which the
pgk-neo cassette was targeted. The exons contained in each mRNA species are displayed
graphically next to them. The mRNA species spanning exons 7-15 of Apc were amplified using
Apc exon7-2 (5'798AAGCAACACCGCAGCCTCCAGTAGT 8223') and Apc exon 15
(5,22 96 GCTGAGCATCTAGTCTAGCTTCTAG 22 72 3') primers. From each population of cells,
equal amounts of RNA were used in the reverse transcription and the follow-up PCR reactions.

Reverse transcription of total cellular RNA followed by polymerase chain reaction analysis
(RTPCR) using primers to several exons of Apc (including exons 1, 3, 5, 6, 7, 9, 9a, 10, 14 and
15) showed that all known alternatively spliced Apc mRNA species were expressed at reduced
leves in the Apc cells and that the mRNA species contained all exons of the Apc gene save the
eighth (Fig. 2B). This exon is composed of 99 nucleotides; hence, upon translation, an mRNA
resulting from deletion of this 8th exon would yield a polypeptide 33 amino acids shorter than its
wild-type counterpart. This truncated protein would not be resolvable from the wild-type APC
protein in our western blot analyses.
We concluded that the mutation that we created by homologous recombination in the Apc
gene has two effects on its expression: the fusion of the 7th directly to the 9th exon of the
processed mRNA and a reduction in the level of this RNA. Together, these effects resulted in the
synthesis of APC protein molecules lacking the residues encoded by the 8th exon that are
expressed at a small fraction (<1%) of the wild type level.
The functionality of this minimally truncated APC protein has been addressed by other
investigators by engineering a second distinct mutant allele of Apc that we have termed Apcdel 8
and also results in the precise deletion of the eighth exon from the Apc mRNA. To create this
allele, oligonucleotide insertion was used to introduce a translation termination codon at codon 270
(Fig. 3). The mutation also deletes a 1.0 Kb fragment of Apc that includes codons 282-311 of
exon 8 and the 5' portion of intron 8, and replaces it with a copy of the pgk-neo -polA cassette
(Fig. 3). PCR-amplification of the reverse-transcribed products of RNA from homozygous Apcdel
88 embryonic fibroblasts and colonic tissues, followed by sequencing of the PCR products
confirmed, as was the case with the Apc 8 allele described above, the direct fusion of the seventh to
the ninth exon of the mRNA species (data not shown). However, in contrast to Apc 8 , the Apcd e l 8
allele yields mRNA and protein at levels that are equivalent to those associated with the wild-type
Apc gene (data not shown).
Figure 3
del 8The Apc targeting vector was constructed by introducing a termination codon at the second
codon of exon 8 by oligonucleotide insertional mutagenesis. The remaining sequences of the eighth
exon and a 0.9 Kb portion of intron 8 were deleted and replaced by the pgk-neo -polA expression
cassette. The neo and the HSV-tk cassettes were inserted in the same orientation as the Apc. The
del 8presence of the targeted Apc allele in the genomic DNA was detected by Southern analysis on
Hind lII-digested genomic DNA using a probe from intron 7. This probe detects a 4.2 Kb band in
the heterozygote cells in addition to the wild-type 7.0 Kb fragment.
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del 8Mice homozygous for the Apc allele develop normally, do not develop polyps, and are
indistinguishable from wild-type mice for the first 2 years of age. The normal development of
del8/del8 del8/+ del8/del8Apc embryos and the absence of tumors in the adult Apc and Apc mice
demonstrated that the slightly truncated APC protein lacking the residues encoded by the 8th exon
is fully functional. Hence, we deduce that the Apc8 allele expresses essentially wild-type protein
but at a severely reduced level and that any phenotypic effects associated with the Apce allele must
be ascribed to its very low level of expression.
We also examined the effect on protein expression of the ApcMin allele, which carries a
Min
nonsense mutation in the fifteenth exon of the mouse Apc gene-(Apc , codon 850) that was
induced by chemical mutagenesis (Moser et al., 1990; Su et al., 1992). ApcMin/Min embryos die
by E7.5, making it impossible to generate ApcMin/Min embyonic fibroblasts. Instead, the effect of
the ApcMin mutation on APC expression was analyzed in the embyonic stem cells. Western
blotting analyses on ApcMin/+ and homozygous ApcM in/ M in ES cells revealed that, in contrast to
Apc8, the ApcM in allele encodes a truncated protein (100 Kd); this ApcMin -encoded protein is
Min/+
coexpressed with wild-type protein (300 Kd) at comparable levels in the Apc cells (Fig. 2A).
Spontaneous Polyp Initiation in The Aipc8- Mice
In human carriers of mutant APC alleles, the adenomatous polyps in the colon usually
become apparent only by 20-30 years of age (Groden et al., 1991; Nishisho et al., 1991; Spirio et
8/+
al., 1993). For this reason, we followed 129Sv/C57BL6 (129Sv/B6) Fl Apc mice and their
wild-type littermates for a period of two years, screening at different ages for the presence of
gastrointestinal polyps. Intestinal adenomas were found in Apc8 /+ mice only when they reached
one-and-a-half to two years of age (Table 1 & Fig. 4A). Even at this advanced age, forty percent of
the heterozygotes were free of polyps. The number of polyps in the heterozygotes ranged between
zero and seven with an average of one adenoma per mouse (Table 1). We also examined fifty-eight
wild-type 129Sv/B6 Fl mice aged between one-and-a-half and two years and found no adenomas
in any of these control mice (Table 1).
Table 1
Intestinal Adenomas (Polyps). The effect of germline inheritance of the Apc8 and ApcMin
mutations on intestinal adenoma formation in 129/B6 Fl mice were compared by counting the
number of adenomas in the intestine of Apc8/+ and ApcMinW+ mice under a dissecting microscope.
Effects of alleles of Apc on formation of intestinal polyps
Mouse # of Mice Age Average # of Polyps Range
(mo) per Mouse
129sv/B6 F1 Apc 8 /+ 63 18-24 1 0-7
129sv/B6 F1 ApcMin/+ 20 5-10 110 45-135
129sv/B6 F1 Apc+/+ 58 18-24 0 NA
Figure 4
Tumors in Apc8 mice. (A) An intestinal adenoma from a 129Sv/B6 Fl Apc8/ + mouse (93X
magnification). (B) The arrow points to a unilateral facial osteoma in a 12-month-old 129Sv
Apc8 + p53 +  mouse. (C) Foci of squamous cell metaplasia of the salivary gland (arrows) in a
129Sv/B6 Fl Apc 8/ + mouse (400X magnification).
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The hallmark of a tumor suppressor gene is the inactivation of both of its alleles in a tumor
cell (Weinberg, 1991). For this reason, we undertook Southern blot analysis of the genomic DNA
of polyps removed from Apc81 mice. These polyps were composed of both epithelium-derived
adenomatous cells and contaminating mesenchymal cells including fibroblasts, macrophages and
other blood cells. When compared to the constitutional DNA of the heterozygotes, genomic DNA
from the great majority of these adenomas displayed a reduced ratio of the wild-type to the mutant
Apc8 allele; Fig. 5A represents some examples of analysis of these adenomas. These results
suggest that the wild type Apc allele was lost from many and perhaps all of these polyps. This in
turn suggests that the Apc8 allele has minimal effect on cell phenotype when present in a
heterozygous configuration and that it acts in a recessive manner on intestinal epithelial cells.
Figure 5
Loss of heterozygosity (LOH) in tumors. (A) LOH at the Apc locus in the intestinal adenomas and
the facial osteomas from mice carrying the Apc8 allele. Lane 1 is control tail DNA from a
heterozygous 129Sv Apc 8/ + p53 +/ mouse. Lanes 2-7 are facial osteomas from 129Sv Apc8/ +
p53 +/ mice. Lanes 8-10 are three intestinal adenomas from a 129Sv/B6 F1 Apc 81 mouse. The
arrows depict the 6.2 Kb wild-type Apc and the 5.0 Kb mutant Apc8 fragments. (B) LOH at the
p53 locus in the facial osteomas. Lanes 1-4 are facial osteomas from 129Sv Apc 8 + p53+  mice.
The Top arrow points to the mutant 3.0 Kb band and the middle arrow to the 1.3 Kb wild-type
band. The lowest arrow marks the 1.0 Kb fragment which appears due to cross-hybridization of
the probe to DNA corresponding to a p53 pseudogene. Lane 5 is DNA size marker.
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We then compared these Apc8/+ mice with those of the Min strain. The ApcMin mutation is
similar to those mutations in humans that result in the classical polyposis characterized by the
formation of hundreds of adenomas. This class of mutations encode truncated proteins that retain
the oligomerization repeats. In stark contrast to the Ap8 heterozygotes, mice carrying the ApcM in
mutation in an identical genetic background and raised in the same colony developed an average of
110 adenomas within 150 days (Table 1). These Min mice died by 5-10 months of age from
intestinal obstruction (Table 1), confirming earlier reports of others (Moser et al., 1990).
Therefore, as is the case in humans, distinct mutant alleles of the Apc gene cause the development
of profoundly different numbers of adenomatous polyps in mice.
Fifteen percent of all 129Sv/B6 mice developed lymphomas, leukemia, sarcomas or lung
adenomas by 24 months of age regardless of their genotype at the Apc locus. Since, the Apc+/+
mice developed the same frequency of these tumors as the Apc8/+ mice did (data not shown), we
concluded that these extra-colonic lesions arose due to the intrinsic cancer predisposition of mice
having a 129Sv/B6 genetic background.
Effect of ENU Mutagenesis on Polyp Initiation in Apc&8  Mice
The effects of the Apc 8 mutation on intestinal polyp formation was also gauged by
exposing an F1 litter, derived from a cross of a 129Sv Apc8/ + heterozygote with a wild-type
C57BL/6 mouse, to the alkylating carcinogen ethylnitrosourea (ENU). These mice were exposed
to a single ENU dose of 50 micrograms per gram of body weight at 105 days of age. The animals
were not genotyped at the time of injection to ensure identical treatment of wild-type and
heterozygous mice. A total of 60 polyps were found in six heterogzygous mice (average of 10 with
a range of 8-12 polyps per mouse) while none were found in their five wild type littermates.
Southern blot analysis of the genomic DNA of ten polyps removed from ENU-treated
Apc mice showed the presence of the bands of equal intensities corresponding to both the Apc
and the wild-type allele of Apc (data not shown). These results suggested, though did not prove,
that ENU-mediated inactivation of the wild-type Apc allele had accelerated the formation of polyps
in the Apc8/+ mice. More importantly, they demonstrated that the Apc 8 allele can predispose to
greatly increased rates of polyp formation under certain experimental conditions.
Extracolonic Tumors in The Apc8 ±+ Mice
Members of some human FAP families display extracolonic tumors, most commonly facial
osteomas, epidermoid cysts, or one of a variety of fibromas, a condition known as Gardner's
syndrome (Bulow, 1990; Gregory and Ho, 1992; Gurbuz et al., 1994; Leppard and Bussey, 1975;
Leppard, 1974). In such families, some carriers develop both colonic and extracolonic
abnormalities while others exhibit only growths in the colon (Nishisho et al., 1991). This suggests
the involvement of yet other genes that influence the development of the extracolonic tumors.
In the 129Sv or 129Sv/B6 mice carrying the Apc8 mutation, such extracolonic growths
were not observable. In order to ascertain whether the Apc8 allele might cause such extracolonic
tumors in another genetic background, we crossed 129Sv Apc8  mice with mice lacking one copy
+1-
of the p53 tumor suppressor gene (129Sv p53 ) (Jacks et al., 1994). As documented by others,
mice inheriting a mutant p53 gene are predisposed to a variety of tumors (Donehower et al., 1992;
Jacks et al., 1994). In a cohort of seventeen 129Sv Apc8 + p53 + / mice aged between 12 to 18
months, fifteen mice developed unilateral and the remaining two mice developed bilateral osteomas
of the facial bones. These affected the maxillary and mandibular bones and occasionally the orbital
bones and those of the skull (Fig. 4B & Table 2). Southern blot analysis of the DNA extracted
from these facial osteomas confirmed that the tumors had lost the wild type allele of both Apc and
p53 and had retained the targeted alleles of both genes (Fig. 5, A and B).
Table 2
Facial Osteomas. Mice with mutations of Apc 8 or ApcMin with or without mutations of p53 were
monitored for up to two years for signs of facial osteomas. C57BL/6 ApcMin/+ or 129 Apc8/ +
mice were crossed to 129 p53+!- mice and their Fl and F2 progeny were monitored closely.
Effects of alleles of Apc on formation offacial osteomas
Mouse Mice with Facial Osteoma Age
Mice Generated (mo)
129sv Apc8 /+p53+/- 17/17 12-18
129sv Apc8 /+ 0/77 18-24
129sv/B6 F1 Apc8 /+ 0/63 18-24
129sv/B6 F1 ApcMin/+ 0/55 5-10
129sv/B6 F1 ApcMin/+ p53+/- 0/24 5-10
129sv/B6 F2 ApcMinl/+ p53-/- 0/35 2-6
129sv p53+/- 0/46 12-18
129sv/B6 F1 p53+/- 0/43 12-18
129sv/B6 F2 p53-/- 0/38 2-6
+/-We have not observed this unusual tumor in a series of 46 129Sv p53 or 38 other
129Sv/B6 p53 mice (Table 2). This observation indicates that Apc8 mutation can also predispose
mice to an unusual extracolonic tumor seen in humans carrying mutations at the APC locus. We
also observed that these facial osteomas had a high propensity of metastasizing into the lung and
the liver. We have not detected any facial osteomas in a cohort composed of 55 (129Sv/B6 Fl)
Min/+ Min/+ +/- Min/+ -/-Apc i n , 24 (129Sv/B6 F) Apc p53 and 35 (129Sv/B6 F2) Apc p53 mice,
perhaps because these mice die from intestinal obstruction or p53-specific tumors within 2-10
months (Table 2).
P53 dosage reduction did not affect polyp initiation as measured by the number of intestinal
adenomas or polyp progression as judged by increase in size, degree of dysplasia or the acquisition
of an invasive phenotype in either the Apc8/ + or ApcMin/+ mice. We concluded from this study
that, when in heterozygous configuration, Apc8 allele predisposes mice to one of the extracolonic
tumors of Gardner's syndrome.
Aberrant Differentiation in Adult Apc-8 + Mice
Seventy percent of Apc8/+ mice also developed squamous cell metaplasia of the salivary
glands (Fig. 4C). These lesions were composed of keratin-filled cysts surrounded by one or a few
layers of squamous cells. Such lesions reflect abnormal differentiation of the salivary gland
epithelial cells in that this gland is normally devoid of squamous cells. Whether these lesions have
lost the wild type allele of Apc was not determined due to the difficulty in isolating them and their
microscopic size. In two instances, the Apc8/+ mice were affected by squamous cell carcinomas of
the salivary gland. These two tumors were composed of large numbers of keratin cysts surrounded
by squamous cells (data not shown). This suggests that these squamous lesions of the salivary
gland have a propensity to progress to tumors. Moreover, the Harderian gland of approximately
10% of the Apc 8/+ mice also contained similar squamous cysts. We also note that none of their the
Apc+/+ littermates developed these squamous lesions.
APC And Embryonic Development
As mentioned above, breeding of heterozygous Apc8 / mice resulted in no viable
homozygous offspring, confirming the reports of others that the functioning of the Apc gene is
essential for normal development (Moser et al., 1995). To understand the effects of Apc 8 on
mouse development, we examined litters from the crosses between Apc8/+ mice during E 8.5 and
E 17.5 of gestation. One fourth of the embryos were homozygous mutant at E9.5 of gestation but
the fraction of the homozygous mutants decreased in later stages of development. Only two
homozygous mutant embryos were found in a group of 40 embryos isolated at E12.5 and no
mutant embryos were obtained thereafter. The phenotype of Apc8/ 8 embryos is less severe than the
phenotype of the ApcMin/ M i n embryos, which die by E 7.5 (Moser et al., 1995).
The organs of the homozygous mutant embryos caudal to the brachial region had a normal
appearance (Fig. 6, A & C). Histological examination of embryos at E 11.5 revealed that the
viscera including the primitive gut had developed normally although this was not confirmed by
immnuohistochemical analysis using differentiation-specific markers.
The Apc8/ 8 embryos displayed clear defects in craniofacial development (Fig. 6C). While
closure of the neural tube in the wild type and the heterozygous embryos was complete by E 9 of
gestation, the rostral end of the neural tube remained open in all homozygous mutant Apc 818
embryos. Furthermore, the embryonic mesenchyme that is the progenitor of the bones of the face
and the skull was severely malformed (arrow in Fig. 6C).Based on these observations, we
speculated that normal APC is required for the normal development of the bones in the head and
the face, the same bones that are inflicted with osteomas in adult Gardner's syndrome patients.
This notion was reinforced through the creation of the chimeras described below.
Figure 6
Effect of Apc8 on embryonic development. (A) An Apc +/ + and its Apc8/ 8 littermate (right) at
El 1.5. (B) Mid-sagittal section of an Apc+/ + at El 1.5. (C) Mid-sagittal section of an Apc8/ 8 at
El 1.5. Embryonic mesenchyme (arrow) that is the progenitor of the facial bones in the adult
mouse develops abnormally.

APC And Tissue Formation
The early death in utero of Apc8 homozygotes prevented us from assessing the full effects
of loss of Apc on the development and differentiation in most organ systems. To circumvent this
difficulty, we generated chimeric embryos composed in part of homozygous mutant cells. We first
8/8 8/+
created homozygous mutant Apc88 ES cells by subjecting the 129Sv heterozygous Apc ES
cells to high concentrations of the drug G418 (Mortensen et al., 1992). These homozygous cells as
well as heterozygous control ES cells that had retained the wild-type Apc following selection in
high G418 were injected into wild-type C57BL/6 (B6) blastocysts.
Control chimeras created by injection of three independent clones of heterozygous Apc8/+
ES cells that had remained heterozygous following G418 selection appeared normal at birth and for
the one year that followed, even when these ES cells contributed to as much as 90% of the coat
color in the chimeras. Descendants of these introduced heterozygous ES cells contributed to the
germline tissue of chimeric mice, indicating that the earlier exposure of ES cells to high
concentration of G418 did not have any deleterious effect on them.
In contrast, all chimeric mice derived from blastocysts injected with homozygous mutant
Apc8 8 cells died hours after birth. Injection of as few as two Apc 8/ 8 cells per 64-cell blastocyst
resulted in the formation of craniofacial abnormalities in the newborns. Some pups were
anencephalic while others were born with an open cranium and cleft palate (data not shown).
Moreover, 2/20 of the embryos developed craniopharyngiomas (Fig. 7A), which in humans is
seen as a rare childhood brain tumor.
In addition, the homozygous mutant chimeras developed numerous skin fibromas termed
alternatively acrocorns or cutaneous tags (Fig. 7, C & D). These benign lesions, often present in
several dozen per animal, were sometimes several millimeters in length and were found more
commonly on the extremities and the face. The cells of hair follicles also formed abnormal
structures termed epidermoid hair cysts (Fig. 7E). We observed the largest number of the skin
fibromas in those chimeras that we generated through injection of 10-20 homozygous mutant cells
per embryo. Glucose phosphate isomerase (GPI) enzyme analysis, which shows the relative ratio
of the isomers expressed by the 129 or B6 cells in a chimeric tissue, of several of these fibromas
showed that they were composed of 40% 129Sv Apc 8/ 8 cells and 60% B6 Apc +/ + cells (data not
shown).
The newborn Apc 8/ 8 chimeras also displayed squamous cell metaplasia of the salivary and
the harderian glands which was indistinguishable from that observed in the adult Apc8/ + mice
(Fig. 7F). Furthermore, a large fraction of the villi in the intestine of these chimeras had a dilated
appearance. The connection between the formation of these dilated villi and the formation of
adenomatous polyps remains unclear at present.
Finally, the facial bones in the Apc8/8 chimeras looked overgrown upon gross
examination. Histological examination revealed that all intramembraneous bones in the
homozygous mutant Apc 8/ 8 chimeric newborns were dysplastic and displayed early signs of bone
tumors (Fig. 7B). However, the endochondral bones that include the majority of the bones in the
body displayed normal morphology when examined histologically (data not shown).
Figure 7
Effect of Apc 8 on tissue formation and differentiation in newborn chimeras composed of C57BL/6
Apc+/ + and 129Sv Apc8/ 8 cells. (A) Craniopharyngioma (arrow, 50X magnification). (B) A
dysplastic facial intramemraneous bone (arrows, 200X magnification). (C) Superficial view of
skin fibromas (arrows, 6X magnification). (D) Histology of a skin fibroma (arrow, 20X
magnification). (E) Epidermoid hair cyst (black arrow) and the finger-like projections of epithelial
cells into dermal mesenchyme (white arrow) in skin (200X magnification). (F) Squamous cell
metaplasia of the salivary gland (arrow, 400X magnification). (G) Transverse section of the
normal villi in the intestine of newborn chimeras (arrows, 100X magnification). (H) Transverse
section of the dilated villi in the intestine of newborn chimeras composed of C57BL/6 Apc+/ + and
129Sv Apc8/ 8 cells (arrows, 100X magnification).
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Discussion
Hypomorphic Alleles of APC As The Cause of Human Attenuated Polyposis
In the present study, we have compared the effects on polyp formation of two alleles of the
murine homologue of the Adenomatous Polyposis Coli gene (Apc), one causing a drastic reduction
in the expression of Apc and another encoding a truncated APC protein. We observed that mice
expressing wild-type APC protein at levels slightly more than 50% of normal, as seen in
heterozygous Apc8 + mutants, developed an average of one polyp after 18 months, while other
Min/+
mice expressing 50% wild-type protein and 50% truncated protein, as seen in the Apc
heterozygotes, developed an average of 110 polyps in five months (Fig. 2A & Table 1). It is
unlikely that the observed difference in polyp number in the Apc8/ + and ApcMin/ + mice was
caused by loci other than Apc because the effects of genetics and environment were controlled by
expressing both alleles in mice of common genetic background and raising the mice in the same
environment.
The findings of the present study are subject to two interpretations. One proposes that an
allele encoding a truncated form of APC (ApcMin) capable of oligomerization creates many polyps
while an allele making very little full length protein (Apc8) is unable to do so.While our results are
suggestive of and are compatible with a dominant-negative mechanism of action of truncated forms
of the APC protein, they do not provide definitive evidence in favor of it.
Instead, our findings show that another mechanism, that proposed by Varesco et al., can
explain the low polyp number in the AAPC families. Our findings support the notion that
hypomorphic alleles of APC that reduce but do not completely eliminate APC expression can
suppress polyp formation and cause attenuated polyposis when transmitted through the germline.
According to this interpretation, the mutant Apc8 allele studied here, through expressing
approximately 1% of an essentially wild type protein, is able to regulate cell proliferation in a
relatively normal fashion, even when present in a homozygous configuration. This in turn would
suppress the tendency of the intestinal epithelium to spawn polyps.
APC And Differentiation of Intramembraneous Bones
The present study indicates that APC plays an important role in both normal differentiation
and in the suppression of cellular proliferation in developing intramembraneous bones. The
mesenchyme that is the embryonic progenitor of the bones in the face and the skull develops
abnormally in Apc8/ 8 embryos (Fig. 6). Moreover, by the last day of embryonic development,
these embryonic tissues form bones that are dysplastic and display early signs of tumor phenotype
(Fig. 7B). This suggests that mutant alleles of APC compromise normal differentiation and
simultaneously initiate benign growths in the facial bones. Moreover, osteomas that progress to
tumors arise in the bones of the face and the skull of 129 Apc8/ + p53+/ - mice (Fig. 4B & Table 2),
the same small group of bones whose differentiation is abrogated by the loss of APC in
development. These effects in turn may explain the predisposition of these bones to subsequent
transformation, resulting in the osteomas that are seen in patients suffering from Gardner's
syndrome. Based on these observations, we propose that APC-deficient cells in these tissues fail to
participate in terminal differentiation, and that this failure in turn places them at risk for subsequent
events leading to neoplasms.
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CHAPTER 3
Suppression of Intestinal Neoplasia by DNA Hypomethylation in Mice
Introduction
Methylation of mammalian DNA is found as the covalent modification of the fifth carbon position
of the pyrimidine ring of cytosines in CpG dinucleotides (Adams and Burdon, 1982; Antequera
and Bird, 1993; Gardiner-Garden and Frommer, 1987). Newly replicated DNA lacks this
methylation in the nascent strand. Shortly after passage of the replication fork, a maintenance DNA
methyltransferase methylates CpG dinucleotides on the newly synthesized strand at sites opposite
to those methylated in the parental strand, thereby recreating the spectrum of methyl groups that
existed prior to replication. To date, only one mammalian DNA (cytosine-5) methyltransferase
enzyme (EC 2.1.1.37) has been identified and characterized (Bestor et al., 1988; Leonhardt and
Bestor, 1993). The carboxy-terminal part of this protein shares sequence similarity with the
conserved catalytic domain of prokaryotic DNA (cytosine-5) methyltransferases (Kumar et al.,
1994; Lauster et al., 1989; Posfai et al., 1989). The mammalian enzyme has an additional large
amino-terminal extension lacking sequence similarity to other known DNA methyltransferases.
This amino-terminal region is thought to be a regulatory domain and is known to contain signals
necessary for the targeted localization of the enzyme to replication foci in the nucleus (Leonhardt et
al., 1992).
Changes in the pattern of DNA methylation have been correlated with a number of different
processes in mammals. These include the expression level of genes (Yeivin and Razin, 1993),
chromatin structure (Kass et al., 1993; Keshet et al., 1986; Tazi and Bird, 1990), the timing of
DNA replication (Selig et al., 1988), genomic imprinting (Barlow, 1993; Li et al., 1993) and
somatic X-chromosomal inactivation in females (Monk and Grant, 1990; Singer-Sam and Riggs,
1993). Whether DNA methylation is a cause or consequence of these processes remains to be
resolved. Nevertheless, it is clear that DNA methylation is an essential process in mammalian
development, since mouse embryos deficient for the known DNA methyltransferase do not survive
past mid-gestation (Li et al., 1992).
Several observations implicate DNA methylation in cancer pathogenesis. Changes in the
pattern of DNA methylation are commonly seen in human tumors (Baylin et al., 1991; Jones and
Buckley, 1990; Laird and Jaenisch, 1994; Spruck et al., 1993). Some loci tend to show increased
levels of DNA methylation (Baylin, 1992; Issa et al., 1994; Ohtani-Fujita et al., 1993), while
others are hypomethylated (Feinberg and Vogelstein, 1983; Feinberg and Vogelstein, 1983; Goelz
et al., 1985; Hanada et al., 1993; Rao et al., 1989; Vorce and Goodman, 1991). The global level
of DNA methylation is generally lower in tumor cells than in normal cells (Feinberg et al., 1988;
Gama-Sosa et al., 1983). This decrease in the overall level of DNA methylation is curious in light
of the normal to high levels of DNA methyltransferase expression usually seen in tumor cells (El-
Deiry et al., 1991; Issa et al., 1993; Kautiainen and Jones, 1986).
Some investigators have proposed that changes in DNA methylation contribute to
oncogenesis by affecting the expression levels of proto-oncogenes and tumor-suppressor genes.
Thus, DNA hypomethylation would allow increased expression of oncogenes; alternatively, DNA
hypermethylation would help to silence tumor-suppressor genes. However, there is no direct
evidence that either mechanism is operative in oncogenesis. Indeed, it is not even clear whether the
changes in DNA methylation play a causal role in oncogenesis or whether they are merely a
consequence of the transformed state of the tumor cell.
We have designed experiments in an attempt to distinguish between these alternatives.
Using a combination of genetics and pharmacology, we have manipulated the levels of functional
DNA methyltransferase in mice and determined the consequences for early steps of the neoplastic
process. To do so, we used mice heterozygous for the ApcMin mutation (Min mice) as a model
system to assess the role of DNA methylation in early neoplastic transformation (Luongo et al.,
1993; Luongo et al., 1994; Moser et al., 1990; Su et al., 1992). Min mice develop multiple
intestinal adenomas within the first few months of life (Luongo et al., 1994; Moser et al., 1992;
Moser et al., 1990). The number of intestinal polyps present in these mice at specific ages offered
us a readily quantifiable measure of any effects that changes in DNA methylation might have on the
incidence or rate of polyp formation.
Min mice carry a germline point mutation in the Apc tumor-suppressor gene, the mouse
homolog of the human APC gene, which, when present in mutant form in the human germ line,
results in the syndrome of familial adenomatous polyposis coli (FAP) (Su et al., 1992). FAP
patients develop as many as a thousand benign colorectal polyps, some of which progress to
malignancy if they are not removed (Groden et al., 1991; Ichii et al., 1992; Joslyn et al., 1991;
Miyoshi et al., 1992; Nakamura, 1993; Powell et al., 1992). Similarly, mice carrying the Min
allele of the Apc gene develop one hundred or more intestinal polyps in the first 6 months of life.
These polyps thus provide a model system for the early stages of human colorectal cancer, for
which changes in DNA methylation patterns and in methyltransferase expression have been well
documented (El-Deiry et al., 1991; Feinberg et al., 1988; Gama-Sosa et al., 1983; Issa et al.,
1993; Silverman et al., 1989).
Mice carrying germ-line mutations in the DNA methyltransferase gene have previously
been reported (Li et al., 1993; Li et al., 1992). Mouse embryos homozygous for either the DnmtN
allele (Li et al., 1992) or the stronger DnmtS allele (Li et al., 1993) die before birth. Heterozygous
mice have approximately half wild-type levels of DNA methyltransferase expression, which is
apparently sufficient to maintain normal levels of DNA methylation (Li et al., 1992).They appear
otherwise phenotypically indistinguishable from their wild-type littermates.
In the present study, we further perturbed methyltransferase activity through use of the
DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-dC), which is known to titrate out
the enzyme activity by a covalent trapping mechanism (Jiittermann et al., 1994; Santi et al., 1983;
Santi et al., 1984). The combination of Dnmt heterozygosity and treatment with 5-aza-dC might be
predicted to reduce the functional levels of DNA methyltransferase to below the threshold needed
for the maintenance of normal DNA methylation patterns. In this paper we employ this combined
strategy to study the effects of reduced DNA methyltransferase activity on the number of intestinal
adenomas appearing in mice carrying the Min allele of the Apc gene.
Materials and Methods
Mice
Mice were maintained in the facilities of the Whitehead Institute for Biomedical Research and were
fed ad libitum. Their diet consisted of Agway Prolab Rat, Mouse and Hamster 3000 chow, which
has a crude protein content of at least 22%, a crude fat content of at least 5% and a crude fiber
content of at most 5%. C57BL/6 ApcMin/+ mice were purchased from the Jackson Laboratories,
Bar Harbor, Maine. 129/SV DnmtS/+ mice were generated in our facilities (Li et al., 1993; Li et
al., 1992).
5-aza-dC Injections
129/SV DnmtS/+ female mice were crossed to C57BL/6 ApcMin / + males. Progeny were weighed
on a Mettler balance and injected weekly with either 5 gLg 5-aza-dC per 5 g body weight (rounded
to the nearest multiple of 5 g) or with its solvent, phosphate-buffered saline (PBS). 5-aza-dC
(Sigma Chemical Co., St. Louis, MO, catalog number A-3656) was prepared as a 2.5 mg/ml
solution in PBS and stored in aliquots at -700C. Injections were performed with a 100 .1 Hamilton
700 series syringe with a Luer tip and a PB600 dispenser attachment, allowing injection of 50
discrete 2 Cl volumes. The injections were started on day 7 of age and continued for 100 days (14
injections), after which the mice were monitored for an additional 80 days and then sacrificed.
Polyp Analysis
The entire intestine was excised immediately following sacrifice, fixed and washed with Bouin's
fixative and subjected to a systematic microscopic screen for polyp formation along the entire
length of the intestine. Adenomas were counted if they had reached a size of at least several villi.
The investigator counting the adenomas was blind to both Apc and Dnmt genotypes. Adenomas
destined for DNA analysis were micro-dissected from intestines that had been washed with PBS,
before being fixed with Bouin's fixative.
DNA Methylation Analysis
DNA was prepared from frozen tissue samples as described previously (Laird et al., 1991). Five
gLg of genomic DNA was digested with the restriction enzyme HpaII (New England Biolabs,
Beverly, MA) as specified by the manufacturer. After agarose gel electrophoresis followed by
Southern blotting, the filters were hybridized with a probe containing a
Allelic Loss Analysis
The murine Apc cDNA sequence was obtained from GenBank (accession no. M88127) (Su et al.,
1992). A 619-bp fragment spanning the site of the Min mutation was amplified from genomic
DNA samples by PCR using oligonucleotides MAPC-15 (Apc Sequence 2859 - 2841) (5'
-TTCCACTTTGGCATAAGG C-3') and MAPC-9 (APC Sequence 2241 - 2258) (5'-
GCCATCCCTTCACGTTAG-3'). The PCR products were gel-fractionated on a 2% agarose gel,
Southern blotted and hybridized with three probes in sequential hybridizations. The three probes
were Min-Sense(Apc Sequence 2542 - 2556) (5'-AGAAGTTAGGAGAGA-3'), Apc-Sense (Apc
Sequence 2542 - 2556) (5'-AGAAGTTTGGAGAGA-3') and Apc-Uni (Apc Sequence 2530-
2544) (5'-TCTGAGAAAGACAGA-3'). Min-Sense hybridizes specifically to the ApcMin mutant
allele while Apc-Sense hybridizes specifically to the wildtype allele. Apc-Uni hybridizes to both
alleles. The hybridization signals were quantitated using a Fuji phosphoimager. The signal levels in
the Apc-Uni hybridization were used to normalize the amount of DNA in each lane.
Results
Effects of Decreased DNA Methyltransferase Activity on the Number of Intestinal Adenomas
In order to study the effects of DNA methyltransferase levels on intestinal polyp formation, we
crossed 129/SV DnmtS/+ female mice with C57BL/6 ApcMin/ + males. In addition, we determined
the maximal dose of 5-aza-dC that mice could tolerate during an extended treatment protocol
starting at one week of age. This dose, 5 gtg of 5-aza-dC per 5 grams body weight, was given
weekly by subcutaneous injection to the progeny of the cross described above. Control offspring
were injected with phosphate-buffered saline (PBS) instead of 5-aza-dC. The injections were
performed by investigators blind to the genotypes of the animals.
Previous experience indicated that at 100 days of age, intestinal polyps are just at the
threshold of detectability in this strain background. During the subsequent 80 days, such polyps
grow to a size that is readily visible. For this reason, mice were injected for 100 days (14
injections) . The drug treatment was then discontinued and the number of polyps was monitored 80
days later, allowing us to gauge the effects of DNA methyltransferase levels on polyp initiation and
early growth during the first 100 days of life. In doing so, we avoided any cytotoxic or cytostatic
effects that 5-aza-dC might have on the expansion of cell populations in the polyps during the
growth period from 100 to 180 days. Figure 1 shows growth curves for the four different
genotypes generated in this cross. As is apparent, the treatment with 5-aza-dC did not have a
statistically significant effect on the body weights of the mice.
Figure 1
Growth curves of mice treated weekly with either PBS or 5-aza-dC. 129/SV DnmtS/+ female mice
were crossed to C57BL/6 ApcMin / + males. Ungenotyped progeny were weighed and injected
weekly with either 5 gg 5-aza-dC per 5 g bodyweight or with its solvent, phosphate-buffered
saline (PBS). The injections were continued for 100 days (14 injections), after which the mice
were monitored for an additional 80 days and then sacrificed. The average weights were calculated
for each of the genotypes, sexes and treatments. The weight measurements were plotted by week.
However, the symbols are indicated only every five weeks to preserve clarity. Squares indicate
males. Circles indicate females. Open symbols indicate PBS treatment. Closed symbols indicate 5-
aza-dC treatment. Panel A shows Dnmt+/+, Apc+/+ mice. Panel B shows Dnmt+/+, ApcMin/ +
mice. Panel C shows DnmtS/+, Apc +/+ mice. Panel A shows DnmtS/+, ApcMin / + mice.
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A subset of animals was sacrificed at 100 days to determine the DNA methylation levels in
the colon immediately following 5-aza-dC treatment. Figure 2 shows an analysis of DNA
methylation levels of genomic colon DNA derived from the four categories of experimental
animals. We compared DNA methylation levels by Southern blot analysis of restriction digests
with the DNA methylation-sensitive enzyme Hpall, hybridized with a centromeric satellite repeat
probe (Sanford et al., 1987) (see Figure 2). In this assay, reduced levels of DNA methylation are
revealed by a relative increase in lower-molecular-weight bands. The analysis in Figure 2 shows
that both Dnmt heterozygosity and 5-aza-dC treatment have a synergistic effect in causing
hypomethylation of on colon DNA. The effect of 5-aza-dC alone appears to be stronger than that of
Dnmt heterozygosity.
Figure 2
DNA Methylation Analysis of Genomic Colonic DNA from Mice Treated Weekly with or without
5-aza-dC. Mice derived from a cross between 129/Sv DnmtS/+ females and a C57BL/6 male were
injected weekly with 5-aza-dC for 100 days (14 weeks) or untreated. Genomic DNA from colons
collected from 100-day-old mice was isolated as described previously(Laird et al., 1991) .
Analysis of DNA methylation levels involved digestion of genomic DNA by the methylation-
sensitive restriction enzyme HpalI, followed by hybridization with a centromeric satellite repeat
probe (Chapman et al., 1984) for a reflection of the global DNA methylation status The Dnmt
genotypes and treatments are indicated above the lanes.
No Drug 5-aza-dC
Dnmt +/+ S/+ +/+ S/+
M 1 2 34 56 78
The number of intestinal polyps at sacrifice at 180 days was determined by examination of
the mucosa over the entire length of the intestine under a dissecting microscope. Figure 3 shows
the averaged results obtained for the various experimental groups. Mice wild-type at the Apc locus
did not develop intestinal polyps with any combination of Dnmt genotype or drug treatment.
ApcMin / + heterozygous mice developed an average of 113 polyps in the Dnmt+/+ PBS control
group. DnmtS heterozygosity reduced the number to a statistically significant lower average of
only 46 polyps. In addition, adenomas in DnmtS /+ mice were on average smaller than those in the
Dnmt+/+ Min cohort (data not shown). A more pronounced effect was seen in theApcMin / +
heterozygous mice treated with 5-aza-dC. Treatment of Dnmt wild-type mice with 5-aza-dC
reduced the number of polyps from 113 to an average of 20. The combined effects of Dnmt
heterozygosity and 5-aza-dC treatment resulted in only 2 intestinal adenomas.
Figure 3
The number of intestinal polyps in mice treated weekly with either PBS or 5-aza-dC. 129/SV
DnmtS / + female mice were crossed to C57BL/6 ApcMin / + males. Ungenotyped progeny were
weighed and injected weekly with either 5 gg 5-aza-dC per 5 g bodyweight or with its solvent,
phosphate-buffered saline (PBS). The injections were continued for 100 days (14 injections), after
which the mice were monitored for an additional 80 days and then sacrificed. The entire intestine
was excised immediately following sacrifice, fixed and washed with Bouin's fixative and subjected
to a systematic microscopic screen for polyp formation along the entire length of the intestine. The
investigator counting the polyps was blind to both Apc and Dnmt genotypes. The average number
of polyps for each group is shown as a bar with the average also indicated above or within the bar.
The standard error of mean for each value is indicated by the thin error bars. The treatments,
genotypes of the mice, and number of mice in each experimental group are indicated below the
bars. All mice for this experiment were generated by the same limited number of parents and were
maintained in the same room with the same food and cage conditions.
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Early Administration of 5-aza-dC is Required for its Effect on Polyp Number
While treatment of Min mice with 5-aza-dC had a dramatic effect on the number of intestinal
polyps, the available evidence did not provide strong indications whether the effect was attributable
to an early influence on the rate of initiation of adenoma formation or, alternatively, to a later
cytostatic or cytotoxic influence of 5-aza-dC on already initiated adenomas. An indication that 5-
aza-dC affects polyp initiation came from experiments in which drug treatment was delayed until
day 50 in a cohort of C57BL/6 Min mice. In this strain background, the majority of polyps
become visible between day 50 and day 100 of age (A.F., unpublished data, and (Moser et al.,
1992; Moser et al., 1990)).
Figure 4
The number of intestinal polyps in mice with various timed treatments and time of sacrifice.
C57BL/6 ApcMin / + males were crossed to either 129/SV (circles) or to C57BL/6 female mice
(squares). The progeny were started on weekly injections of 5 gg 5-aza-dC per 5 g bodyweight at
either 50 days (closed squares) or 7 days of age (closed circles). Control mice (open symbols)
were either injected with PBS or monitored without injection. In all cases, the injections were
continued until the mice were 100 days old. The mice were sacrificed at either 100, 150 or 180
days of ages, as indicated and subjected to an intestinal polyp count as described for Figure 3. The
sizes of the experimental groups were as follows: open squares: n=6; closed squares: n=9; open
circles: n=2, n=5 and n=13 for 100, 150 and 180 days respectively; closed circles: n=3, n=2 and
n=12 for 100, 150 and 180 days respectively. The treatments are indicated schematically at the
bottom of the figure.
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Loss of Heterozygositvy at the Apc Locus
The precise nature of the interactions of DNA methylation and the mutant ApcMin allele in tumor
development were not made clear by these analyses. The paradigm developed from extensive study
of the Apc and similarly behaving tumor suppressor genes dictates that loss of the wildtype Apc
allele should accompany tumor development (Boynton et al., 1992; Brewster et al., 1994; Ichii et
al., 1992; Levine, 1993; Nakamura, 1993; Scrable et al., 1990; Tamura et al., 1994; Weinberg,
1991). We wished to ascertain that this genetic mechanism operated in all of the experimental
groups studied, regardless of the status of their Dnmt locus or their history of 5-aza-dC treamtent.
We tested polyps from the different cohorts for loss of heterozygosity at the site of the
ApcMin mutation. A segment of DNA encompassing the mutation was amplified from DNA
derived from polyps and from adjacent normal tissue. The PCR products were hybridized
consecutively with oligodeoxynucleotide probes specific for the ApcMin allele, the Apc+ allele and
finally with a probe recognizing both alleles. The relative strengths of the signals derived from the
ApcMi n - and Apc+-specific probes were calculated after quantitation on a phospho-imager and
subsequent normalization to the signal deriving from the probe recognizing both alleles. Loss of
heterozygosity in polyps should reveal a reduction in the relative level of the Apc+ signal and an
increase in the relative level of the ApcMin signal in polyps compared to normal adjacent tissue.
Figure 5 shows the analysis of a representative series of polyps from Dnmt wild-type mice,
along with control DNAs derived from tail biopsies from ApcMin/ + and Apc +/ + mice. The results
obtained for all polyps analyzed are summarized in Table 1. Loss of the wild-type allele was seen
in the majority of polyps derived from all experimental groups. These results are in agreement with
the loss of heterozygosity at the APC locus seen as an early event in human cancer (Boynton et
al., 1992; Brewster et al., 1994; Ichii et al., 1992; Nakamura, 1993; Tamura et al., 1994). The
high frequency of loss of heterozygosity at the Apc locus is close to the 100% loss of Apc
heterozygosity in ApcMin-induced intestinal adenomas found by Luongo et al. (Luongo et al.,
1994).
Figure 5
Analysis of allelic loss at the Apc locus in colon adenomas. Intestines from randomly chosen mice
from the experiment shown in Figures 1 and 2 were washed in PBS. Large distinct adenomas were
excised and processed for DNA isolation as described previously (Laird et al., 1991). In addition,
normal intestinal mucosa adjacent to the polyp was excised and is shown immediately to the right
of each polyp in the figure. The normal tissue in lane 9 is the control for both lanes 7 and 8. Lanes
10 and 11 contain samples derived from tail biopsies as control DNAs. Lane 10 is from an Apc +/ +
mouse. Lane 11 is from an ApcMin/+ mouse. PCR reactions were performed as described in
Experimental Procedures. The PCR products were resolved by gel electrophoresis, blotted, and
hybridized consecutively with oligodeoxynucleotide probes specific for the ApcMin allele (Panel
A), the Apc + allele (Panel B) and finally with a probe recognizing both alleles (Panel C).
PROBE
ApcMin Allele
123456789x1011
1 2 3 4 5 6 7 8 9 10 11
- - I
Apc+ Allele B
Universal C
•IIZP7ZJJU_--~i-- I
CONTROL
DNAS
Table 1
Analysis of allelic loss at the Apc locus in intestinal adenomas. Intestines from randomly chosen
mice from the experiment shown in Figures 1 and 2 were washed in PBS. Large distinct adenomas
were excised and processed for DNA isolation as described previously (Laird et al., 1991). In
addition, normal intestinal mucosa adjacent to the polyp was excised as a reference standard. PCR
reactions were performed as described in Experimental Procedures. The PCR products were
resolved by gel electrophoresis, blotted, and hybridized consecutively with oligodeoxynucleotide
probes specific for the ApcMin allele, the Apc+ allele and finally with a probe recognizing both
alleles. The relative hybridization signals were quantitated with a phospho-imager. Signals were
first normalized using the hybridization signal specific for both alleles (Apc-Uni probe).
Subsequently, the ratio of ApcMin to Apc+ hybridization was calculated. Most polyps had ratios of
more than 2.0. The four polyps defined as not showing loss of heterozygosity had ratios between
0.9 and 1.1, within the range seen for all normal adjacent tissues. WT control = adenomas from
129Sv/B6 ApcMin/ + Dnmt+/+; HET control= adenomas from 129Sv/B6 ApcMin/ + DnmtS/+; WT
5-aza-dC (0-100)= adenomas from 129Sv/B6 ApcMin/+ Dnmt+/ + treated with aza-dC for a 100
days after birth; WT 5-aza-dC (50-100)= adenomas from 129Sv/B6 ApcMin/+ Dnmt+/ + treated
with aza-dC for days 50-100 after birth; HET 5-aza-dC (0-100)= adenomas from 129Sv/B6
ApcMin/+ DnmtS/+ treated with aza-dC for a 100 days after birth.
Experimental
Group
Number of
Polyps Analyzed
Polyps with Loss
of
Heterozygosity
Polyps with no
Loss of
Heterozygosity
WT Control
HET Control
WT 5-aza-dC (0-100)
WT 5-aza-dC (50-100)
HET 5-aza-dC (0-100)
Total
We found several polyps that lacked any sign of loss of heterozygosity (See Figure 5 and
Table 1). Such cases do not seem to be over-represented in any particular cohort. It is possible that
these polyps have lost the function of the wild-type allele through another mechanism, such as the
acquisition of a mutation elsewhere in the Apc gene. Alternatively, loss of function of the wild-
type Apc protein may not be an absolute requirement for polyp formation. In support of this, we
have recently obtained evidence for a dominant mode of action for the truncated protein product of
the ApcMin allele by comparing the phenotypes of mice heterozygous for different Apc mutations
(for a discussion see Chapter 1).
Discussion
DNA Methyltransferase is an Oncogenic Determinant in Min-Induced Intestinal Neoplasia
Mice carrying the Min allele of the Apc gene are predisposed to intestinal polyps which become
readily observable at several months of age (Luongo et al., 1993; Luongo et al., 1994; Moser et
al., 1992; Moser et al., 1990; Su et al., 1992). As demonstrated here, the number of these polyps
can be reduced in two ways - through treatment with the drug 5-aza-dC or through introduction of
a mutant allele of the DNA methyltransferase gene. These two perturbants are also united by a
common biochemical mechanism of action. 5-aza-dC, when incorporated into DNA, causes the
formation of stable covalent adducts between DNA methyltransferase and the DNA, resulting in the
depletion of free, active enzyme from the cell (Jiittermann et al., 1994; Santi et al., 1983; Santi et
al., 1984). The DnmtS mutation achieves the same end result through inactivation of a
chromosomal gene copy encoding this enzyme. Indeed, both Dnmt heterozygosity and 5-aza-dC
treatment result in a reduction of genomic DNA methylation levels as represented by an analysis of
centromeric repeat sequences.
The genesis of these polyps depends upon the frequency with which they are initiated and
their subsequent ability to proliferate to a size that makes them visible under the dissecting
microscope. Thus, the present phenomena need to be interpreted in light of these two events
governing observed polyp number. The initiation of polyp formation would appear to depend upon
low frequency stochastic events, in that the number of distinct clones of polyps is many orders of
magnitude lower than the number of cells in the target tissue. This stochastic event could involve
the loss of the wild-type Apc allele that initially coexists with the mutant ApcMin allele in all cells
of the intestinal epithelium. This is a possibility that could be neither proven nor refuted by the
present data.
The decrease in polyp number in mice having reduced levels of active DNA
methyltransferase was opposite to the result expected for a model in which global DNA
hypomethylation contributes to the neoplastic process in colorectal cancer. The effect of DNA
methyltransferase on Min-induced intestinal neoplasia appeared to be on both polyp number and
size but not morphology. The adenomas in the DnmtS/+ heterozygous mice appeared to be
somewhat smaller, but this was not be confirmed by a statistical morphometric analysis. We did
not find any evidence for a difference in the state of differentiation or progression of the adenomas
from the different experimental groups as assessed by histological examination of the polyps in
Min mice from all four cohorts.
Significantly, a substantial reduction in polyp number was achieved in the absence of 5-
aza-dC treatment. This decrease, seen in the context ofApcMin/+ heterozygosity, is the first
example of an observed phenotypic difference between Dnmt wild-type mice and DnmtS/+
heterozygotes, which appear to have normal levels of DNA methylation (Li et al., 1992).
Furthermore, these results demonstrate that Dnmt is a genetic modifier of the Min phenotype. It is
the second such modifier to be described, the first being the AKR/J allele of Mom-1 (Dietrich et
al., 1993; Moser et al., 1992). Dnmt and Mom-1 are distinct loci, however. Mom-1 maps to
mouse chromosome 4 (Dietrich et al., 1993), while Dnmt maps to mouse chromosome 9
(Copeland et al., 1993).
As can be seen in Figure 4, the delay in the start of 5-aza-dC treatment abolished its
inhibitory effect on the number of polyps counted at day 100. Furthermore, there was no readily
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apparent difference in the size of polyps from mice that had received a delayed 5-aza-dC treatment
compared to their PBS-treated littermates. These results suggested that the initiation of polyp
formation occurs prior to day 50 of age and is followed by a period of expansion of cell
populations in already initiated polyps in the subsequent 50 day period. In order to exert its effects
on polyp number, 5-aza-dC must be present during this critical formative period rather than during
the subsequent proliferative phase. As such, we consider it unlikely that 5-aza-dC acts through a
cytotoxic or cytostatic effect on the cells in already formed adenomatous cell clones.
It is also apparent from Figure 4 that the majority of polyps at day 180 in mice treated from
day 0 to 100 appeared only after cessation of drug treatment. These adenomas may represent
rapidly growing polyps initiated after day 100, since the experiments described above argue against
an inhibitory effect of 5-aza-dC on the expansion of previously initiated polyps. This raises the
possibility that continued treatment with 5-aza-dC could lead to the virtual elimination of polyp
formation.
An early, rate-limiting stochastic event rather than a later proliferative process would appear
to be the target of inhibition by the 5-aza-dC that we have administered to these mice. We conclude
this from our observations of the comparative effects of this drug administered at weekly intervals
beginning either at the first week of life or only at day 50. The first protocol involving early
administration severely depresses polyp number; delayed administration in contrast has no effects
on polyp number or size. During days 50 to 100 of life, these polyps undergo a size proliferation
that causes them to become visible in the dissecting microscope. Therefore, we conclude that 5-
aza-dC has minimal effects on proliferation but profound effects on the earlier, initiation, which
must occur well before day 50.
Consistent with this conclusion is the work that documents the cytostatic/cytotoxic effects
of 5-aza-dC treatment. It was found that these anti-proliferative effects are not mediated through
loss of DNA methylation per se, but rather through the formation of stable covalent complexes
between the DNA methyltransferase enzyme and the incorporated cytosine analog (Jiittermann et
al., 1994; Santi et al., 1983; Santi et al., 1984). Consequently, cells that have lower levels of DNA
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methytransferase are less sensitive to growth inhibition by 5-aza-dC (Jiittermann et al., 1994). In
the present study, we observed the exact opposite: the ability of 5-aza-dC to suppress polyp
formation was stronger in mice with levels of DNA methyltransferase reduced due to the DnmtS
mutation.
DNA Methyltransferase Levels and Polyp Formation - Possible Mechanisms
Studies on DNA methylation changes in human cancer cells have presented a somewhat confusing
picture. Hypotheses to explain the involvement of DNA methylation in cancer fall broadly into two
classes. The first class of models propose that changes in DNA methylation contribute to the
oncogenic process through effects on gene expression. The other class propose that the major role
of DNA methylation in cancer is mediated through the disproportionately high rate of mutation of
methylated cytosine residues.
Among the models that address gene expression-mediated effects of DNA methylation in
oncogenesis, two opposing mechanisms have been proposed. One model proposes that the
commonly observed global DNA hypomethylation in human tumors is of selective advantage to the
tumor cell through facilitated proto-oncogene expression (Feinberg and Vogelstein, 1983)
(Hanada et al., 1993; Rao et al., 1989; Vorce and Goodman, 1991). In the alternative model, high
expression of the DNA methyltransferase is thought to drive hypermethylation of specific loci such
as tumor-suppressor genes or genes specific to differentiated cell types (Baylin et al., 1991; El-
Deiry et al., 1991; Greger et al., 1989; Issa et al., 1994; Issa et al., 1993; Kautiainen and Jones,
1986; Ohtani-Fujita et al., 1993; Silverman et al., 1989). This would allow outgrowth of
undifferentiated neoplastic cells. The suppression of polyp formation by the reduction of DNA
methyltransferase and DNA methylation levels is inconsistent with the first mechanism, which
favors on oncogenic effect of DNA hypomethylation. Our results are consistent with the tumor-
suppressor gene hypermethylation model, although one would have to argue that reduction of
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global DNA methyltransferase levels would affect local DNA hypermethylation. It is not clear how
regional DNA hypermethylation is achieved in the face of global DNA hypomethylation.
In contrast to the gene-expression-mediated models discussed above, the mutation-
mediated models propose that DNA methylation contributes to oncogenesis through a
disproportionately high mutation rate of 5-methylcytosine residues (Jones et al., 1992; Laird and
Jaenisch, 1994; Spruck et al., 1993). Deamination at C-4 of both methylated and unmethylated
cytosine residues is known to occur spontaneously to yield thymine and uracil, respectively
(Ehrlich et al., 1986; Frederico et al., 1990; Shen et al., 1994; Wang et al., 1982). A uracil residue
is ultimately substituted by thymine if it is not repaired prior to DNA replication. The occurrence of
C-to-T transition mutations is considerably higher for 5-methylcytosine than for unmethylated
cytosine residues. In fact, mutations of this sort are of significance in human tumorigenesis.
Approximately 47 % of the characterized point mutations in the p53 tumor-suppressor gene in
colorectal tumors are nucleotide transitions within CpG dinucleotides, the target for DNA
methylation (Greenblatt et al., 1994). This frequency contrasts with the fact that CpG dinucleotides
occur within the coding region of the wild-type human p53 gene at a frequency of 3.3% (39 out of
1179). The target size for mutagenesis at either nucleotide within CpG dinucleotides is therefore
6.6%. Mutations at CpG dinucleotides are thus over represented approximately 7-fold in human
colorectal tumors (Greenblatt et al., 1994). Reduced cellular DNA methylation levels could lead to
a lower rate of spontaneous C-to-T transitions. If rate-limiting mutational events, in addition to the
loss of the wild-type Apc allele, were required for polyp formation, then a reduced rate of C-to-T
transitions could result in a lower number of intestinal polyps.
The high mutation rate of methylated cytosine residues might also be achieved through a
different mechanism that directly involves the DNA methyltransferase enzyme (reviewed in: (Laird
and Jaenisch, 1994)). The covalent enzyme adduct formed between DNA methyltransferase and its
substrate cytosine has been found to destabilize the amine group of the latter, resulting in an
enhanced rate of deamination. Normally, this adduct is formed only ephemerally; the presence of
the methyl donor S-adenosyl methionine (SAM) results in the rapid completion of the reaction and
103
the disappearance of this destabilized intermediate. But in the absence of sufficient amounts of
SAM, the half-life of this intermediate may be substantially extended, resulting in turn in a great
increase in cytosine deamination. This has been demonstrated experimentally for a prokaryotic
DNA methyltransferase (Shen et al., 1992). If such a mechanism were also applicable to the
mammalian enzyme, limiting levels of SAM in the intestinal epithelium could result in a mutagenic
process with an activity correlating with DNA methyltransferase levels. We note in passing that
diets deficient in methionine have been reported to predispose humans to increased numbers of
colonic polyps (Giovannucci et al., 1993). Whether this is only an adventitious association or
derives from a mechanism associated with DNA methyltransferase-mediated deamination and
mutation is not revealed by presently available evidence. Experiments in rodents have shown that
methyl-deficient diets, which lead to SAM depletion, enhance liver tumorigenesis (Mikol et al.,
1983; Shivapurkar et al., 1986).
Recently, the laboratories of Peter Jones and Richard Roberts have found evidence for yet
another mechanism through which DNA methyltransferase enzymes could exert an effect on
cytosine mutation rates (Yang et al., personal communication and Klimasauskas and Roberts,
personal communication). Both groups have demonstrated that a prokaryotic DNA
methyltransferase is capable of high-affinity binding to G:U mismatches. In addition, the enzyme
is then capable of converting the uracil residue to thymine by the transfer of a methyl group. G:U
mismatch repair would be inhibited directly by the binding of the DNA methyltransferase as well as
indirectly by the conversion of U to T, which is less efficiently repaired in a mismatch with G
(Brown and Brown, 1989; Shenoy et al., 1987). Whether the mammalian DNA methyltransferase
exhibits similar properties remains to be seen.
Future experiments should address the precise effects of 5-aza-dC treatment and the
inactivated Dnmt allele on the mutational rate of defined genes within specific tissues of the mouse.
Such experiments should indicate whether these perturbants directly suppress mutation rate and
have profound effects on the rate of polyp initiation in the Min mice.
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Chapter 4
Phenotype of Mice Lacking Functional Deleted in Colorectal Cancer (DCC) Gene
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Introduction
Deleted in Colorectal Cancer (DCC )was isolated as a candidate tumor suppressor gene from the
region of chromosome 18q that is frequently subjected to LOH (Fearon et al., 1990). DCC
encodes a group of structurally similar 175-190 Kilodalton (kDa) transmembrane proteins which
are members of the immunoglobulin gene superfamily. These proteins are characterized by the
presence of four immunoglobulin domains and six fibronectin type III repeats in their extracellular
domains (Fearon et al., 1990). Some members of this family of proteins are implicated in neural
morphogenesis, including the neural cell adhesion molecule (NCAM) (Doherty and Walsh, 1992).
Several studies of DCC expression have provided results that would seem at odds with the
proposed tumor suppressor role of this gene. First, high level expression of the DCC gene
product might be expected in the intestine if DCC functions to regulate intestinal differentiation or
proliferation. However, the level of DCC RNA in the normal colonic tissue, composed of both
epithelial and non-epithelial cells, is at the threshold of detection by the polymerase chain reaction
(PCR) (Fearon et al., 1990), and it is unclear whether this RNA is translated into protein, as some
investigators have had difficulty detecting DCC protein expression in colonic cells (Turley et al.,
1995).
Second, as described above, the hallmark of a tumor suppressor gene is its homozygous
inactivation in tumor cells (Cavenee et al., 1983; Weinberg, 1991). The DCC gene represents an
anomaly in this regard. To date, analysis of the DCC alleles retained in human colonic tumors has
led to the discovery of mutant alleles in only 2 of 60 colonic tumors affected by 18q LOH (Cho et
al., 1994). An additional 12% of the tumors carry insertions in one of the DCC introns (Fearon et
al., 1990), but the effect of these insertions on DCC function is not known.
The absence of detectable mutations in DCC in most colonic tumors is unusual for a tumor
suppressor gene but does not exclude a role for DCC in tumor suppression. For example, the cells
in an adenomatous polyp may employ a mechanism other than mutation of the DCC gene to reduce
or eliminate its product. Evidence for this comes from the observation that DCC RNA is either
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drastically reduced or completely lost in these tumors (Fearon et al., 1990; Kikuchi-Yanoshita et
al., 1992) but is detectable by PCR in RNA pools prepared from whole colonic tissue that includes
several cell types including the epithelial cells (Fearon et al., 1990). A study of a group of 18
colonic tumors showed that RNA spanning the 3' end of DCC was absent in 10 tumors and RNA
spanning the 5' end of DCC was not detectable in any of these tumors (Thiagalingam et al., 1996).
Although initial studies of DCC function focused on its possible involvement in intestinal
development and pathogenesis (reviewed in (Cho and Fearon, 1995)), it was evident from its
initial isolation that one of the major sites of DCC expression was in the nervous system (Fearon et
al., 1990), in particular on axonal processes (Hedrick et al., 1994). The idea that DCC might
function in neural development was further reinforced by the identification of a structurally-related
protein, neogenin, as a transmembrane protein expressed by retinal axons during the growth of
these axons to their targets in the chick embryo (Vielmetter et al., 1994).
Recently, studies have suggested that DCC may function as a component of a receptor
complex that mediates the effects of the axonal chemoattractant netrin-1 on the commissural axons
of the spinal cord of vertebrates (Keino-Masu et al., 1996). Commissural neurons differentiate in
the dorsal portion of the spinal cord and pioneer a ventrally-directed circumferential pathway that
leads them to a specialized group of cells at the ventral midline of the spinal cord termed floor plate
cells (Colamarino and Tessier-Lavigne, 1995). During development of the nervous system, these
migrating axons are guided to the floor plate at least partly by a chemoattractant, netrin- 1, secreted
by floor plate cells (Kennedy et al., 1994; Serafini et al., 1994). Netrin-1 is a member of a
phylogenetically conserved family of laminin-related molecules that have been implicated in axonal
guidance in Caenorhabditis elegans, Drosophila melanogaster and vertebrates (Harris et al., 1996;
Ishii et al., 1992; Kennedy et al., 1994; Mitchell et al., 1996; Serafini et al., 1994; Wadsworth et
al., 1996). Netrin-1 can promote the outgrowth of spinal cord commissural axons into collagen
matrices and reorient the growth of these axons in vitro (Kennedy et al., 1994; Serafini et al.,
1994). Moreover, in the developing mouse embryo, netrin-1 mRNA is expressed at high levels by
floor plate cells and at lower levels in the ventral two-thirds of the spinal cord; these distributions
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have led to the hypothesis that there is an increasing dorsal-to-ventral gradient of netrin-1 protein in
the spinal cord that serves to guide the migration of commissural axons to the floor plate (Kennedy
et al., 1994).
An involvement of DCC-related proteins in mediating the axonal guidance effects of netrins
was evidenced through complementary studies in worms, flies and vertebrates. Loss-of-function
phenotypes and genetic interactions in C. elegans and Drosophila have suggested that homologues
of the DCC protein function in the response pathway of netrin family members (Chan et al., 1996;
Kolodziej et al., 1996), but direct biochemical interactions between the ligands and the putative
receptors have been reported in those species. In vertebrates, a biochemical interaction between
netrin-1 and DCC has been demonstrated (Keino-Masu et al., 1996), and DCC has been implicated
in mediating netrin effects on spinal commissural axons in vitro through antibody perturbation
studies, but the significance of this interaction for guidance of axons by netrin-1 in vivo has not
been addressed.
To help elucidate the functions of the DCC gene in mice, we have inactivated its homologue
(Dcc) in the mouse genome through use of homologous recombination and have examined the
effects of this inactivation on both the intestine and the developing nervous system. The observed
phenotypes of the mice are consistent with the hypothesis that DCC is part of a receptor for netrin-
1 in vivo both in the spinal cord and in the developing brain but fail to provide support for the
hypothesis that DCC controls cell proliferation in the normal or neoplastic mouse intestine.
Materials and Methods
Generation And Analysis of Mice with DccX3 Mutation
Embryonic stem cell culture, generation of chimeric mice, Southern and western blot analyses were
performed according to standard procedures.
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Tumor Analysis
All mice in this study were maintained in the facilities of the Whitehead Institute for Biomedical
Research and were given Agway Prolab Rat, Mouse and Hamster 3000 chow ad libitum. The
chow has a crude protein content of at least 22%, a crude fat content of at least 5%, and a crude
fiber content of at most 5%. After euthanization, the entire gastrointestinal tract was removed,
dissected along the cephalocaudal axis, and washed in phosphate buffered saline. Adenomas were
at least twice as wide as a villus, at most 5-6 millimeters in diameter and were readily visible under
a dissecting microscope. Adenomas were removed surgically, fixed in Bouin's fixative,
dehydrated in graded alcohols, embedded in paraffin, sectioned at 6 mm, and stained with
hematoxylin and eosin (H&E). For LOH analysis, adenomas were removed surgically and DNA
was prepared. C57BL/6 ApcMin/ + mice were purchased from the Jackson Laboratory (Bar
Harbor, Maine).
Generation of Compound Heterozygous ApcMin Dcc:lAc±.+Dcc±-Mice
C57BL/6 ApcMin/ + and 129/Sv Dcc+/ " animals were crossed to generate 129Sv/B6 Fl ApcM in/ +
Dcc+/- mice. These Fl mice were then backcrossed to 129/Sv mice; the compound heterozygote
progeny of this latter cross had the mutant allele of both the Apc and the Dcc gene in the cis
configuration.
Immunohistochemical Analysis of Postnatal Day 1 (P1) Intestines
Single and multilabel immunohistochemical analyses of postnatal day 1 (P1) 129/Sv Dcc "/ ', Dcc+/ "
and Dcc+/+ mice were conducted in a single blinded fashion. Each member of a litter of thirteen P1
mice, derived from a cross of 129/Sv Dcc+/" animals, received an intraperitoneal injection of 5'-
bromo-2'-deoxyuridine (BrdU; Sigma; 120 mg/kg body weight) and 5-fluoro-2'-deoxyuridine
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(Sigma; 12 mg/kg) 90 minutes prior to sacrifice. Following sacrifice, an incision was made in the
abdominal wall. Each mouse was then placed in Bouin's solution for 12 h followed by 70%
ethanol. The gastrointestinal tract was removed en bloc, displayed so that its entire cephalocaudal
axis could be surveyed on a single slide, and then embedded in paraffin. 5 mm-thick sections were
cut. Sections from each animal were initially stained with hematoxylin and eosin to define epithelial
architecture and cellular morphology.
Some antigens or glycoconjugates could only be detected after enzymatic unmasking. This
unmasking involved incubation of sections for 15 minutes (min) at 370C in a 1 mg/ml solution of
chymotrypsin (prepared in 7 mM CaC12, pH 7.8). All sections, whether pre-treated with protease
or not, were then incubated with blocking buffer [bovine serum albumin (1%, wt/vol), powdered
skim milk (0.2%; omitted for lectin staining), Triton X-100 (0.3%) in PBS] for 15 min at room
temperature. After an overnight incubation at 40C with primary antisera, antigen-antibody
complexes were visualized using: (i) gold-labeled secondary antibodies with silver enhancement
(Amersham; final dilution in PBS blocking buffer = 1:40), (ii) Cy3-labeled donkey anti-goat or
rabbit secondary antibodies (Jackson Immunoresearch; 1:500 ) or (iii) Cy3-labeled sheep anti-
digoxigenin (1:1000). Lectins were used as fluorescein isothiocyanate- (FITC), peroxidase- or
biotin-labeled conjugates. Bound biotinylated lectins were visualized with F1TC-conjugated
strepavidin (1:100; Sigma) while peroxidase-labeled lectins were detected with metal-enhanced 3'-
3'diaminobenzidine. Slides were washed in PBS, incubated with bis-benzimide (Sigma; diluted
1:20,000 in PBS) for 10 min at room temperature to visualize nuclei, washed several times with
PBS, and were then mounted in PBS/glycerol (1:1 v/v) or counterstained with hematoxylin,
dehydrated, and mounted in Permount (Fischer).
A panel of 11 antisera were used. They included (i) goat anti-BrdU (specificity = S-phase
cells; final dilution = 1:3000), (ii) rabbit anti-rat liver fatty acid binding protein (L-FABP;
specificity in developing and adult normal 129/Sv mouse intestine = villus enterocytes; 1:1000);
(iii) rabbit anti-intestinal fatty acid binding protein (I-FABP; 1:1000; enterocytes); (iv) rabbit anti-
C/EBPa (1:500; nonproliferating epithelial cells); (v) rabbit anti-pan-cadherin (1:2000; epithelial
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cadherins; Sigma), (vi) rabbit anti-laminin (1:1000, Sigma), (vii) rabbit anti-collagen IV (1:1000;
Collaborative Biomedical Products); (viii) rabbit anti-serotonin (1:4000); (ix) rabbit anti-substance
P (1: 1000); (x) rabbit anti-cryptdin (1:25; Paneth cells); and (xi) rabbit anti-enhancing factor
(1:200; Paneth cells).
Nine lectins were used, all at a final concentration of 5 mg/ml: (i) Jacalin (Artrocarpus
integrifolia agglutinin (stains small intestinal enterocytes (primarily Golgi and brush border) plus a
subset of enteroendocrine and goblet cells); (ii) Peanut agglutinin (stains brush border of jejunal
enterocytes, small intestinal enteroendocrine cells and a subset of goblet cells, a subset of colonic
enterocytes); (iii) Tirchosantes kirilowii (stains Paneth and goblet cells plus a subset of enterocytes
in the small intestine plus all three epithelial cell lineages in the colon); (iv) Dolichos biflorus
agglutinin (stains all four principal small intestinal epithelial cell lineages; enterocytes and subset of
goblet cells in the colon); (v) Helix pomentia agglutinin (stains Paneth cells, brush border of
enterocytes, subset of goblet cells located in the lower villus or in the nascent P1 crypt, rare
enteroendocrine cells, subset of colonic enterocytes, goblet cells in the lower half of colonic
crypts); (vi) Griffonia simplifolica, stains Paneth cells and subset of small intestinal goblet cells,
subset of colonic goblet cells; (vii)Ulex europaeus agglutinin type I (stains a majority of small
intestinal goblet cells, proliferating and nonproliferating cells in the P1 intervillus epithelium,
colonic enterocytes and subset of colonic goblet cells); (viii) Cholera toxin B subunit (stains
proximal half of small intestine = goblet cells, enteroendocrine cells, weak staining of brush border
and Golgi apparatus of enterocytes; distal half of small intestine = subset of goblet cells, strong
staining of enterocytic brush border and Golgi apparatus, colon = enterocytes); and (ix) Sambucus
nigra agglutinin (stains all goblet cells in small intestine and colon).
The number of goblet cells was defined in the proximal, mid and distal thirds of the small
intestine and in the colon. PAS/Alcian Blue-stained goblet cells in 20 well-oriented, nascent
crypt-villus units were counted/region/mouse (n = 2 animals/genotype). Paired Student's T test
was performed to assess whether any differences in the total number of goblet cells/region of Dcc"
/', Dcc+ /" and Dcc+/+ mice were statistically significant.
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Generation of Dcc"l: Embryonic Stem Cells
Homozygous mutant Dcc" " ES cells were generated from 129/Sv Dcc+/" ES cells using a
previously described method (Mortensen et al., 1992). 104 or 105 heterozygous cells were plated
on gelatinized 10-cm dishes and 24 h later medium containing 400-600 mg/ml G418 was added. In
each dish, an average of 10 colonies survived two weeks of culturing in the G418 medium. These
colonies were picked, passaged, and genotyped. Fifty percent of the colonies had lost the wild type
allele of Dcc and showed only the mutant allele by Southern analysis (data not shown). We
assumed that these colonies had lost the wild type Dcc allele, duplicated the mutant Dcc allele and
its PMCI-neo-polA cassette, and thus became resistant to high concentrations of G418 by virtue of
having two copies of neo. The colonies that survived high G418 but remained Dcc+/" served as the
control for the homozygous mutant cells. The homozygous mutant or the control heterozygous ES
cells were injected into B6 blastocysts to generate chimeric mice. Some of the chimeras created by
injection of three independent clones of homozygous Dcc "/ " cells displayed the same behavioral
abnormalities as the constitutionally homozygous mutant pups. Others appeared normal at birth,
lived to adulthood, and displayed less severe behavioral abnormalities such as abnormal limb
flexure. The Dcc" - cells in these viable chimeras contributed to the germline: when bred with wild
type mice, these Dcc "/ chimeras gave rise almost exclusively to Dcc+/ - progeny. Interbreeding of
the resulting Dcc+/l mice resulted in Dcc "" pups with a phenotype identical to the Dcc- " pups
generated from the heterozygous chimeras.
Whole-Mount Immunostaining of B6 Dcc+/+<->129/Sv Dcc"/ " intestines
Intestinal wholemounts were prepared from adult C57BL/6 Dcc+/+<->129Sv Dcc/-chimeric mice
(Hermiston and Gordon, 1995; Hermiston et al., 1993) and incubated with peroxidase-conjugated
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UEAl. Peroxidase activity was visualized using metal enhanced DAB. Note that some B6 goblet
cells express glycoconjugates recognized by the UEAl lectin.
Brain histology and spinal cord histochemistry
Brains were processed for histochemistry by standard procedures. Immunohistochemistry on 20
pm sections of spinal cord was performed with antibodies to TAG-1 (4D7, gift of M. Yamamoto)
and NF-M (gift of V. Lee). For TAG-i staining, sections were blocked in 1% heat-inactivated
normal goat serum, 0.1% Triton X-100 and 0.2% fish skin gelatin in phosphate buffered saline
(PBS), incubated with 1:200 dilution of 4D7 supernatant overnight, washed with blocking solution
(6 x 30 min), incubated overnight with 1:250 dilution of Cy3 conjugated anti mouse IgM (Jackson
ImmunoResearch), washed as above, and mounted in Fluoromount G (Fisher) (all steps
performed at 40C). Staining with anti-NF-M (1:5,000 dilution; 1:250 dilution of Cy3-conjugated
anti-mouse IgG (Jackson ImmunoResearch) used as secondary antibody) was performed in the
same way except that sections were boiled in 150 mls of citric acid buffer (0.1% citric acid sodium
salt dihydrate, pH 6) for 10 minutes prior to use. For whole-mount immunohistochemistry, E11.5
spinal cords (without dorsal root ganglia) were removed from the vertebral column, fixed in 4%
paraformaldehyde in PBS at 40C overnight, blocked for 3 hr in PHT (PBS / 1% heat-inactivated
goat serum / 0.1% Triton X-100), incubated with 4D7 (1:100 dilution in PHT) for 2 days, washed
with 20 changes of PHT over 2 days, incubated with Cy3-conjugated secondary antibody (1:700
dilution in PHT) for 2 days, washed with 30 changes of PHT over 3 days, and mounted in
Fluoromount G. All steps were performed at 40C, except for the blocking which was performed
at room temperature. Dye-tracing experiments were performed as described previously (Stoeckli
and Landmesser, 1995).
Results
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Inactivation of the mouse homologue of DCC
To extend our understanding of the human DCC gene, we inactivated its homologue (Dcc) in the
mouse genome. The DccX3 targeting vector (Fig. 1A) was introduced into 129/Sv D3 embryonic
stem (ES) cells (Gossler et al., 1986). Southern blot analysis demonstrated that three of the 200
gancyclovir- and G418-resistant ES cell clones screened had acquired a copy of the neomycin
transferase (neo) gene in the mouse Dcc locus by homologous recombination (Fig. IB). We term
this mutant allele Dcc.
Mouse chimeras generated from two of these Dcc+/- ES cell clones transmitted the Dcc"
allele through their germline. Interbreeding of the resulting heterozygous Dcc+/ " mice produced
homozygous offspring that appeared to be grossly normal at birth but died within 24 hours. In one
study, twenty-two of eighty-eight newborn mice died within the first day of life. All that died were
found to be Dcc-/- when genotyped. The littermates that survived were either Dcc+/+ or Dcc+/ in
the expected Mendelian ratio. The Dcc"- neonatal mice homozygous for the Dcc- (null) allele
exhibited striking behavioral phenotypes, including the inability to suckle, labored respiration,
abnormal body posture, and abnormal limb flexion in response to pinch stimuli, suggesting that
DCC might be essential for normal development of the nervous system (see below).
Immunoblots of proteins extracted from the brains of the Dcc-/ " pups and their normal
littermates were probed with a previously characterized antibody that recognizes the intracellular
domain of the DCC protein (Ekstrand et al., 1995). The results confirmed that the DccX3 mutation
caused complete loss of DCC protein expression in the homozygous mutant mice (Fig. 1C).
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Figure 1
Construction of DccX3 Mutation. (A) The DccX3 targeting vector was constructed using
fragments of the 129/Sv mouse Dcc gene, extending from intron two to intron three. The third
exon of Dcc spans most of the protein's second immunoglobulin-like domain and contains codons
138-232. The PMCI-neo-polA expression cassette was inserted at the Afl-II site in the third exon
of Dcc leading to the generation of a new Bam-HI restriction site within the third exon of a targeted
gene. The HSV-thymidine Kinase (tk) cassette, under the control of the pgk promoter, was
inserted adjacent to sequences from the third Dcc intron. The HSV-tk and PMCI-neo-polA
cassettes are transcribed in the same transcriptional orientation as the Dcc gene. X (Xba I), H
(Hind I), A (Afl II), B (Bam HI), K (Kpn I) and N (Not I) are restriction endonuclease sites.
(B) Targeting Dcc in the ES cells. Southern analysis of Barn-HI-digested DNA from ES cell clones
using a probe from intron 3. Some clones contain a DccX3-specific 11-Kb restriction fragment in
addition to the >20 Kb fragment corresponding to the wild-type Dcc allele.
(C) Protein Analysis. DCC was immunoprecipitated from total brain protein (Dcc" - in lanes 1 & 2;
Dcc+/+ in lane 3) using an antibody directed to C-terminus of DCC and western blotted as
described previously (Ekstrand et al., 1995). The full-length 190 kDa DCC protein is indicated by
arrow. Lane 4 represents a (+) control which is a DCC-deficient human cell line transfected with a
DCC-expressing construct and Lane 5 is a (-) control which is the same cell line before transfection
(Ekstrand et al., 1995).
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Tumor predisposition in Dcc+ "mice
To determine if heterozygosity at the Dcc locus causes tumor predisposition in mice, we followed a
cohort of nearly two-hundred 129Sv/C57BL6 (129Sv/B6) Fl Dcc+ / mice for two years. Dcc+/-
animals were monitored closely and screened at different ages for the presence of tumors in their
gut and extra-intestinal tissues. Only three Dcc+/ mice displayed signs of sickness, each being
observed at ~18 months of age. One of these animals had six adenomas in its duodenum. The
other two mice had brain neoplasms, one an astrocytoma, the other a meningioma. While these
observations suggested that aged Dcc+/ mice have a predisposition to tumors, whether
heterozygosity at the Dcc locus contributed to their formation could not be determined unless the
the incidence of tumors in aged Dcc+/- mice were compared to that of aged Dcc+/+ littermates.
For this purpose, we performed autopsies on ninety-eight Dcc+/ mice and thirty-six
Dcc+/+ littermates, aged 1.5 to 2 years. In addition, the entire intestine of each animal was
examined for the presence of adenomas. The heterozygous and the wildtype mice developed
adenomas at a low frequency (Table 1). A total of 22 adenomas were found in 9 mice from the
Dcc+ /- cohort (one mouse with seven adenomas, two with four adenomas, one with two
adenomas, two with one adenoma and eighty-nine mice with no adenomas). Examination of thirty-
six Dcc+/+ mice revealed adenomas in six mice, one in each. This study showed that Dcc+/ mice
had no significant increase in predisposition to adenoma formation when compared to wild type
controls (Table 1). Thirty percent of the animals had leukemias, soft tissue sarcomas, adenomas or
adenocarcinomas of tissues outside of the gastrointestinal tract or lymphomas; the frequency of
these lesions was not affected by the presence of the mutant allele of Dcc either. Most of these
tumors had not resulted in overt signs of sickness in the mice at the time of sacrifice and were
detected only during histological examination of the removed tissues. Finally, no brain tumors
were found either in the Dcc+/- or in the Dcc+/+ cohort.
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Table 1
Tumors in Dcc+ / - mice. +Mice are 18-24 month-old Fl and F2 129Sv/B6; *n is the number of
mice autopsied; #number and fraction (inside the parantheses) of mice that had a given class of
tumor or neoplasia. indicate the number of mice with each . Gastrointestinal lesions are adenomas
and were detected by examination of the gastrointestinal lumen under a dissecting microscope. A
total of 22 adenomas were found in 9 mice from the Dcc+/- cohort (one mouse with seven
adenomas, two with four adenomas, one with two adenomas, two with one adenoma and eighty-
nine mice with no adenomas). Examination of thirty-six Dcc+/+ mice revealed adenomas in six
mice, one in each. The majority of the lesions in liver (hepatomas or hepatocarcinomas), lung
(adenomas or adenocarcinomas), uterus (adenomas), the hematological lesions and sarcomas were
detected only by histological & microscopic examination of the tissues removed at autopsy.
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Tumors in Dcc+/ " mice
Genotype+
Epithelial
Gastrointestinal
Liver, lung & uterine
Mesenchymal
Leukemia & lymphoma
Sarcoma
Dcc+/-
(n=98)*
9 (9%)#
11(11%)
11 (11%)
8(8%)
Dcc+/+
(n=36)*
6 (17%)#
7 (19%)
4(11%)
2 (6%)
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Table 1
If loss of DCC played a causative role in the development of the intestinal adenomas
described above, the wild type Dcc allele would be expected to be lost in the tumors recovered
from Dcc+/- mice. Southern blot analysis of genomic DNA prepared from four adenomas from the
above cohort of 18 month-old heterozygotes (including one from the mouse with six such lesions)
and a brain tumor indicated that both the wild-type and the mutant Dcc alleles had been retained
(data not shown). Similar analysis, described below, indicated that our analytical procedures were
easily able to detect loss of the wild-type Dcc alleles in other adenomas of comparable size.
Although it appears unlikely that these lesions arose due to the Dcc mutation, we cannot rule out
the possibility that expression of the wild type Dcc allele was repressed in these lesions through
mechanisms other than LOH.
Effect of Dcc inactivation on the growth and progression of adenomatous polyps
Loss of Dcc expression could affect the progression of intestinal or colonic adenomas previously
initiated by the partial or complete loss of Adenomatous polyposis coli (Apc) function. This notion
is supported by the observation in humans that LOH of 18q correlates with an increase in the size
of colonic adenomas (Fearon and Vogelstein, 1990; Vogelstein et al., 1988). Moreover, some
studies have linked the loss of Dcc expression to morphological changes such as the acquisition of
a more dysplastic phenotype or to the appearance of adenomas that are of a more villus than tubular
appearance (Fearon, 1995).
To examine this possible interaction, we introduced the null Dcc allele into the germline of
the Min mouse (Moser et al., 1990) which carries a mutant Apc allele (ApcMin) in its germline that
predisposes it to develop small intestinal and colonic adenomas (Moser et al., 1992; Moser et al.,
1990; Su et al., 1992). The intestinal pathology of the Min mouse is similar to that of humans in
which germline APC mutations result in familial adenomatous polyposis (Groden et al., 1991;
Nishisho et al., 1991). In mice, both the Apc gene and the Dcc gene are on chromosome 18
(Luongo et al., 1993). The frequency of polyp formation and the phenotype of the adenomas in
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mice carrying the Min allele of Apc was not affected by the presence of the Dcc- allele on opposite
chromosomes, i.e., in trans configuration (data not shown).
Prior studies had demonstrated that nearly all adenomas in intestines of ApcMinW+ mice lose
not only the wild type allele of Apc but also the entire chromosome 18 harboring the wild type Apc
allele (Luongo et al., 1994). This loss affects any heterozygosity that may exist at the Dcc locus,
which happens to be located within 30 centimorgans of the Apc gene on chromosome 18 (Luongo
et al., 1993). We took advantage of this linkage by introducing the mutant Dcc allele into the
chromosome carrying the ApcMin mutation. We then bred mice having a genotype in which this
doubly mutant chromosome was present opposite a fully wild-type chromosome 18.
A cohort of forty-seven ApcMin Dcc-lApc+ Dcc+ mice was established that carried the
mutant alleles of these two genes in a cis configuration. A cohort of twelve ApcMin Dcc+lApc+
Dcc+ littermates was used as control. LOH analysis on the DNA of adenomas from ApcM in Dcc"
/Apc+ Dcc+ mice followed by densitometric analysis showed that 8/10 of the adenomas in the cis
compound heterozygous mice had lost the wildtype Dcc allele (adenomas numbered 1-3, 5-8, and
10 in Fig. 2A), as is seen for the linked wild-type Apc in virtually all adenomas in Min mice (Laird
et al., 1995; Levy et al., 1994; Luongo et al., 1994).
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Figure 2
Effect of Dcc on tumor progression in the mouse intestine. (A) Southern blot analysis of adenomas
extracted from the intestines of compound heterozygote (ApcMin Dcc-lApc+ Dcc+ ) mice.
Controls are constitutional DNA of tissues from Dcc+/- mice. Representative histological section of
two of these adenomas are shown in panels C & E. The band corresponding to the wildtype DNA
transfers less effeciently in Southern blots due to its larger size (>20 Kb) but a change in the ratio
of the intensity of the two bands can be determined using densitometric analysis (B) A benign
adenomatous polyp from a 6 month-old ApcMin/+ Dcc+/+ mouse stained, as in subsequent panels,
with hematoxylin and eosin. (C) A benign adenomatous polyp from a 6 month-old ApcMin Dcc-
/Apc+ Dcc+ mouse. (D) An invasive adenocarcinoma from a 6 month-old 129 ApcMin/+ Dcc+/+
mouse. Arrow points to carcinomatous cells that have invaded the muscularis mucosa. (E) An
adenocarcinoma from a 6 month-old 129 ApcMin Dcc-lApc+ Dcc+ mouse. Arrow points to the site
of invasion in the muscularis mucosa by carcinomatous cells.
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Germline heterozygosity for the mutant Dcc allele in the cis configuration with respect to
the ApcMin allele did not affect initiation of tumorigenesis in the intestine as assessed by a polyp
count (Table 2). Moreover, the absence of DCC had no effect on the average size of the adenomas
(Table 2). Histological analysis failed to reveal a change in the morphology of the adenomas; for
example, they showed no tendency to progress to a more villous phenotype (Fig. 2 B & C). An
equal proportion (approximately 1/20) of the adenomas in both groups of mice exhibited local
invasion, with extension of cyst- and finger-like projections of adenomatous cells deep into
muscularis mucosa (Fig. 2 D & E). Thus, loss of the wild type allele of the Dcc gene occurred in
the majority of intestinal adenomas in the cis compound heterozygous mice but it could not be
correlated with tumor progression (Fig. 2).
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Table 2
Effect of Dcc inactivation on formation of ApcMin-induced intestinal adenomas and their growth.
+Mice are first, second, or third-generation backcross of 129Sv/B6 Fl into 129/Sv; age = 6-12
months. * n is the number of mice analyzed. # n is the number of adenomas analyzed in mice of
the same age (6 months old).
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Effect of Dcc Inactivation on Polyp Number and Size
Genotype+ Average Number Average Size
of Adenomas per mouse (mm)
ApcMin/+ Dcc+/- 56 2.66(n=47)* (n=452)#
AncMin/+ Dcc+/l+ 59 2.69(n=12)* (n=335)#
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Intestinal epithelial proliferation and differentiation in newborn Dcc'Lmice
To determine whether DCC had any detectable role in regulating the normal proliferation and
differentiation programs of the self-renewing intestinal epithelium, we compared this tissue
prepared from five newborn (P1) Dcc"/ " mice with those from three Dcc+/ + and five Dcc+ / "
littermates. Inspection of hematoxylin- and eosin-stained sections prepared along the length of the
duodenal-ileal axis revealed no differences in villus height or cellular architecture (Fig. 3 A & B).
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Figure 3
Multilabel Immunocytochemical Studies of the Intestinal Epithelium of P1 129/Sv
Dcc"- Mice
(A, B) Sections, prepared from Dcc "/ " and Dcc+/+ mouse jejunum (panels A and B, respectively),
were stained with hematoxylin and eosin. The villi were cut either parallel or perpendicular to the
crypt-villus axis. Arrows point to M-phase cells in the intervillus epithelium.
(C) Jejunum from a P1 Dcc "" mouse that had been injected with BrdU 90 minutes prior to
sacrifice. The section was incubated with goat anti-BrdU sera (visualized with Cy3-labeled donkey
anti-goat Ig) and biotin-conjugated Dolicos biflorus agglutinin (DBA, visualized with FITC-
conjugated strepavidin). Closed arrowheads point to proliferating, BrdU+ (red) cells in the
intervillus epithelium. Rare BrdU+ lymphocytes are evident in the lamina propria (open
arrowheads). DBA recognizes a glycoconjugate present on the enterocyte brush border (open
arrow) and in the mucus globules of goblet cells (closed arrow).
(D) Comparable segment of 129/Sv Dcc+/ + jejunum stained as in Panel C.
(E) Triple label of a jejunal segment from a Dcc "/ " mouse. The section was incubated with rabbit
anti-liver fatty acid binding protein (L-FABP) sera (visualized with Cy3-donkey anti-rabbit Ig),
FITC-conjugated CholeraToxin B subunit (CTB), and bis-benzimine (dark blue nuclear stain). L-
FABP (red-purple) is present in villus enterocytes. CTB binds to goblet cells (green; closed
arrows) and to the brush border of enterocytes located on the villus and in nascent crypts (open
arrow).
(F) Section of duodenum from a Dcc "/ mouse incubated with rabbit anti-CEBPa sera and gold-
labeled goat anti-rabbit Ig. Antigen-antibody complexes were visualized by silver staining (IGSS).
Nuclei were counterstained with hematoxylin. CEBPa-positive enterocytes are present on the lower
half of the villi (closed arrows) and in nascent crypts (closed arrowheads).
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(G) Jejunum from a Dcc "/ mouse stained with rabbit anti-serotonin sera (visualized with IGSS).
Nuclei were counterstained with hematoxylin. Immunoreactive enteroendocrine cells (black,
arrows) are present in the nascent crypt and in the villus epithelium.
(H) Triple labeling of a section of ileum from a Dcc "/ " mouse. Collagen IV in the extracellular
matrix (red) was stained with rabbit anti- collagen IV sera (visualized with Cy3-donkey anti-rabbit
Ig). FITC-conjugated Helix pomentia agglutinin (HPA) labeled glycogonjugates located in the
enterocytic brush border (green, open arrow) and in the mucus globules of goblet cells (green,
closed arrow). Nuclei were visualized with bis-benzimine. Bar = 25 mm.
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We examined the proliferative status of intestinal epithelial cells in the newborn Dcc / ',
Dcc+/', and homozygous wild type mice by injecting them with a bolus of bromodeoxyuridine
(BrdU) 90 minutes prior to sacrifice. S-phase cells were confined to the intervillus epithelium in
all animals. Moreover, the number and distribution of BrdU-positive cells within the intervillus
epithelium were identical between all groups of littermates (Fig. 3C & D).
Expression of the CCAAT enhancer-binding protein (C/EBPa) also provides a sensitive
index of the proliferative state of enterocytes, the principal intestinal epithelial cell lineage
(Chandrasekaran and Gordon, 1993). C/EBPa was present at highest concentrations in epithelial
cells located in the intervillus epithelium and the lower half of duodenal and jejunal villi in a pattern
that was identical in the epithelia of Dcc"- , Dcc+/- , and Dcc+ /+ mice (Fig. 3F). Together, these
findings indicated that loss of Dcc does not affect intestinal epithelial proliferation on the first day
after birth.
The role played by DCC in epithelial differentiation was examined using a panel of lectins
and antibodies. Glycoconjugate production is a sensitive reporter of perturbations in intestinal
epithelial differentiation (Falk et al., 1994). Changes in glycoconjugate production can be
monitored by noting the cellular patterns of lectin binding to intestinal sections (Falk et al., 1994).
Loss of Dcc produced no apparent changes in the pattern of lectin binding to the enterocytic lineage
(e.g., Fig. 3C & E). Substance P- and serotonin-producing enteroendocrine subpopulations are
good markers of the spatial complexity of this lineage's differentiation program along the crypt-
villus and duodenal-ileal axes (Roth and Gordon, 1990). Loss of Dcc did not have any detectable
qualitative or quantitative effects on either of these subpopulations (Fig. 3G).
Some immunochemical and in situ hybridization studies of the adult human colon have
suggested that DCC is a cell surface protein most prominently represented in goblet cells (Hedrick
et al., 1994). Spatial and developmental changes in goblet cell differentiation are readily detected
by lectin binding patterns (Falk et al., 1994). Our panel of 9 lectins (see Methods) revealed no
differences in goblet cell subpopulations between Dcc--, Dcc+/- and wild type littermates (Fig.
3C, E & H). Periodic Acid Schiff (PAS) and Alcian Blue together stain essentially all goblet cells
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in the P1 mouse intestine. There was no statistically significant difference (p>0.05) in the number
of PAS/Alcian Blue-positive goblet cells in the proximal, mid, or distal small intestine or in the
colon of Dcc-/ " mice compared to their Dcc+/- or Dcc+/+ littermates.
The Paneth cell lineage is confined to the base of small intestinal crypts and undergoes a
characteristic developmental stage-specific sequence of expression of marker gene products from
E15 to P28 (Bry et al., 1994). Loss of Dcc did not produce any precocious induction of these
markers at P1 (data not shown).
The basement membrane underlying the intestinal epithelium receives contributions from
both epithelial and mesenchymal cell populations (Louvard et al., 1992). Laminin and collagen IV
are prominent components of this basement membrane. Loss of Dcc did not affect the amount or
distribution of these proteins along the nascent crypt-villus or duodenal-colonic axis (Fig. 3H).
Together, these studies indicate that Dcc does not have any observable effect on the development of
the intestinal epithelium of newborn mice.
Proliferation, migration and differentiation in the intestinal epithelium of adult B6 Dcc+/+<-
>129/Sv Dcc"L" chimeric mice
The early death of Dcc"/ homozygous mice at P1 prevented us from assessing the function of Dcc
in the adult intestine. To circumvent this difficulty, we generated chimeras composed in part of
Dcc-/ " cells. First, we produced homozygous mutant 129/Sv Dcc- " ES cell lines by subjecting
129/Sv Dcc+ / " ES cells to high concentrations of G418 (Mortensen et al., 1992). Cells from three
independent Dcc- " ES cell clones were then injected into normal C57BL/6 (B6) Dcc+/+ embryos.
Hereafter, such chimeras are identified by the notation B6 Dcc+/+ <-> 129/Sv Dcc-/ - .
Work of others has shown that crypts in the intestine of adult mice are monoclonal
(reviewed in (Gordon et al., 1992)). Thus, in B6<->129/Sv chimeric mice, the crypts are
populated by either B6 or 129/Sv cells but not by a mixture of both (Hermiston and Gordon, 1995;
Hermiston et al., 1993). However, each villus is populated by cells originating in several adjacent
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crypts (reviewed in (Gordon and Hermiston, 1994)) and may therefore be polyclonal in origin.
Hence, a B6<->129/Sv chimeric intestine contains patches of 129/Sv and B6 crypt-villus units.
These can be readily distinguished because 129/Sv but not B6 enterocytes bind the lectin Ulex
europeaus agglutinin type 1 (UEA1) (Hermiston and Gordon, 1995; Hermiston et al., 1993); &
Fig. 3).
A portion of the B6 Dcc+/ +<->129/Sv Dcc "/ " chimeras appeared normal at birth and lived
to adulthood. Intestinal wholemounts were prepared from eight-week old B6 Dcc+/+ <->129/Sv
Dcc "" chimeras in which the 129/Sv contribution to coat color was about 50%. These were then
stained with the UEA1 agglutinin. Some of the villi encountered at the border of ES cell- and host
blastocyst-derived epithelium were polyclonal, being composed of cells originating from both
129/Sv-Dcc "/ - and B6-Dcc+/+ crypts. These polyclonal villi contained vertical coherent columns
of wholly UEAl-positive 129/Sv (Dcc-/-) enterocytes and adjacent columns of wholly UEAl-
negative B6 (Dcc+/ +) enterocytes (Fig. 4).
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Figure 4
Wholemount of An Adult Chimeric B6 (Dcc+/ +) <->129/Sv (Dcc "/ ) Small Intestine. A segment of
jejunum from the wholemount preparation is shown, viewed from the luminal surface. Villi are
apparent as finger-like projections. The arrow points to a representative polyclonal villus. This
villus contains 3 columns of UEA l-positive (brown) Dcc "-/ enterocytes. These columns of cells
extend from adjacent crypts to the tip of the villus. The columns of Dcc "" cells are separated by
columns of UEAl-negative Dcc+/+ enterocytes (white) supplied by B6 crypts.
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The presence of these two easily distinguished cell populations on a single villus provided
us with an opportunity to precisely assess the effects of Dcc loss. The ES-derived Dcc-/- UEA1+
cellular columns extended from the base to the tip of each polyclonal villus. The border between
ES and B6 Dcc+/+ columns was well defined (Fig. 4), indicating that the absence of Dcc function
did not affect the normal orderly migration of cells from the crypt to the villus tip. Moreover, the
two sides of such polyclonal villi were indistinguishable morphologically. Villi that were
composed exclusively of UEA+ Dcc+/+ B6 cells had the same height as adjacent villi composed of
wholly Dcc-"/ 129/Sv cells (Fig. 4). These similarities in height indicated that the absence of Dcc
did not perturb the rate of cell production in crypts and/or the rate of cell loss from villi.
Finally, no intestinal adenomas or tumors of other tissues were found in a cohort of ten
two-year-old chimeric mice at the time of their sacrifice. In these chimeric mice, the 129/Sv Dcc-"/
cells contributed to at least 90% of the coat color. We presume that these mutant cells constituted a
similar percentage of the colonic epithelium as well. An indication of significant contribution by
129/Sv Dcc-"/ ES cells to the internal organs of these chimeric mice came from breeding of four of
these chimeras to C57BL/6 mice. Virtually all resulting progeny over a period of one year had
agouti coat color and were Dcc+/- indicating that the large majority of germ cells in these mice were
the descendants of 129/SV Dcc-/ - ES cells.
Defects in spinal commissural axon projections in Dcc-'mice
To investigate the function of DCC in the nervous system, we first examined whether loss of DCC
function affected the growth of commissural axons in the developing spinal cord, because of
previous results from in vitro studies which indicated that DCC is involved in mediating the effects
of netrin-1 on these axons (Keino-Masu et al., 1996). In the mouse, commissural neurons
differentiate in the dorsal spinal cord between embryonic day 9.5 (E9.5) and E11.5 (EO = day of
vaginal plug), and extend their axons to the floor plate (Colamarino and Tessier-Lavigne, 1995).
We have found that DCC is expressed by commissural axons in the mouse at these stages
141
(assessed by immunohistochemistry, data not shown; see also (Cooper et al., 1995)), as it is at
comparable developmental stages in the rat (E 11-E13) (Keino-Masu et al., 1996).
To assess the trajectories of commissural axons at E9.5-El 11.5 in the mouse, we labeled
these axons in transverse sections of spinal cord at forelimb levels using an antibody to TAG-i, a
surface antigen that is expressed by commissural axons as they project to the floor plate (Dodd et
al., 1988). In wildtype embryos and embryos heterozygous for the Dcc- allele, commissural
axons were seen to take their normal dorsal-to-ventral trajectory. As illustrated for an E 11.5
embryo (Fig. 5A), commissural axons initially extend in the dorsal spinal cord along a dorsal-to-
ventral trajectory near the edge of the spinal cord until they arrive at the level of the developing
motor column. At early stages when the motor column is still small (E9.5), some of the axons
continue to grow along the edge of the spinal cord all the way to the ventral midline (Wentworth,
1984). But as the motor column increases in size, most of the commissural axons that reach the
motor column break away from their trajectory along the lateral edge of the spinal column and
project medially to the motor column or through the motor column in a ventromedial direction
toward the floor plate (Fig. 5A).
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Figure 5
Defects in Commissural Axon Projections in Dcc-/ - Embryos. Trajectories of commissural axons
in sections of a wildtype (A, C) and Dcc-/ - (B, D) E 11.5 embryos, visualized by
immunohistochemistry using an antibody to TAG-1. In wildtype embryos, commissural axons (c)
extend along a dorso-ventral trajectory in the dorsal spinal cord (A), then project along a
ventromedially-directed trajectory to the floor plate (fp) at the ventral midline of the spinal cord (C).
In Dcc-" - embryos, commissural neurons are present (see TAG-1+ cell bodies ), but fewer axons
extend in the dorsal spinal cord (B) and fewer yet extend into the ventral spinal cord (D). Many of
those that do project along aberrant trajectories within the ventral spinal cord (arrows in D).
Projections of sensory axons, and the ventral roots, appear largely normal (B). Arrowheads in (C)
and (D) indicate a population of TAG-1+ cells adjacent to the floor plate.
Additional abbreviations: d, dorsal root ganglion; drez, dorsal root entry zone; mc, motor column;
v, ventricle.
Scale bars are 100 gm in (A, B), 50 Sm in (C, D).
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In E9.5-E11.5 embryos homozygous for the null Dcc allele, the projections of
commissural axons were markedly disrupted (Fig. 5 and data not shown). In the dorsal spinal
cord, there was a reduction in the number of commissural axons, though those that did extend
appeared to adopt a normal dorsal-to-ventral trajectory. There was also a significant reduction in
the number of axons that penetrated the ventral spinal cord. Interestingly, in some sections (see
Fig. 5B and 5D), some axons were observed that projected all the way to the floor plate. In other
sections, however, no axons were seen reaching the floor plate (data not shown). This
heterogeneity along the rostrocaudal axis was evident is sagittal views of the spinal cord (Fig. 6),
where small numbers of axons, often clustered at particular locations along the rostro-caudal axis,
can be seen reaching the floor plate in some regions (arrowheads in Fig. 6B), while many regions
are devoid of such axons. In addition to this reduction in the number of commissural axons
projecting into the ventral spinal cord, there appeared to be a misrouting of many of the axons that
did project into this region. Whereas in the wildtype spinal cord, the axons that enter the ventral
half of the spinal cord are largely directed toward the ventral midline (Fig. 5C), in the Dcc-l -
embryos the axons appeared more randomly directed, with some projecting more medially and
others more laterally (Fig. 5D). These defects revealed by TAG-1 staining were fully penetrant, as
they were observed in all Dcc"/ - embryos examined (over 10 transverse sections of n = 8 embryos,
and whole-mounts of n = 8 embryos), but in none of the wildtype littermates (n = 6 and 5,
respectively).
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Figure 6
Few Commissural Axons Reach the Floor Plate in Dcc- - Embryos.
Sagittal views (side views) of spinal cords from a wildtype (A) and a Dcc-/- (B) El 11.5 embryo
that were subjected to whole-mount immunohistochemistry with an antibody to TAG-1 to visualize
commissural axon trajectories. Dorsal is up, ventral down (arrowhead indicates floor plate) (drez
indicates sensory axons coursing longitudinally in the dorsal root entry zone). The characteristic
microsegmented projections of commissural axons along a dorso-ventral trajectory to the floor
plate is visible in the wildtype embryo (A). In contrast, in the mutant (B) many fewer axons
extend within the dorsal spinal cord, and only a few reach the floor plate (arrow). Open arrowhead
indicates TAG- 1 + cells located adjacent to the floor plate (see also Figure 5D).
Scale bar is 100 pm.
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The defects in commissural axon projections did not appear to reflect a major reduction in
the number of commissural neurons, the presence of which could be demonstrated through their
expression of the cell surface marker TAG-1. The distribution of TAG-1+ cell bodies in the spinal
cord in the mutant appeared similar to that observed in wildtype and heterozygous littermates,
though the cell bodies in the latter case were obscured by the numerous TAG-1+ axons that were
present (compare Fig. 5A and 5C with Fig. 5B and 5D). One difference, however, was the
observation that in the mutant spinal cords TAG-1 staining was stronger in locations closer to the
dorsal midline (roof plate) than was in the corresponding regions of wild-type or heterozygous
littermates (compare Fig. 5A and 5B). The distribution of TAG-1+ cell bodies in mutants was
actually very similar to the distribution of Dcc transcripts at these stages (see (Keino-Masu et al.,
1996), Figure 5D), reflecting the distribution of the cell bodies of commissural neurons. TAG-1
staining is not normally observed on the cell bodies of the dorsal-most commissural neurons,
because TAG-1 expression is usually downregulated on cell bodies as neurons extend axons
(Dodd et al., 1988). Thus, the continued expression of TAG-1 in the most dorsal regions
correlates with and may be caused by the reduced extension of commissural axons.
This analysis assumed that TAG-1 is a reliable marker of commissural axons as they grow
to the floor plate not just in wildtype but also in Dcc-/ - embryos. However, since DCC and TAG-1
are normally coexpressed on these axons, it also seemed possible in principle that a change in the
distribution of TAG-1 immunoreactivity in the spinal cord of mutant embryos could reflect not a
change in the growth of commissural axons but rather a change in the expression of TAG-1 by
these axons caused by the absence of DCC protein. To address this possibility, we examined the
trajectories of commissural axons by injecting the fluorescent lipophilic dye DiI into the cell bodies
of these neurons in the dorsal spinal cord, which diffused down their axons. The pattern of axonal
projections visualized in this way at E11.5 was very similar to that observed by TAG-1
immunoreactivity both in wildtype embryos (compare Fig. 5A, 5C and Fig. 7A, 7B), and in Dcc-l -
embryos (compare Fig. 5B, 5D with Fig. 7D-F), indicating that TAG-1 is in fact a reliable marker
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of commissural axons in the mutant embryos. Again, the defects appeared fully penetrant, as they
were observed in 9/9 Dcc-" - embryos.
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Figure 7
Defects in Commissural Axon Projections Revealed by Dye-tracing in the Spinal cord of Wildtype
and Dcc- " Embryos. DiI was injected into the dorsal spinal cord of wildtype (A, B), heterozygous
(C), and homozygous mutant Dcc-/ - E11.5 embryos (D-F) and allowed to diffuse down
commissural axons. Axonal projections were visualized in transverse vibratome sections from
these embryos. Note that less DiI was injected in the wildtype embryo than in the other embryos
shown.
(A, B, C). Combined phase contrast and fluorescence micrograph (A), and fluorescence
micrograph (B), of a wildtype embryo, showing the normal trajectory of commissural axons to the
floor plate (arrowhead in (B)). Note the presence of ipsilaterally projecting axons originating in the
dorsal spinal cord, which do not express TAG-1 (see Figure 5). A similar pattern of projection is
observed in Dcc+/ - embryos (C) (n = 12/12).
(D - F). Trajectory of axons labelled from the dorsal spinal cord in 3 different Dcc-/ - embryos.
The trajectory of presumptive commissural axons is similar to that seen by TAG-1 labeling (Figure
5): many fewer axons project into the ventral spinal cord; some axons project ventromedially but
are not particularly directed towards the floor plate (E, F), and many axons wander within the
motor column (G). Few axons reach the floor plate (arrowheads in (D -F)). Axons projecting
along the lateral edge of the motor column, which are presumptive ipsilaterally projecting axons,
are observed in all cases. Similar results were observed in 9/9 embryos.
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The defects in commissural axon projections appeared to be specific to this class of axons,
inasmuch as the pattern of TAG-1 expression did not reveal obvious defects in the development of
the axons associated with both sensory and motor neurons, the latter of which express DCC
(Keino-Masu et al., 1996) (Fig. 5A and 5B). This was further confirmed by staining sections
using an antibody to neurofilament protein, which labels all axons present in the spinal cord. As
was the case with the TAG-1 antibody, this staining failed to reveal any obvious defects within the
spinal cord in the projections of axons other than commissural axons (Fig. 8). It also revealed a
clear reduction in the size of the ventral commissure though not its complete absence (Fig. 8 and
data not shown), consistent with the projection of some commissural axons to the floor plate in the
mutant animals.
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Figure 8
Neuronal Differentiation in Wildtype and Dcc- ' Embryos Visualized Using Anti-Neurofilament
Antibodies. Axonal trajectories were visualized by immunohistochemistry using an antibody to
NF-M in sections of caudal spinal cord from wildtype (A) and Dcc-/ - (B) El 1.5 embryos,
revealing a reduction in the number of commissural axons (c) projecting to the floor plate (fp) as
well as a reduction in the size of the ventral commissure (vc) in the mutant, but no obvious defects
in pattern of motoneurons in the motor column (mc) and of their axons (ma), or of sensory
neurons in the dorsal root ganglia (d) (see also Figure 5).
Scale bar is 100 gm.
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Defects in brain development in Dcc"- mice
The defects in commissural axon projections in the spinal cord were similar to those observed in
netrin-l-deficient animals, though more severe (Serafini et al., 1996; see Discussion). In addition
to defects in spinal cord development, netrin-1-deficient animals show multiple defects in brain
development: the absence of corpus callosum and hippocampal commissure, a reduction in the
anterior commissure, the presence of an unusual commissure at the junction of midbrain and
hindbrain, and the absence of pontine nuclei in the rostral hindbrain (Serafini et al., 1996). We
therefore examined whether any defects were apparent in morphogenesis or axonal projections in
horizontal sections of brains from newborn Dcc-/ - mice.
Striking defects were indeed observed in these mutants which were similar to those
observed in netrin-1-deficient animals. The corpus callosum and hippocampal commissure
appeared to be completely absent in the Dcc"-- mice (Fig. 9A and 9B). The axons that normally
form these commissures appeared to be present but failed to cross the midline and remained
ipsilateral, projecting to aberrant locations and forming tangles ("Probst bundles"). The anterior
commissure in Dcc-/ - mice was also severely reduced; the large anterior and posterior limbs of the
anterior commissure (Fig. 9C) did not form and join near the midline (data not shown), although in
most mutant animals we detected a reduced commissure at the midline which, based on its
horizontal projection pattern, might correspond to a portion of the posterior component of the
anterior commissure. Figure 9D shows the largest such commissure that was detected. As in
netrin-l-deficient animals, these defects did not reflect a generalized defect in commissure
formation, as the habenular and posterior commissures both appeared to be intact in these animals
(Fig. 9E and 9F).
In addition to these forebrain defects, two phenotypes in the brainstem were observed in
the Dcc-/ - mice. First, an enlarged commissure that is not normally present was observed in the
anterior medullary velum which forms the roof of the fourth ventricle in the junctional region
between hindbrain and midbrain (Fig. 9G and 9H). Second, the pontine nuclei at the base of the
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rostral hindbrain appeared to be absent in the mutant animals (Fig 91 and 9J). Thus, the defects
seen in the Dcc -deficient animals were similar to those observed in netrin-1-deficient animals
(Serafini et al., 1996). The various defects observed in the homozygous animals were not
observed in heterozygous littermates (data not shown).
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Figure 9
Defects in Brain Commissures and Absence of Pontine Nuclei in Dcc-/ - Embryos. Horizontal
sections from brains of wildtype or heterozygous neonatal pups (A, C, E, G, I), and homozygous
mutant pups (B , D, F, H, J) stained with hematoxylin and eosin (rostral is up in each).
(A, B). Sections through the region of the corpus callosum (CC) and hippocampal commissure
(HC) of a wildtype (A) and Dcc-/ - (B) pup, showing the absence of these commissures in the
mutant. Axons that normally form the commissures appear to be present in the mutant but to
coalesce in aberrant swirls (Probst bundles, arrowheads). These commissures were both present
in the heterozygous pups (data not shown).
(C, D) Sections through the region of the anterior commissure (AC) showing both the anterior
limb (aAC) and posterior limb (pAC) of this commissure in a wildtype pup (C). The anterior
commissure is much reduced in the homozygous Dcc-'-mutant (D). The anterior limb is not
observed approaching the posterior limb in any section; instead, an aberrant bundle of axons
(arrow in D) was observed approaching the midline at more rostral levels, which may consist of
misrouted axons that normally form the anterior limb. The posterior limbs were much reduced but
not, apparently, completely absent, and in most mutants a reduced commissure was observed
(arrowhead). The anterior commissure appeared normal in heterozygous pups (data not shown).
(E, F) The habenular commissure (HaC) and posterior commissure (PC) are present in wildtype
(data not shown), heterozygous mutant (E), and homozygous mutant (F) pups. Note that the
caudal extension of the posterior commissure shown in (F) is also observed in appropriate sections
in wildtype and heterozygous pups (data not shown).
(G, H) In Dcc'/-pups (H), a thick commissure (arrowhead) is observed in the roof of the fourth
ventricle in the region of the hindbrain-midbrain junction, that is not observed in wildtype pups (G)
or heterozygous pups (data not shown) in this region (arrow in (G)).
(I, J) The pontine nuclei (PN) at the base of the rostral hindbrain in wildtype (data not shown) and
heterozygous (I) pups are not detected in Dcc-/-pups (J).
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Additional abbreviation: Cb, cerebellum.
Scale bars are 175gm in (A, B, E, F), 135gm in (C, D), 150gm in (G, H), 200 gm in (I, J).
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Discussion
Candidacy of DCC as a Tumor Suppressor Gene in Colon Cancer
The experiments described here were initially designed to assess the role of the human DCC gene
in colonic tumorigenesis through manipulation of its mouse homologue. At the outset of these
experiments, we anticipated that mice carrying a null allele of the Dcc gene would exhibit an
increased susceptibility to tumorigenesis. While we observed a small number of tumors in several
tissues in aged Dcc+/- mice, this number was no greater than that observed in wild-type mice
(Table 1), and those lesions examined genetically gave no evidence of loss of the remaining wild
type Dcc allele. These observations argue against a causal role for the mutant allele in the
pathogenesis of the tumors that were observed.
A potentially more sensitive test of a tumor suppressor role of DCC involved inactivation of
both alleles of Dcc in mouse intestinal adenomas, since loss of DCC has been implicated to play a
causative role in the progression of early adenomas to intermediary adenomas (Boland et al., 1995)
and intermediary adenomas to advanced adenomas (Boland et al., 1995; Fearon et al., 1990;
Vogelstein et al., 1988) in human colon. Mice of the ApcMin genotype are predisposed to
developing large numbers of intestinal polyps (Moser et al., 1990; Su et al., 1992), a condition
very similar to familial adenomatous polyposis seen in humans (Groden et al., 1991; Nishisho et
al., 1991). Moreover, somatic mutation of APC occurs in an early stage in the majority of
sporadic human colonic tumors (Powell et al., 1992). Since DCC has been described as a tumor
suppressor gene whose expression is eliminated after APC inactivation during colonic tumor
progression (Boland et al., 1995; Fearon, 1995; Fearon and Vogelstein, 1990; Vogelstein et al.,
1988), we expected that its loss in the mice would accelerate the progression of or modify the
phenotype of polyps initiated in the ApcMi /+ mice. We observed no such effect in adenomas that
carried only the inactivated allele of Dcc. (Table 2 and Fig. 2).
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A third line of investigation addressed any part played by the Dcc gene in intestinal
morphogenesis in the mouse. We reasoned that if DCC played an ongoing role in the control of
proliferation of intestinal epithelial cells, then its absence from the embryonic gut or adult intestine
would, with great likelihood, have a readily observable effect on proliferation or the development
of colonic crypts, villi, and the associated epithelial cell populations. The absence of Dcc had no
effect on proliferation or intestinal morphogenesis (Fig. 3 and 4).
Taken together, these three lines of investigation argue that Dcc plays little if any part in the
physiology of the intestinal epithelium in the mouse. The implications of these findings for the
human DCC gene and its role in human colorectal tumorigenesis are less clear, however. Of
importance, the evidence from other lines of work has failed to implicate DCC conclusively as a
tumor suppressor gene in colon cancer.
One line of evidence has come from tissue culture experiments and suggests that DCC can
reverse the tumorigenic phenotype (Narayanan et al., 1992). In those experiments, high levels of
anti-DCC RNA appeared to cause a non-specific cytostatic effect in Rat-1 cells and thus the cells
had to be passaged in culture to select for clones able to tolerate anti-DCC RNA (Narayanan et al.,
1992). The selected clones were found to be more tumorigenic than the parental cells, but the long
term culture of these cells may have inadvertantly selected for those with increased tumorigenicity.
Moreover, the rationale underlying the mechanism of action of an anti-sense RNA on cells that do
not express detectable levels of a sense transcript is unclear.
In a second study, DCC-overexpression in an immortalized human keratinocyte cell line
caused poor growth in vitro and reduced tumor growth in vivo (Klingelhutz et al., 1995). While
compatible with a physiologic role for DCC in constraining cell proliferation, this latter study is
difficult to interpret for two reasons. First, high levels of DCC protein (which is not normally
expressed in these cells) may, like many ectopically expressed proteins, exert non-specific
cytostatic effects on cells. Second, these studies were not undertaken in cell lines generated from
human colon carcinomas in which a tumor suppressive function for DCC is proposed.
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The strongest evidence in support of the role of DCC as a tumor suppressor stems from
observations of the reduction or loss of DCC RNA in cell lines or xenografts derived from human
colon carcinomas (Fearon et al., 1990; Kikuchi-Yanoshita et al., 1992; Thiagalingam et al., 1996).
Even this evidence is not conclusive however. A similar LOH of 18q and loss of DCC RNA
expression can be observed in many pancreatic tumors (Hohne et al., 1992), in which another gene
on chromosome 18q21, termed DPC4, has recently been identified as a tumor suppressor (Hahn
et al., 1996). Its importance in pancreatic tumorigenesis is strongly supported by the discovery of a
number of inactivating mutations affecting this gene in a series of tumor samples (Hahn et al.,
1996). Hence, in these tumors, loss of DCC expression may be a consequence of events affecting
a linked gene rather than the primary target of inactivation during tumor progression.
Thus, the evidence accumulated to date supporting a role of DCC as a tumor suppressor
operating in the human colon is far from conclusive. The findings of the present study in mouse
also fail to add support to the candidacy of DCC as a tumor suppressor gene. In contrast, the role
played by DCC in another, quite distinct tissue site has been demonstrated definitively by a
confluence of recent studies of C. elegans, Drosophila melanogaster , rat (Chan et al., 1996;
Keino-Masu et al., 1996; Kolodziej et al., 1996) and the mouse (this study), which indicate that
the products of the DCC gene and its homologs serve as receptors to morphogens that guide axonal
migration during the development of the nervous system.
These disparate observations in humans, rodents and invertebrates can be rationalized in at
least two ways. It is possible that the mouse and human genes have assumed distinct roles during
the divergent evolution that has separated rodents from primates. If this were so, then the lack of
an effect of DCC loss on the growth, differentiation and neoplastic transformation of cells in the
mouse intestine would provide little insight into the role of DCC in human colon cancer
pathogenesis. Arrayed against this possibility of such divergent roles of DCC in humans and mice
is the evidence that DCC plays a highly conserved function in axonal guidance in organisms as
divergent as worms, fruit flies and vertebrates (Chan et al., 1996; Keino-Masu et al., 1996;
Kolodziej et al., 1996) (and this study). Such highly conserved function for DCC homologs in
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these organisms suggests that in humans, as in other species, the major role of DCC is in axonal
guidance. Also, some investigators have had difficulty verifying the presence of DCC protein in
the human colonic epithelium (Turley et al., 1995) while the DCC protein is readily detectable in
the developing human brain (Hedrick et al., 1994). Nevertheless, the fact that DCC does not act as
a tumor suppressor gene in mice does not completely rule out a role for DCC in tumor suppression
in humans.
The second, alternative possibility is that in human colon cancer, as is seemingly the case in
pancreatic cancer, the loss of DCC expression is a consequence of events affecting a linked gene
and that DCC is not the primary target of inactivation during tumor progression. According to this
scenario, the observed LOH of 18q21 affects not only the DCC gene but other neighboring genes
as well, one or more of which is the bonafide target of inactivation during colon tumor
progression. The definitive proof of this possibility can only come from the identification of a
gene on 18q that undergoes LOH and whose retained allele is also mutated in the majority of
colonic tumors. This linked gene is unlikely to be either DPC4 or JV18 because their retained
alleles appear to be mutated in only a fraction of human colon tumors that suffers 18q LOH
(Thiagalingam et al., 1996).
DCC is required for commissural axon projections in the spinal cord
Whereas Dcc-/ - mice show no obvious phenotypes in intestinal development or increased tumor
susceptibility, the present results indicate profound effects of loss of DCC protein on the
development of axonal projections in the central nervous system. These defects are observed in the
same classes of axons that are affected in netrin-1-deficient animals (Serafini et al., 1996). Our
observations are therefore consistent with the hypothesis that DCC is a component of a receptor
mechanism for netrin-1, a model that was suggested by the finding that DCC is a netrin-1-binding
protein expressed on spinal commissural axons whose function is required to mediate the
outgrowth-promoting effects of netrin-1 on these axons in vitro (Keino-Masu et al., 1996).
163
Commissural axon projections are defective in the spinal cord of Dcc-" - embryos, as they
are in netrin-1-deficient animals (Serafini et al., 1996). Although the similarity in phenotypes is
striking, commissural axons appear more foreshortened in the Dcc-/ - than in the netrin-1-deficient
mice (compare this study and Serafini et al., 1996). One possible explanation for this difference is
that the netrin-1 allele that was studied is not a complete null allele, and residual netrin-1 function is
present in those animals (discussed in Serafini et al., 1996). This residual netrin function could
account for the less severe phenotype that is observed in that study. Hence, it is possible that the
phenotype of mice lacking all netrin-1 function would be identical to the Dcc null phenotype
reported here. Such an observation would indicate that netrin-l is the sole ligand for DCC in the
spinal cord, and that DCC is absolutely required for netrin-1 effects on commissural axons.
An alternative possibility is that DCC is required not just to mediate responses to netrin-1,
but also to mediate the responses of commissural axons to other cues that collaborate with netrin- 1
to guide these axons. In C. elegans, although the DCC homologue UNC-40 is involved primarily
in migrations that depend on the netrin homologue UNC-6, it is also required for certain migrations
that do not require UNC-6 function (Hedgecock et al., 1990). This raises the possibility that
UNC-40 has ligands other than UNC-6. By extension, it seems plausible that DCC has ligands
other than netrin- 1, accounting for the more severe phenotype observed in the spinal cord of Dcc-
deficient animals.
Whichever of these models is correct, it is important to note that the defect in axon growth
in the spinal cord of Dcc"/ - mice is selective for commissural axons. In particular, motor axons,
which also express DCC but do not respond to netrin-l in vitro (Keino-Masu et al., 1996;
unpublished observations), do not show projection defects like those observed for commissural
axons in the Dcc-" - embryos. This observation provides an argument against a model in which
DCC is simply a structural component of axons required for their extension, and instead supports
the idea that the defects in commissural axon growth in the Dcc-/ - embryos reflect the inability of
this class of axons to transduce environmental signals, including netrin-1.
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We note that some commissural axons do in fact succeed in reaching the floor plate in the
Dcc-deficient mice (Serafini et al., 1996). Taken together, these observations point to the existence
of a DCC-independent mechanism for guidance of commissural axons to the floor plate. It is
possible that netrin-1 itself can function via a DCC-independent mechanism to guide commissural
axons. Perhaps just as likely is the existence of cues distinct from netrin-1 that guide commissural
axons toward the floor plate and function via a DCC-independent mechanism. One candidate for
such a cue is a second chemoattractant distinct from netrin-1 made by floor plate cells, whose
existence was suggested through analysis of the in vitro guidance activities of floor plate cells from
netrin-1-deficient animals (Serafini et al., 1996).
DCC as a mediator of netrin- 1 effects in the brain
The finding of defects in brain morphogenesis in Dcc-/ - animals that are similar to those observed
in netrin-1 deficient animals suggests that DCC is in the response pathway for netrin-1 effects in
the brain. It is not known how the defects in the brain arise in either the netrin-1- or the Dcc-
deficient animals, although the distribution of netrin-1 mRNA in relation to the axons and cells that
are affected has suggested that netrin-l might function as a guidance cue whose absence is the
direct cause of the misroutings that are observed (Serafini et al., 1996). This is true not just for the
defects in axonal projections that are observed, but also for the absence of pontine nuclei, which
normally arise from a long-range migration of postmitotic pontine neuronal cell bodies. The
absence of the nuclei could therefore conceivably reflect a failure of migration of these neurons
(discussed in Serafini et al., 1996). Whatever the precise role played by netrin-1 in these events,
however, our results suggest that its effects are mediated by DCC or a receptor complex of which
DCC is a necessary component. If the defect in formation of pontine nuclei does in fact arise from
a failure of cell migration, this would indicate that DCC functions to guide cell migrations in
addition to axonal migrations.
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Our results do not address whether netrin-1 has other functions in the brain that are
mediated by receptors other than DCC. One candidate for a distinct netrin-l receptor in the brain is
the DCC-related protein neogenin (Vielmetter et al., 1994), which can also bind netrin-l (Keino-
Masu et al., 1996). Conversely, as discussed above, our results also do not exclude the possibility
that some DCC functions in the brain are mediated by ligands other than netrin-1.
Nonetheless, our results showing a similarity in phenotypes of Dcc"- and netrin-1"/ - mice
parallel the finding of interactions between netrin and DCC homologues in invertebrates that are
implied by similarities of phenotypes of mutations in ligands and receptors in those species (Chan
et al., 1996; Harris et al., 1996; Ishii et al., 1992; Kolodziej et al., 1996; Mitchell et al., 1996),
and support the hypothesis that DCC is a component of a netrin receptor mechanism. Taken
together, these studies provide strong support for the hypothesis that the wiring of the nervous
system involves rules and mechanisms that are strongly conserved among nematodes, insects and
vertebrates (Goodman, 1994).
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Chapter 5
Role of p53 in Apoptosis in Colon cancer
172
Introduction
Studies using cultured cells have ascribed several distinct cell physiologic functions to the p53
tumor suppressor gene. Its product, the p53 protein, may respond to DNA damage by triggering
either growth arrest during the G1 (Lane, 1992) or G2 (Agarwal et al., 1995; Stewart et al., 1995)
phases of the cell cycle or, alternatively, programmed cell death (Lane, 1992). In this manner,
p53 may protect the normal cell from proceeding to replicate damaged DNA (Lane, 1992).
Conversely, inactivation of p53 function may render a cell's genome more mutable, thereby
accelerating the accumulation of mutations that represent rate-limiting steps in tumor progression.
Mechanistically related to the role of p53 in genomic surveillance may be its role in
mediating cellular senescence, which is hypothesized to be triggered by telomeric collapse. This
senescence prevents cells from progressing to an immortalized state. The inactivation of p53
function during tumor progression allows evolving premalignant cell populations to circumvent
senescence, thereby facilitating progression to a state of immortality (Bond et al., 1994; Harvey
and Levine, 1991; Harvey et al., 1993; Metz et al., 1995; Shay et al., 1995).
Apoptotic death may also be triggered in cells in response to the activities of certain
oncogenes. Several studies have demonstrated that oncogenes such as myc and E1A trigger an
apoptotic response in a variety of cultured cells (Evan et al., 1992; Qin et al., 1994; Rao et al.,
1992; Wu and Levine, 1994) that represents an obstacle to the further clonal expansion of these
oncogene-bearing cells. In some cells, this apoptotic response has been shown to be p53-
dependent (Hermeking and Eick, 1994; Lowe et al., 1994; Lowe et al., 1993; Qin et al., 1994;
White, 1994; White et al., 1992; Wu and Levine, 1994). Hence, an inactivating mutation of p53
may enable cell populations carrying an oncogenic mutation to avoid attrition through apoptosis
and thus allow them to benefit from the growth impetus provided by the mutant oncogene.
Evidence supporting this model comes from studies in mice showing that normal p53, by
activating apoptosis, is able to suppress the progression of tumors initiated by the expression of
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viral oncogenes (Howes et al., 1994; Kim et al., 1993; Morgenbesser et al., 1994; Symonds et al.,
1994).
Finally, p53-dependent apoptosis is also observed in cells that are anoxic, as might occur in
tumors that are inadequately perfused by vasculature (Graeber et al., 1996). Together, these
reports indicate that p53 is an important regulator that enables normal cells to halt growth or to
enter apoptosis in response to a variety of physiologic stresses.
We focus here on the contribution of p53 inactivation to colon cancer. In many human
colon carcinomas, loss of p53 heterozygosity (LOH) occurs as the last in a defined succession of
mutations affecting the adenomatous polyposis coli gene (APC), the N- or Ki-ras proto-oncogene,
a presumed tumor suppressor gene on chromosome 18q, and mutation of one of the two alleles of
p53 gene (Fearon and Vogelstein, 1990; Vogelstein et al., 1988). This LOH of the p53 gene in
human colonic adenomas coincides with the appearance of highly dysplastic cells within less
dysplastic, intermediate grade adenomas (Boland et al., 1995). Such highly dysplastic
adenomatous cells are presumably the immediate precursors of colon carcinomas.
This loss of p53 function during a defined step in colonic tumor progression must be
rationalized in terms of the known biochemical and physiologic functions of the wild type p53 gene
and protein. For example, if p53 prevented colonic cells from replicating damaged DNA, one
might predict that p53 inactivation would occur relatively early in tumor progression, thereby
increasing the overall rate of mutation and accelerating the advance of colonic cell clones through
subsequent stages of this process.
On the other hand, if the role played by normal p53 in colonic adenomas were to induce
apoptosis in response to the cumulative effects of mutations affecting the APC, ras and other
genes, then inactivation of p53 would benefit tumor progression only at a late stage. Alternatively,
if p53 were responsible for inducing senescence following extensive cell division, loss of this
gene would be expected only at a late stage in tumor progression. With these models in mind, we
examined the effects of p53 loss on an early and an intermediate stage of colonic progression.
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Materials and Methods
Polyp Count
After euthanization, the entire gastrointestinal tract of a mouse was removed, dissected along the
cephalo-caudal axis, and washed in phosphate buffered saline. Adenomas ranged in size from at
least twice the width of an average size villus to at most 5-6 millimeter in diameter and were readily
visible in the intestines upon inspection under a dissecting microscope at 60X magnification. For
histological analysis, the entire intestine was removed surgically, fixed in Bouin's fixative,
dehydrated in graded solutions of alcohol, embedded in paraffin, sectioned at 6 gm, and stained
with hematoxylin and eosin (H&E).
All mice in this study were maintained in the facilities of the Whitehead Institute for
Biomedical Research and were fed ad libitum. Their diet consisted of Agway Prolab Rat, Mouse
and Hamster 3000 chow, which has a crude protein content of at least 22%, a crude fat content of
at least 5% and a crude fiber content of at most 5%.
Genotyping And Southern Blot
C57BL/6 ApeMinl+ mice were purchased from the Jackson laboratory (Bar Harbor, Maine). Min
progenies were genotyped by PCR (initial step of 10 min. @ 95"C, 3 min. on ice, followed by
addition of dNTP's and Taq enzyme, then one cycle of 2 min. @ 940C; followed by 35 cycles of 2
min. @ 95"C, 2 min. @ 55"C, 3 min. @ 720C; followed by one cycle of 5 min. @ 72"C) in two
independently run reactions with each reaction used to genotype a mouse's constitutional DNA
with regard to either the Min (ApcMin) or the wild-type (Apc+) allele of Apc. The reaction used to
genotype for the Min allele contained the ApcMin -specific primer (
5253GAGAAAGACAGAAGTTA25493' ) and the universal downstream primer (
5'285 9TTCCACTTTGGCATAAGGC 284 13' ) (Luongo et al., 1994).The reaction used to
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genotype for the wild-type allele contained the Apc+-specific primer (
5'224 1GCCATCCCTTCACG TTAG22 583' ) and the universal downstream primer (Luongo et
al., 1994). These primers are readily available from Research Genetics Inc. Huntsville, AL using
the order numbers: MGS 28566 (ApcMin), MGS 28568 (universal) and MGS 28567 (Apc+).
A colony of 129 p53+/- mice was started using the gift of one 129 p53+/ - mouse from
Tyler Jacks (Center for Cancer Research and the Howard Hughes Medical Institute, M.I.T.). Mice
were genotyped for the p53 locus by PCR (initial step of 10 min. @ 95"C, 3 min. on ice, followed
by addition of dNTP's and Taq enzyme, then one cycle of 1 min. @ 94°C; followed by 35 cycles
of 30 seconds @ 92"C, 1 min. @ 55"C, 1 min @ 72"C; followed by one cycle of 5 min 72"C) in
two independently run reactions with each reaction used to genotype a mouse's constitutional DNA
with regard to either the mutant (p53-) or the wild-type (p53+) allele. The reaction used to
genotype for the wild-type allele contained the p53X6S primer
(5'TTATGAGCCACCCGAGGT3') and the down stream primer p53X7AS
(5'TATACTCAGAGCCGGCCT3'). The reaction used to genotype for the mutant allele contained
the p53--specific primer Neo 18.5 (5'TCCTCGTGCTTTACGGTATC3') and the down stream
primer p53X7AS. These primers are readily available from Research Genetics Inc. Huntsville, AL
using the order numbers: MGS 24828 (p53X6S), MGS 24829 (p53X7AS) and MGS 31359 (Neo
18.5). PCR reactions for both Apc and p53 loci tested were initially attempted by multi-plexing the
three PCR primers together, but superior results were obtained by amplifying the two alleles in
independent reactions.
For loss of heterozygosity (LOH) analysis, adenomas were removed surgically and DNA
was prepared from them using standard methods. Southern blottings were performed as described
previously (Jacks et al., 1994).
Statistical Analysis
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Polyp multiplicities were compared using a modification of the Wilcoxon's Sum of Ranks Test as
described by H. Mann and D. Whitney (Zar, 1974). The incidence of apoptotic cells in adenomas
was compared using the Student t-test.
Gamma-Irradiation
Mice were subjected to 8 grays of gamma-irradiation using a cesium source. Eight hours later the
mice were euthanized and their intestines fixed in fomalin and prepared for cell death analysis.
Quantifying The Apoptotic Cells
TUNEL assay was performed on 5-6 micron paraffin-embedded sections of adenomas or normal
intestines. To do this, the sections were deparaffinized in Xylenes (Sigma) (2X8 min) and
dehydrated through sequential steps of 100% ethanol (2X3 min), 90% ethanol (3 min), 70%
ethanol (3 min) and distilled H20 (3 min). Each tissue section was then treated with 100
microliters of pepsin (Sigma) (0.5% V/W in H20), incubated at 37"C (60 min in humid air) and
washed in phosphate buffered saline (PBS-, 3X3 min). The samples were then treated with
Saponin (0.055% V/W in H20, 30 min) at room temperature and washed with PBS- (3X3 min).
Then, the samples were incubated in 3% H202 at room temperature for 60 min and washed in
PBS- (3X3 min). The samples were treated with the terminal transferase mix [Terminal
deoxytransferase enzyme (TdT, Gibco-BRL), TdT buffer (Gibco-BRL), biotin-16-dUTP
(Boehringer Mannheim) and H20] and incubated at 370C (60 min in humid air). The reactions
were terminated by adding the TdT reaction termination buffer (15 min) and washing the samples
in PBS- (3X3 min). The nuclei that had incorporated the biotinylated dUTP were detected using
the DAB (SK4100, Vector Laboratories) and the ABC Kits (PK4000, Vector labs). The samples
were washed in PBS- (2X3min), dehydrated through sequential steps of 70% and 100% ethanol (3
min each), dried and mounted.
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Counts of the apoptotic cells were performed using a light microscope at 1000X
magnification. Only the TUNEL-positive epithelial cells were counted; the mesenchymal cells were
excluded from our analyses. The fractions of the sloughed cells that remained in the tissue
preparation varied form one preparation to the next and were therefore excluded from the counts.
Only the apoptotic epithelial cells that remained a part of the solid tissue were counted. The
TUNEL-positive cells had the appearance of apoptotic cells described previously (Anilkumar et al.,
1992). The apoptotic cells appeared shrunken and fragmented and often had pyknotic nuclei. A
'halo' was often seen around the TUNEL positive cells.
Human Colonic Adenomas
Adenomas in Table 2 were obtained from sequential lists of resected tumors from the Ann Arbor
Veterans Affairs Medical Center and the Henry Ford Hospital (Detroit, Michigan) and fixed in
formalin soon after removal. Microallelotyping of these adenomas using markers on chromosome
17p were reported (Boland et al., 1995). These tumors and the detailed clinical and
histopathological data regarding these tumors are available upon request from R. S. Bresalier.
Results
p53 and initiation of mouse intestinal adenomas
In order to examine the effect of p53 inactivation on colonic epithelial cells that are still at a
relatively early stage in tumor progression, we used mice of the Min strain (Moser et al., 1990), in
which the first of the mutational steps involved in colonic tumor progression - mutation of the Apc
gene - is already present in all colonic epithelial cells. Because of the germline ApcMin mutation
carried by these mice (Su et al., 1992), these mice are strongly predisposed to intestinal adenomas
(polyps) (Moser et al., 1992; Moser et al., 1990) of the type seen in humans who carry germline
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mutations of the APC gene and suffer from familial adenomatous polyposis (Groden et al., 1991;
Nishisho et al., 1991). In order to determine the effects of mutations of p53 on the initiation and
development of adenomas in these mice, we bred a mutant allele of the p53 gene (Jacks et al.,
1994) into the germline of ApcMin/ + mice.
Thus, 129 Apc +/ + P53+/- (Jacks et al., 1994) mice were crossed to C57BL/6 ApcMin/+
p53+/ + (Moser et al., 1990) mice to generate 129/B6 F1 ApcMin/+ p53+/ - progeny. F2 and F3
progeny were generated by breeding F1 or F2 siblings, respectively. Because there was no
statistically significant difference (p>0.2) between the average number of adenomas among the Fl,
F2 and F3 ApcMin/+ p53+ 1+ mice (FIG. 1), the effect of p53 dosage reduction on polyp incidence
was gauged in mice of a mixed 129/B6 genetic background.
The effects of p53 inactivation on the incidence, size and progression of polyps in mouse
intestine were then ascertained. As part of this analysis, we examined the entire length of the
gastrointestinal tract of these mice, registering both the size and the number of polyps. The great
majority of the adenomas in these ApcMin/+ mice were found to be localized to the small intestine
regardless of the genotype of these mice at the p53 locus (data not shown). Min mice in this colony
rarely developed colonic or gastric adenomas.
Homozygosity for a germline inactivating mutation of p53 did not enhance polyp initiation
in the small intestines of the Min mice (FIG. 1) confirming previous reports (Clarke et al., 1995).
Statistical analysis indicated that the number of adenomas did not increase after 80 days of age in
any of the three Min groups in which the ApcMin mutation was present in a p53+/+, p53+ - or
p53-/" background. Thus, we counted polyps at various ages beyond 80 days and assumed that
these numbers accurately reflected the cumulative number of polyps arising in the mice. The
ApcMin/+ P53-/ - mice showed a mean number of adenomas per mouse (94 adenomas, n=l 1)
similar to the ApcMin/ + p53+/- (83 adenomas, n= 26) and ApcMin/+ p53+/ + mice (86 adenomas,
n=29) (Fig. 1). The difference between the ApcMin/ + P53-/ - mice and other Min cohorts was not
statistically significant (p=0.2). The number of adenomas varied from 30 to 267 in the ApcMin/+
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p53+1/ and from 27 to 197 in ApcMin/+ p53+/- cohort and from 27 to 211 in the ApcMin / + p53-/-
cohort.
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Figure 1
Effect of p53 dosage reduction on polyp initiation in the Min mice. Mice are 129Sv/B6 Fl, F2 and
F3. The Y-axis shows the number of adenomas observed along the entire length of intestine of
mice of 80-days of age and older. Number of adenomas was determined by counting the adenomas
in the intestine of each mouse under a dissecting microscope as described in the methods section.
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Approximately two-thirds of the Apc +/ + p53-/ - progeny also developed a single adenoma
at the ileocecal junction but none of the Apc+/+ p53+/+ or Apc+/+ p53+/ - mice developed such
adenomas (data not shown). We did not further study this effect of p53 inactivation on the rate of
initiation of adenomas at this particular anatomical site. Moreover, since we focused on the role of
p53 in intestinal polyp initiation in this study, possible cooperative effects ofApcMin allele and the
p53 mutation on tumor initiation in other organs were not examined.
We determined the extent of progression of the adenomas that did appear by examining
their size and histological and morphological appearance (Vogelstein et al., 1988). Significantly,
the absence of a functional p53 gene afforded no growth advantage to the adenomas once they
were initiated. We detected no difference in the size of the p53"/ - , p53+/ - or p53+/+ adenomas in
age-controlled Min mice upon macroscopic examination. Furthermore, histological analysis
showed that all adenomas in the Min mice were benign, similar in morphology, and characterized
by a similar degree of dysplasia regardless of their genotype at the p53 locus (data not shown). In
fact, we did not observe any histological difference among any of the adenomas in p53-/ - mice
examined between the ages of 80 and 132 days and of any of the adenomas in the P53+1+ and
P53+1- groups examined between 80 and 210 days of age.
The above experiments suggested that elimination of p53 function had little effect either on
the initiation of adenomas or their subsequent progression from early to intermediate stage polyps.
This notion was reinforced by Southern blot analysis performed on DNA samples prepared from
twenty adenomas of ApcMin/ + p53+ - mice. This analysis showed that the adenomas in ApcMin/+
p53+ - mice retained both the mutant and the wild type allele of p53 even up to 150 days of age
(FIG. 2). This retention of the wild type p53 allele contrasts with previous analysis of the fate of
the wild type Apc allele in adenomas of ApcMin/+ mice, which showed that the wild type Apc
allele is invariably discarded as adenomas progress (Laird et al., 1995; Levy et al., 1994; Luongo
et al., 1994). Hence, elimination of the surviving wild type p53 allele conferred no growth
advantage on adenomatous cells while loss of the wild type Apc function was indeed
advantageous.
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Figure 2
LOH analysis of the p53 locus in adenomas from ApcMin/+ p53+/ - mice. Lane 1 is the
constitutional DNA from the normal tissue (NT) of a ApcM in/+ p53+/ mouse. Lanes 2-10 are
adenomas from five-month old ApcMin/+ p53+ - mice. The top arrow points to the mutant 3.0 Kb
band and the middle arrow to the 1.3 Kb wild-type band. The lowest arrow marks the 1.0 Kb
fragment that appears due to hybridization of the probe to DNA corresponding to a p53
pseudogene.
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In sum, germline inactivation of p53 neither increased the rate of initiation of adenomas in
the ApcMiW+ intestines nor did it appear to affect their size. We concluded that any effects that loss
of p53 function may have on the growth properties of adenomatous cells were not sufficient to
affect either the size or morphology of adenomas in the early stages of colon tumor progression in
the mouse.
p53-dependent apoptosis in ApcMin-induced adenomas
While p53 inactivation had no apparent effect on the overall rate of progression of adenomatous
polyps in the Min mice, it remained possible that p53 loss influenced adenoma development in
more subtle ways by affecting the rate of apoptosis of the cells in the polyps. For this reason, we
examined the incidence of apoptotic cell death in the p53-wild type and p53-deficient benign mouse
adenomas.
In the normal intestine, the proliferative zone is found in the crypts and in the base of the
villi while the apoptotic zone is largely in the tips of the villi (Gordon and Hermiston, 1994). In
addition, a small fraction of epithelial cells in the proliferative zone are also seen to be in the
process of undergoing apoptotic cell death (Anilkumar et al., 1992; Clarke et al., 1994; Merritt et
al., 1994). These apoptotic cells of the proliferative zone, to the extent that they can be observed,
are largely confined to the crypts of the intestinal epithelium (Anilkumar et al., 1992; Clarke et al.,
1994; Merritt et al., 1994). The presence of the apoptotic cells of intestine can be demonstrated on
thin paraffin-embedded sections of this tissue using the TUNEL, (terminal deoxynucleotide
transferase-mediated dUTP-biotin nick end labeling) assay (Gavrieli et al., 1992).
We first tested the sensitivity of the TUNEL assay, as used by us, in two circumstances in
which apoptosis is a frequent occurrence. Macrophages that have just engulfed apoptotic cells can
be readily identified upon microscopic examination of the Peyer's patches of the mouse intestine
(Earnshaw, 1995). All nuclei of the apoptotic cells that were engulfed by macrophages registered
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positive in our TUNEL assay in several formalin-fixed sections of Peyer's patches (data not
shown).
We also verified the sensitivity of our assay by examining the apoptotic cells in irradiated
intestines. Gamma-irradiation of p53+/+ intestines is known to result in the appearance of many
cells with pyknotic nuclei in the normal crypts (Clarke et al., 1994; Merritt et al., 1994).In several
experiments, all of the intestinal epithelial cells having pyknotic nuclei following 8 grays of
ionizing radiation registered positively in our TUNEL assay (FIG. 3A & B). We also extended the
reports of others (Clarke et al., 1994; Merritt et al., 1994) that this gamma-irradiation-induced
apoptosis is p53-dependent, in that both the crypts and the adenomas of ApcMin/+ p53-/ - intestines
displayed a low rate of apoptosis similar to that of non-irradiated controls (Table 1, FIG. 3A & B).
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Figure 3
Effects of p53 inactivation and gamma-irradiation on apoptosis in intestine of the Min mice.
(A) Normal small intestine (400X magnification). (B) Small intestinal adenomas
(200X magnification). Intestines were prepared and the apoptotic cells were identified
using the TUNEL assay. "C" and "V" refer to the crypt and the villus respectively.
Arrows mark some of the apoptotic cells.
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We then used the TUNEL assay, as validated above, to gauge apoptotic rates in p53+/+
and p53-/ - adenomas. Our analyses showed that on average, 1.5% of the epithelial cells of
adenomas were undergoing the process of apoptotic cell death at any time (Table 1). In contrast to
the effects of p53 on radiation-induced apoptosis, the presence or absence of p53 had no obvious
effect on the incidence of apoptotic cells in the non-irradiated early adenomas (p=0.3, 1.5% in
p53 +1+ vs 1.6% in p53-/ -, Table 1 & FIG. 3B). Thus, p53 loss did not affect development of
early adenomas through its ability to suppress apoptosis. This was in consonance with our earlier
observations indicating that p53 loss had no effect on the growth rate or histopathology of these
early adenomas.
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Table 1
Effect of p53 inactivation on gamma-irradiation-induced apoptosis in mouse intestinal adenomas. a
Numeric values represent mean percentage of epithelial cells that were apoptotic as determined by a
combination of the TUNEL assay and histological analysis. Percentage apoptotic cells was
measured for each segment of normal intestine or each adenoma by examining five independent
non-overlapping regions.
b n is the number of adenomas or number of segments of the normal intestine where apoptotic cells
were measured.
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Rate of apoptosis in normal crypts and adenomas in
both gamma-irradiated and non-irradiated mice.
Normal crypts Adenomas
P53 non- gamma- non- gamma-
Genotype irradiated irradiated irradiated irradiated
+/+ 1.4%a 11.3% 1.5% 17%
(n= 10)b (n= 10) (n=9) (n= 11)
-/- 0.5% 0.9% 1.6% 2.7%
(n=17) (n=8) (n=25) (n=12)
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P53 inactivation and apoptosis in late-stage human colonic adenomas
In human colonic adenomas, LOH at the p53 gene coincides with the appearance of highly
dysplastic cells within adenomas. These highly dysplastic nodules are often found to arise within
large, less dysplastic, intermediate grade adenomas. This observation has suggested that p53
mutation plays an important role in a relatively late step of colon cancer progression by enabling
intermediate grade adenomas to progress to those having a highly dysplastic phenotype. We
wished to gauge the possible role played by p53 inactivation in modulating apoptosis at this late
stage of colonic tumor progression. The highly dysplastic regions of polyps, which are
presumably the immediate precursors of colon carcinomas, are not frequently encountered in mice.
For this reason, we turned to human biopsy samples and compared highly dysplastic nodules with
closely apposed, less dysplastic precursors, hoping to gauge the influence, if any, of p53 loss on
this progression.
Loss of p53 function in colonic tumors involves two genetic steps. In the first of these, p53
function is partially lost through the appearance of a mutant, dominant-negative allele (Hollstein et
al., 1991; Nigro et al., 1989); the protein product of such an allele has lost its ability to mediate
wild-type p53 signaling but gained the ability to compromise most but not all of the functioning of
the wild-type protein, which continues to be expressed in heterozygous cells. Residual wild-type
p53 function can then be totally eliminated through the loss of the surviving wild type allele and
duplication of the already mutant allele. This second step is characterized by the LOH of
chromosome 17p on which the p53 gene is located (Baker et al., 1989; Baker et al., 1990; Nigro et
al., 1989).
LOH at the p53 locus is detectable in the highly dysplastic regions of about 40% of human
colonic adenomas (Boland et al., 1995). By the time the subsequent conversion to carcinoma is
complete, LOH of the p53 gene is detectable in an additional 20% of colonic growths (Boland et
al., 1995). We focused our attentions on the subset of colonic growths in which LOH of p53 gene
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accompanied the transition to a highly dysplastic phenotype and asked whether p53 inactivation
was accompanied by a change in apoptotic rates.
We measured the incidence of apoptotic cell death in a panel of 8 adenomas having distinct
regions within them that displayed high grades of dysplasia (Table 2A). Previous published
microallelotyping analyses (Boland et al., 1995) had demonstrated that in this panel of 8
adenomas, LOH of markers on chromosome 17p (including the p53 gene) had occurred in the
regions with high grades of dysplasia while the regions with low grades of dysplasia were still
heterozygous for loci on chromosome 17p. These adenomas had been fixed immediately after
surgical or endoscopic excision to minimize necrosis.
TUNEL analysis showed no statistically significant difference between the incidence of
apoptotic cell death before and after the LOH at chromosome 17p in these adenomas (p=0. 14,
Table 2). Thus, two of these adenomas showed an increase, two showed no change and four
showed a decrease in the incidence of apoptosis following the loss of p53.
As mentioned above, LOH of the p53 gene is detectable in only 40% of the adenomas
during the transition to the highly dysplastic phenotype. Analysis of a panel of 6 adenomas from
the group with no detectable p53 LOH revealed that the incidence of apoptosis decreased in 5 of
these adenomas during the transition to a highly dysplastic phenotype even though the p53 LOH
could not be detected during this transition (Table 2). Indeed, the degree of reduction of apoptosis
was comparable to that seen in the adenomas that did suffer LOH. In sum, the transition of
adenomas to a highly dysplastic phenotype is often associated with a decrease in the incidence of
apoptosis but this change could not be correlated with LOH of the p53 gene.
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Table 2
Effect of LOH of p53 on the incidence of apoptosis in human colonic adenomas. a (+) indicates
that LOH of loci on chromosome 17p including the p53 gene was detected in the highly dysplastic
regions (HGD or high grade dysplasia) of adenoma but not in the neighboring regions of the same
adenomas with lower degree of dysplasia (LGD or low grade dysplasia) in a previously reported
study (Boland et al., 1995). (-) indicates that LOH of chromosome 17p was not detectable in either
the regions with high or regions with low grade of dysplasia.
b The numeric values represent mean percentage of the epithelial cells that are were apoptotic.
Percentage apoptotic cell was determined for ten independent non-overlapping segments of the
adenoma or the carcinoma regions using a combination of TUNEL and histological characterization
performed on two tissue sections of each tumor.
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Table 2. Effect of loss of p53 on the incidence of apoptotic
cell death in human colonic carcinomas
Tumor Name in Apoptotic Cellsb
Boland et al. 17p LOHa LGD HGD
2, right + 0.60% 0.51%
4, right + 0.85% 3.35%
11, left + 0.53% 0.63%
8, left + 1.20% 0.51%
13 left + 0.46% 0.82%
17, left + 1.38% 0.38%
22, left + 0.95% 0.57%
29, left + 1.70% 0.57%
3, right - 2.35% 1.30%
15, left - 0.91% 0.87%
10, left - 2.17% 1.11%
28, left - 4.48% 0.35%
20, left - 1.30% 0.97%
21, left - 2.04% 1.52%
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Discussion
Mice predisposed to adenomatous polyposis through mutation of the Apc gene sustain multiple
intestinal adenomas in the first three months of life (Moser et al., 1990). Our initial studies
attempted to gauge the effects, if any, of inactivation of p53 function on the appearance and
subsequent development of these adenomatous polyps. Our results indicate that polyp number and
growth were not affected by the presence or absence of functional alleles of the p53 gene in the
four-month life span of the p53-/ - mice. We concluded that, to the extent that p53 mutation plays a
role in colon cancer progression, such role only becomes important in later stages.
P53 mutations rarely occur in cells of colonic adenomas having a low to intermediate
degree of dysplasia but frequently occur in adenomas as they progress to a high grade of dysplasia
(Boland et al., 1995). This inactivation of p53 at a relatively late stage of tumor progression might
be explained as a necessary response to mutations sustained previously in other growth-regulating
genes including proto-oncogenes and tumor suppressor genes. Thus, earlier mutations in these
growth-regulating genes might provoke apoptosis in colonic epithelial cells, as has been shown for
other types of cells (Hermeking and Eick, 1994; Howes et al., 1994; Kim et al., 1993; Lowe et al.,
1994; Lowe and Ruley, 1993; Morgenbesser et al., 1994; Qin et al., 1994; Symonds et al., 1994;
White et al., 1992; Wu and Levine, 1994), which-may then be countered by the inactivation of
their p53 gene.
The results of the present study argue against such a model. We have gathered evidence
from human adenomas that causes us to propose that avoidance of apoptosis, as mediated by p53
mutation, is not the primary effect of the loss of p53 in intestinal adenomas. Our data show that the
transition of intermediary adenomas to late-stage adenomas often correlates with suppression of
apoptosis, but this reduced incidence of cell death occurs independent of LOH of the p53 gene and
in some tumors loss of p53 correlates with an increase in the incidence of apoptosis. These data
suggest that p53 status is not the sole determinant of apoptosis in intestinal adenomas.
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The conclusion that p53 may be only one of several genes that determine the incidence of
apoptosis in colonic tumors is supported by the studies of Polyak et al that showed that the status
of the P21 gene determine the effect of p53 on apoptosis in colon carcinomas (Polyak et al., 1996).
Another gene that is likely to affect apoptosis in intestinal adenomatous cells and colonic
carcinomas is the BAX gene which is mutated in fifty percent of colon carcinomas with the
microsatellite mutator phenotype [ Rampino, 1997 #1521. One study showed that colon cancer cell
lines with BAX mutations belong to different apoptosis complementation groups [Rampino, 1997
#152]. This further supports the idea that apoptosis in colon cancer is determined by genes of
several different pathways ECasares, 1995 #151].
Together with the data in the present study, these observations re-direct attention to other
functions ascribed to normal p53, including notably p53's ability to mediate cellular senescence.
One attractive possiblity is that the mutation of ras or other growth-regulating genes that occurs
early in colon tumor progression might provoke a senescence in adenomatous cells that may be
countered by the subsequent inactivation of the p53 gene. Such p53 inactivation may then confer
other benefits. Thus, the p53-dependent senescence associated with the excessive generational
doublings may be circumvented, permitting cells to proceed to crisis and immortalization.
Moreover, p53 inactivation may allow other consequences of p53 loss such as increased
angiogenic potential (Dameron et al., 1994), an uncoupling of DNA synthesis from mitosis
EWaldman, 1996 #153] and increased genemoic instability (Boland et al., 1995; Offerhaus et al.,
1992) to conspire to accelerate the progression leading to malignant colonic tumors.
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CHAPTER 6
Summary And Implications
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Implications of this study
In 1990 a team of scientist at Johns Hopkins University proposed that human colon cancer is
caused by a succession of defined genetic alterations including mutation of the Adenomatous
Polyposis Coli (APC) tumor suppressor gene, reduced DNA methylation, mutation of the N- or
Ki-ras proto-oncogene, inactivation of the Deleted in Colorectal Cancer (DCC) gene, and mutation
of the p53 tumor suppressor gene (Fearon and Vogelstein, 1990). To test the veracity of this
genetic model of colon cancer, the technique of gene targeting was used to create genetic alterations
in mice similar to those observed in human colonic tumors and examine their effect on the biology
of normal and neoplastic intestine in mice.
In the first experiment, mice were created that are constitutionally heterozygous for a
mutation in the mouse homologue of the APC gene (Apc). This targeted mutation, named Apc8 ,
reduces the level of APC protein by a factor of a hundred fold. Mice heterozygous for this mutation
(Apc8/+ mice) are predisposed to intestinal adenomas and facial osteomas. However, the low
incidence and the late onset of intestinal adenomas in Apc8/+ mice caused by this hypomorphic
allele of Apc contrasted sharply with the rapid development of large numbers of adenomas induced
Minby another mutation of Apc, Apc M in , that encodes a truncated APC protein. This study showed
that mutation of a gene that is mutated in an early step in human colonic tumors causes intestinal
adenomas in mice and suggested that mice may be used to study human colon cancer. Moreover,
this study showed that, as it is the case in human, distinct mutant alleles of the Apc gene cause the
development of profoundly different numbers of adenomatous polyps in mice.
In the second study, mice that are predisposed to intestinal adenomas were used to address
a controversy regarding human colon cancer. The Hopkins model hypothesized that DNA
hypomethylation plays an early and causative role in the formation of colonic tumors. To examine
the effects of reduced DNA methylation on formation of intestinal adenomas, a combination of
genetics and pharmacology was used. A reduction in the DNA methyltransferase activity in the
ApcMin mice due to heterozygosity of the DNA methyltransferase gene in conjunction with a
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weekly dose of the DNA methyltransferase inhibitor 5-aza-deoxycytidine reduced DNA
methylation and the average number of adenomas from 113 in the control mice to only 2 polyps in
the treated heterozygotes. This study proved that DNA methyltransferase activity contributes
substantially to tumor development in this mouse model of intestinal neoplasia, and that contrary to
the prediction of the Hopkins model, reducing DNA methylation in cells of intestine suppresses the
formation of adenomas instead of promoting it.
In the next study, another controversial component of the Hopkins model regarding the
role of the Deleted in Colorectal Cancer (DCC) gene in colon cancer was tested. The DCC gene
was first identified as a candidate for a tumor suppressor gene on human chromosome 18q, loss of
which contributes to the progression of colorectal cancers. However, the accumulated evidence to
date has failed to implicate DCC conclusively as the colorectal tumor suppressor gene on
chromosome 18q. In vitro experiments have also failed to provide conclusive proof that DCC is a
tumor suppressor gene. Moreover, more recent in vitro studies in rodents had suggested a role for
DCC in a process that appeared to be unrelated to colon cancer, i.e. axon guidance, and provided
evidence that DCC might function as a receptor for the axonal chemoattractant netrin- 1.
To help elucidate the functions of the DCC gene in mice, its homologue (Dcc) was
inactivated in the mouse genome through use of homologous recombination and the effects of this
inactivation on both the intestine and the developing nervous system was examined. Dcc-l -
newborn mice and adult chimeric mice produced from Dcc "/ " embryonic stem cells had no
detectable intestinal pathology. Moreover, Dcc+/- mice did not show any increased predisposition
to intestinal adenomas. When present together with a germline mutation predisposing to
adenomatous polyps, the mutant Dcc allele had no effect on adenoma formation. Furthermore,
adenomas that carried only the mutant allele of Dcc showed no signs of progression to more
advanced lesions. In contrast, Dcc-/ - mice did show defects in the formation of commissures in
the spinal cord and the brain that were strikingly similar to those observed in netrin-l-deficient
mice. These observations failed to provide support for a tumor suppressor function for Dcc, but
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were consistent with the hypothesis that DCC is a component of a receptor for netrin-1 in the
developing spinal cord and brain.
The p53 gene is mutated in colon tumorigenesis at the time of transition of a benign
adenoma to a carcinoma. The reason for loss of both alleles of p53 at a relative late stage in the
progression leading to colonic tumors is not known. Two different models have attempted to
predict the consequences of the loss of p53 in a tumor cell. The guardian of the genome model
predicts that a p53-deficient tumor cell is unable to detect DNA damages that would normally lead
to a cell cycle arrest. The second apoptosis model states that a p53-deficient cell is unable to
activate p53-induced cell death when it receives conflicting growth stimulatory and growth
inhibitory signals. According to both models, a p53-deficient cell would continue dividing in spite
of having suffered DNA damages. The continual growth of such a cell would lead to the
propagation of genetic alterations to the descending cells over time. This in turn would cause the
progression of a benign tumor to a carcinoma.
In order to test the validity of the apoptosis model, the effects of inactivation of the p53
tumor suppressor gene on the incidence of apoptotic cell death were examined in two stages of the
adenoma-to-carcinoma progression in the colon: in early adenomas where p53 mutations are rare
and in highly dysplastic adenomas where loss of p53 occurs frequently. Homozygosity for an
inactivating germline mutation of p53 had no effect on the incidence, the rate of progression, or the
frequency of apoptosis in the cells of ApcMin/+ induced adenomas in mice. To examine the effect
of p53 loss on apoptosis in late-stage adenomas, the incidence of apoptotic cell death was
compared before and after the appearance of highly dysplastic cells in human colonic adenomas.
The appearance of highly dysplastic cells, which usually coincides during tumor progression with
loss of heterozygosity at the p53 locus, did not correlate with a reduction in the incidence of
apoptosis. These studies suggest that wild type p53 retards the progression of benign colonic
adenoma to malignant carcinomas by mechanism(s) other than the promotion of apoptosis.
In conclusion, the genetic model for colon cancer proposed by Fearon and Vogelstein
(Fearon and Vogelstein, 1990) should be revised to incorporate the findings of the present study
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regarding the roles of DNA methylation and the DCC gene in colon cancer (Figure 1). First, the
results of this study suggest that alterations in DNA methylation and not DNA hypomethylation per
se are important for formation of adenomas. Second, our data do not support the candidacy of
DCC as a colon tumor suppressor gene and suggest that the loss of DCC expression may be a
consequence of events affecting a linked gene. According to this scenario, the observed LOH of
18q21 affects not only the DCC gene but other neighboring genes as well, one or more of which
is the bonafide target of inactivation during colon tumor progression. This controversy will not be
resolved completely until another gene on 18q is identified that undergoes LOH and whose retained
allele is also mutated in the majority of colonic tumors.
Are mice good model for studying human cancer?
To date, fifteen bonafide tumor supressor genes have been identified whose mutation or deletion
are associated with one or more types of human cancer (Weinberg, 1996). They include the
retinoblastoma gene (Rb) (Friend et al., 1986), the p53 gene (Malkin et al., 1990), the Wilms'
tumor gene-1 (WT1) (Haber et al., 1990), the breast cancer genes-1 & 2 (BRCAi and BRCA2)
(Futreal et al., 1994; Miki et al., 1994; Wooster et al., 1994), the von Hippel Lindau (VHL) gene
(Latif et al., 1993), the adenomatous polyposis coli (APC) gene (Groden et al., 1991; Nishisho et
al., 1991), the neurofibromatosis type-i (NFi) (Xu et al., 1990), and neurofibromatosis type-2
(NF2) genes (Trofatter et al., 1993), the mismatch repair genes (PMS1, PMS2, MSH2, MUTL &
MLH1) (Bronner et al., 1994; Nicolaides et al., 1994; Papadopoulos et al., 1994), the multiple
tumor susceptibility gene-1 (MTSi) (Kamb et al., 1994), the patched (PTC) gene (Gailani et al.,
1996; Hahn et al., 1996; Johnson et al., 1996; Stone et al., 1996), MMACIIPTEN gene (Liaw,
1997; Steck, 1997), and the tuberous sclerosis-2 (TSC2) gene (Consortium, 1993).
Inheritance of a mutant allele of each of these tumor suppressor genes is linked to a familial
form of human cancer. For instance, patients who are born with a mutant allele of the Rb gene
develop retinoblastoma (Friend et al., 1986). Similarly, the p53 gene is mutated in the Li-Fraumeni
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families (Malkin et al., 1990), WT1 in the Wilms' tumor patients (Haber et al., 1990), BRCA1 and
BRCA2 in some breast cancer families (Castilla et al., 1994; Miki et al., 1994; Wooster et al.,
1994), VHL in the von Hippel Lindau disease (Latif et al., 1993), APC in the familial
adenomatous polyposis (FAP) disease (Groden et al., 1991; Nishisho et al., 1991), NF1 and NF2
in patients with familial neurofibromatosis (Bourn et al., 1994; Rouleau et al., 1993; Trofatter et
al., 1993; Xu et al., 1990), mismatch repair genes in patients with hereditary non-polyposis colon
cancer or the Lynch syndromes (Bronner et al., 1994; Fishel et al., 1993; Hemminki et al., 1994;
Leach et al., 1993; Nicolaides et al., 1994; Papadopoulos et al., 1994), MTS1 in some families
with inherited melanoma (Ranade et al., 1995; Zuo et al., 1996), the patched gene in familial
nevoid basal cell carcinoma (Gailani et al., 1996; Hahn et al., 1996), MMAC1/PTEN in the
Cowden disease (Liaw, 1997; Nelen et al., 1996), and TSC2 in patients with familial tuberous
sclerosis (Consortium, 1993; Wilson et al., 1996).
In addition, a candidate tumor suppressor gene has been identified and named deleted in
pancreatic cancer-4 (DPC4) (Hahn et al., 1996). DPC4 is the only example of a tumor suppressor
gene that has not been linked to any familial form of human cancer but a proposed role for it in
tumor suppression is supported by the observation that both of its alleles are either mutated or
deleted in fifty percent of sporadic (non-familial) pancreatic carcinomas (Hahn et al., 1996).
Tumor suppressor genes can be classified into two groups: the care takers and the gate
keepers (Kinzler and Vogelstein, 1997). Caretakers function to help maintain the integrity of the
DNA of normal cells. This group includes the p53, BRCA1, BRCA2 and the mismatch repair
genes. For instance, the product of the p53 gene, i. e. , the P53 protein can eliminate cells with
damaged DNA from tissues by activating the cells' suicide program (Lane, 1992). BRCA1 and
BRCA2 are hypothesized to participate in the Rad51-dependent DNA repair of double-strand
breaks (Scully et al., 1997; Sharan, 1997). Finally, the mismatch repair genes encode components
of a protein machinery that identifies and corrects DNA mismatches in normal cells by excision
repair (Mellon et al., 1996). Loss-of-function mutations of care taker genes are suspected to
accelerate cancer progression by allowing the accumulation of growth deregulating mutations.
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The gate keepers are usually master genes that regulate the expression of other genes. This
class of tumor suppressor genes includes Rb, WT1, VHL, APC, MTS1, PTC and DPC4. When
these genes are mutated, tumors are formed because large numbers of growth promoting genes are
turned on and growth inhibitory genes are turned off. For instance, the normal product of the Rb
gene inhibits the progression of cells from the G1 to the S phase of cell cycle by inhibiting the
activity of the E2F family of transcription factors (Weinberg, 1996; Weinberg, 1995). MTS1
encodes another cell cycle check point. The protein encoded by this genes, P16INK4A inhibits the
entry of cells into the S phase of the cell cycle by inhibiting the activity of the cyclin-dependent
kinase (CdK)-4 that inactivates the product of the retinoblastoma gene by phosphorylation (Serrano
et al., 1995; Serrano et al., 1993). VHL interacts with transcription elongation factors elongin B
and C to repress transcription elongation (Duan et al., 1995; Kibel et al., 1995). The APC protein
binds to and degrades beta-catenin in the cytoplasm which when accumulated in the cytoplasm can
leak into the nucleus and interact with the Lef/Tcf family of transcription factors and activate gene
transcription (Behrens et al., 1996; Molenaar et al., 1996; Rubinfeld et al., 1993; Su et al., 1993).
Similarly, WT1 is a transcription factor that suppresses tumor growth by affecting the transcription
of other genes (Madden et al., 1991; Rauscher, 1993; Wang et al., 1992).
Two other gate keepers, NF1 and TSC2 are members of the GTPase-activating family of
molecules. These proteins enhance the GTPase activity of small GTPase molecules such as ras in
the cytoplasm and convert them to the inactive or the GDP-bound form (Basu et al., 1992;
Boguski and McCormick, 1993; Bollag et al., 1996; Largaespada et al., 1996). For example, loss
of NF1 activity in the cytoplasm causes the Ras protein to remain in the active GTP-bound form
which in turn leads to the activation of other signalling molecules in the cytoplasm and eventually
lead to the activation of growth promoting genes in the nucleus. The patched (PTC) gene encodes a
transmembrane receptor that represses transcription of genes encoding transforming growth factor
(TGF)-beta and Wnt class of signaling proteins as well as PTC itself (Stone et al., 1996). DPC4 is
a candidate tumor suppressor gene that encodes a gene similar in sequence to the Drosophila
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melanogaster Mad gene and is suspected to be a component of the signalling pathway of
transforming growth factor (TGF)-beta-like proteins (Hahn et al., 1996).
Three tumor suppressor genes, the p53 gene, BRCA1 and BRCA2 function both as
transcription factors and care takers (Chapman and Verma, 1996; Gowen et al., 1996; Lane, 1992;
Scully et al., 1997; Sherr, 1996). Some domains of both BRCA1 and BRCA2 are able to activate
transcription when linked to the DNA-binding domain of other transcription factors (Chapman and
Verma, 1996; Milner, 1997). Likewise, the normal but not the mutant forms of p53 protein can
activate transcription in a sequence-specific fashion (Chen et al., 1993; Crook et al., 1994; Farmer
et al., 1992; Raycroft et al., 1990; Thut et al., 1995). The NF2 protein belongs to a family of
molecules that link actin cytoskeleton to transmembrane protein and MMAC1/PTEN is a
phosphatase that is deleted in sporadic glioblatomas. However, the mechanism of tumor
suppression by the products of these two tumor suppressor genes is not elucidated yet.
To date, knock outs of the mouse homologues of eleven tumor suppressor genes have been
reported. They have reported mutations in the germline of mice in the mouse homologues of the Rb
(Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992), p53 (Donehower et al., 1992; Jacks et
al., 1994), WT1 (Kreidberg et al., 1993), BRCA1 & 2 (Gowen et al., 1996; Hakem et al., 1996;
Liu et al., 1996), APC (Moser et al., 1990; Su et al., 1992), NFI (Brannan et al., 1994; Jacks et
al., 1994), NF2 (Jacks, 1996), mismatch repair genes (PMS1, PMS2, MSH2) (Baker et al., 1995;
Baker et al., 1996; de Wind et al., 1995; Edelmann et al., 1996; Reitmair et al., 1995), and
MTS1/p16INK4A genes (Serrano et al., 1996). In addition, a knock out of the rat homologue of
TSC2 (the Eker rat model) (Kobayashi et al., 1995) has been reported.
While the cells and tissues from mice with mutations of the mouse homologues of human
tumor suppressors genes have beeen very useful in deciphering the biochemical and cell
physiological functions of the proteins encoded by tumor suppressor genes, the mutant mice often
do not model the human diseases. For instance, Rb +/ - , WT1 +/-, BRCAI+/-, BRCA2 +/ - , NF +/-,
NF2+/- and mice with germline mutations of mismatch repair genes do not model the humans with
similar mutations. Moreover, to date there are no reports of increased tumor predisposition in
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WTI+/-, BRCA1 +/ and BRCA2 +/- mice. Rb+/- mice do not develop retinoblastomas and neither
NFI+/- nor NF2+/ - mice develop neurofibromatosis. Likewise, mice with mismatch repair
mutations do not develop colon cancer and MTS1-I - mice do not develop melanoma.
The difference between the phenotype of the mice and humans that carry germline
mutations of homologues of a tumor suppressor gene may be due to many reasons but two are
worth mentioning here. One explanation is that the wild type allele of the tumor suppressor gene is
not mutated or deleted in the cells of the heterozygous mouse at sufficiently high rate to form
tumors. This appears to be the reason why NFI+/- mice do not develop neurofibromas (Jacks,
1996). If the second allele of NF1 is mutated in embryonic stem cells and these cells are then used
to generate chimeric mice, the newborn mice composed partly of homozygous mutant cells develop
tens to hundreds of neurofibromas (Jacks, 1996). Thus the rate of loss of the second allele of NF1
in the neuronal precursor cells appears to be the rate-limiting step for the formation of
neurofibromas in mice. This lower rate of loss of or mutations of the NF1 gene may be due to a
better ability of the mouse cells to repair such mutations or because the mouse NF1 locus has a
lower rate of mutation.
In the case of some tumor suppressor genes, the rate-limiting step in the formation of
tumors in mice may not be loss of the second wildtype allele of the tumor suppressor gene. For
instance, loss of the second copy of Rb is not sufficient for formation of retinoblastoma in mice
(Maandag et al., 1994; Williams et al., 1994). In this instance, the mouse tissue appears to have
other genes whose functions are redundant with those of the Rb gene and has the ability to
eliminate those cells that have lost RB protein by apoptosis (for an expanded discussion see Jacks,
1996). Evidence in support of this hypothesis comes from the observation that transgenic
expression in the mouse retinal cells of the large T antigen, which binds and inactivates Rb and its
close relative p 107 and p 130 as well as the cellular p53 protein, causes the formation of
retinoblastomas (O'Brien et al., 1990; Windle et al., 1990).
However, most mouse strains with mutations of tumor suppressor genes show increased
tumor predisposition in some tissues. For example, Rb+/- mice develop pituitary tumors (Jacks et
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al., 1992; Lee et al., 1992). NF1+/ - mice develop pheochromocytoma and myeloid leukemia
(Brannan et al., 1994; Jacks et al., 1994) and NF2+/- mice are predisposed to sarcomas (Jacks,
1996). Those with a germline mutation of p53 do not develop the full spectrum of the tumors
observed in the Li-Fraumeni families but the p53 +/ - mice are predisposed to lymphomas,
leukemias and sarcomas and p53-/ - mice die within six months from tumors (Donehower et al.,
1992; Jacks et al., 1994). Mice with mismatch repair mutations develop lymphoid tumors and
MTS1-/- mice (which are also deficient in the overlapping gene pl9ARF) develop lymphomas,
leukemias and soft tissue sarcomas (Serrano et al., 1996).
As yet, there are no reports of mice that carry germline mutations of five of the tumor
suppressor genes, i. e., VHL, PTC, MMAC1/PTEN, TSC2 and DCP4 although a rat model of
TSC2 (the Ekert rat) exists (Kobayashi et al., 1995). The phenotype of this rat strain is different
from the tuberous sclerosis disease in human although the rats are predisposed to renal tumors
(Kobayashi et al., 1995).
Thus, mice with mutations of homologues of most tumors suppressor genes often have
increased tumor predisposition in tissues different from those seen in human and therefore, and in
this respect do not provide good models for human inherited cancer syndromes. However, there
are two notable exceptions. Mutations of the APC gene and inactivation of the functions of the
Patched tumor suppressor gene create diseases in mice that are very similar to familial adenomatous
polyposis and nevoid basal cell carcinomas (NBCC) of skin in human, respectively, A knock out
of the Patched gene is not reported yet but overexpression of its ligand sonic hedgehog (Shh),
which in Drosophila mimics loss of PTC function, leads to the development of skin lesions in mice
that very similar to human nevoid basal cell carcinoma. As described above, mutations of the APC
gene result in benign growths or polyps in the intestinal tract of mouse that are very similar to
adenomas that are the precursors of colon cancer in human. However, the site of adenomas caused
by APC mutations differ in the human and the mouse intestinal tract. In Apc+/- mice adenomas
primarily appear in the small intestine while in APC+/- humans most adenomas are colonic.
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There are other similarities between intestinal tumor formation in human and mouse. As
shown in this study, different mutations of Apc have profoundly different effects on polyp number
in the familial adenomatous polyposis in human and mouse. C-terminal truncations of APC protein
lead to a larger number of adenomas than the N-terminal mutations. Moreover, alterations in DNA
methylation appear to be an important step in the formation of adenomas of intestine in both human
and mouse. Finally, inactivation of cyclooxogenase-2 enzyme using non-steroidal anti-
inflammatory drugs such as sulindac leads to polyp suppression in both human and mouse
(Beazer-Barclay et al., 1996; Boolbol et al., 1996; Du Bois, 1995; Giardiello et al., 1996; Oshima
et al., 1996).
The conserved role of APC as the gate keeper for intestinal adenomas in both mouse and
human provides hope for the possibility that other events that occur as late steps in the progression
leading to colon cancer in human could also be important in the progression of mouse intestinal
adenomas. It remains to be seen whether mutations of Apc, ras, the mouse counterpart of the
tumor suppressor gene on human chromosome 18q (and/or the TGF-beta type II receptor which is
mutated in tumors from Lynch syndrome patients) and p53 in a correct temporal order would cause
the progression of benign intestinal adenomas to carcinomas in the mouse intestine.
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Figure 1
Revised genetic model of colon cancer
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